Login
Oncologisch onderzoek.nl
Home
Login
Links
Contact
Registreren
Jarig
Nieuws
<<
<
1
2
3
4
5
10
20
100
200
>
>>
Pagina 2/ 980 - 15 Lijnen per pagina - 14690 Lijnen in deze sectie
Titel
Commentaren
Datum
Auteur
Gerandomiseerde fase 2-studie van neoadjuvant en adjuvant toripalimab voor locoregionaal-gevorderd nasofarynxcarcinoom
(0)
2024-11-08 16:00
Fase 1b-2 studie van equecabtagene autoleucel voor recidiverend of refractair multipel myeloom
(0)
2024-11-08 14:30
Cohortstudie van lange-termijn bijwerkingen en complicaties van behandeling voor prostaatcarcinoom
(0)
2024-11-08 13:00
Gepoolde lange-termijn uitkomsten met nivolumab plus ipilimumab of alleen nivolumab voor gevorderd melanoom
(0)
2024-11-07 16:00
Prospectieve multicohort studie van predictieve waarde van 5-genensignatuur voor respons van NSCLC op ICIs
(0)
2024-11-07 14:30
Risico van psoriasis met immuuncheckpointremmers voor maligniteiten
(0)
2024-11-07 13:00
Uitkomsten met routinematige imaging of symptomatische follow-up na resectie van pancreas ductaal adenocarcinoom
(0)
2024-11-06 16:06
Meta-analyse van veiligheid en werkzaamheid van PD-(L)1 ICIs voor eerder-behandeld gevorderd maligne mesothelioom
(0)
2024-11-06 14:30
Veiligheid en werkzaamheid van crizotinib voor MET-gemuteerd gevorderd niet-kleincellig longcarcinoom
(0)
2024-11-06 13:00
Detectie van actionabele structurele varianten met RNA-NGS toegevoegd aan DNA-NGS in gevorderd niet-kleincellig longcarcinoom
(0)
2024-11-05 16:00
Overzicht van CAR T-cellen en T-celbehandelingen voor maligniteiten
(0)
2024-11-05 14:30
Casus van respons van prostaatcarcinoom met HER2-expressie op trastuzumab deruxtecan
(0)
2024-11-05 13:00
Profiel en voorspellers van infectieuze complicaties met daratumumab-gebaseerde behandelingen voor multipel myeloom
(0)
2024-11-04 16:00
Meta-analyse van histopathologische prognostische factoren in chirurgisch-behandeld HPV-positief OPSCC
(0)
2024-11-04 14:30
Kenmerken en uitkomsten van mammacarcinoom gerelateerd aan ras/etniciteit in Canada
(0)
2024-11-04 13:00
<<
<
1
2
3
4
5
10
20
100
200
>
>>
Pagina 2/ 980 - 15 Lijnen per pagina - 14690 Lijnen in deze sectie
Tags
'gunstig hoog-risico'
“one thousand HER2 patients” project
(chemo)endocrine therapy
[11C] docetaxel
[18F]paclitaxel
%FT
1-day multidisciplinary clinic
1-year versus shorter duration of adjuvant trastuzumab
10-year outcomes
10-year recurrence
15-hydroxyprostaglandinedehydrogenase
15-PGDH
16-gene POLAR molecular signature
16K PRIL
16q23
1703-studie
177-Lu-dotatate
177Lu-PSMA-617 plus maintenance pembrolizumab
18F-FDG opname
18F-FDG PET CT
18F-fluciclovine-PET CT
18F-PSMA-1007 PET CT versus multiparametric MRI
1975-2016
1980-2017
1988-2017
1990 to 2017
1990-2017
1997-2016
1999-2020
1p 19q co-deleted oligodendroglioma
1p 19q codeleted oligodendroglioma
1p 19q non-co-deleted anaplastic glioma
2 induction courses of bacillus Calmette-Guèrin
20-year follow-up
20-year mortality
2000-2014
2003-2007 versus 2013-2017
2006-2016
2006-2019
2008-2018
2010-2016
2010-2019
2010-2020
2018 FIGO stage IIIC SCC of the cervix
2020 UK post-polypectomy surveillance guidelines
2021 cancer mortality prediction in EU and UK
2022 cancer mortality predictions in EU and UK
21-gen recurrence score assay
21-gene assay
21-gene assay and breast cancer mortality
21-gene assay recurrence score
21-gene expression assay
21-gene recurrence score
21-gene recurrence score and BCSS
21-gene RS
21-gene RS and response to neoadjuvant chemotherapy
21-year follow-up
25-hydroxyvitamin D
25-OH-D
25-OH-D level at time of diagnosis
27-hydroxycholesterol
28-year risk of lung cancer
3 versus 1 year adjuvant imatinib
3 versus 6 cycles CEV chemotherapy
3 versus 6 months adjuvant chemotherapy
3 vs. 6 months oxaliplatin-based adjuvant chemotherapy
3-dose COVID-19 mRNA vaccination
321GO
3D brachytherapy
3D-conformal radiotherapy for breast cancer
3DCRT
4 Gy versus 24 Gy radiotherapy
45 and Up Study
4EVER trial
4L lymph node dissection
5-ARIs
5-fraction prone APB
5-fraction whole-breast radiotherapy
5-FU
5-gene peripheral blood signature
5-year final analysis
5-year follow-up
5α-reductase inhibitors
6-MP plus methotrexate
6.5-year outcomes
70-gene ST
70-GS
8-OHdG
8-year follow-up results of CheckMate 214
90-day outcomes
90101 CREATE-studie
90YIT
91-maands update van CALGB 100104-studie
A M ESCC
A M NSCLC
A M STS
A R EC
A R endometrial cancer
A U HER2-negative breast cancer
A.R.R.O.W-studie
A021501 trial
A041202 study
AA versus NHW patients
AAC
AACR
AACR 2015
AACR Academy
AACR Project GENIE
AAML0531 trial
AAML1031 phase III trial
AAML1421 study
AAP
AAP for high-risk metastatic castration-sensitive prostate cancer
AAP with or without cabazitaxel
AAP with or without SBRT
AB
AB12005 study
abatacept for prevention of acute GVHD
ABBV-383
aBC
aBC in young women
ABC-06 trial
ABCB1 genetic variants
ABCD trial
ABCD-study
ABCSG 8A trial
ABCSG-18
ABCSG-18 study
abdominal and gluteofemoral size
abdominal radiation for childhood cancer; subsequent risk of diabetes
abdominopelvic RT for childhood cancer
abemaciclib
abemaciclib for MBC
abemaciclib plus ET
abemaciclib plus fulvestrant for MBC
Abi Race studie
abirateron
abiraterone
abiraterone acetate
abiraterone acetate and prednisolone with or without enzalutamide
abiraterone for prostate cancer
abiraterone or enzalutamide
abiraterone plus olaparib
abivertinib
ablatieve behandeling
ablative radiation therapy
ablative therapy after TACE for HCC
abnormale peritoneale cytologie
ABOUND.2L+ study
ABP plus gemcitabine
abscopal effect
ABSI
ABSOLUTE
absolute dense area
absolute lymphocyte count
absolute lymphocyte count at diagnosis
absolute OPC risk
absoluut neutrofielgetal
ABT-199
ABTC
ABVD
ABVD versus BEACOPP-escalated
AC after NAC and resection
acalabrutinib
acalabrutinib monotherapy
acalabrutinib versus ibrutinib
ACC
accelerated cellular senescence after chemotherapy
accelerated FDA approval cancer drugs
accelerated partial breast irradiation
accelerated partial breast irradiation versus whole breast irradiation
ACCENT database analysis
access to anticancer medicines for children and adolescents in Europe
ACCorD trial
accRCC
accRCC after immunotherapy
ACCRU study SC-1603
accrual
accumulation of chronic disease
ACE
ACE inhibitors versus ARBs
ACE study
ACE-LY-004 studie
acellular dermal matrix in immediate implant-based breast reconstruction
ACES
acetaminophen
ACHIEVE study
acid-suppressive medication
ACIS study
ACLD
acne
ACOSOG Z0011
ACOSOG Z11102 trial
ACP statement
acquired resistance to immune checkpoint inhibitors
acquired resistance to osimertinib
acraal melanoom
ACRIN 6686-studie
acromegaly
aCSCC
aCSCC in kidney transplant recipients
AcSé Pembrolizumab trial
AcSé phase 2 study
AcSé study
ACT
ACT-2 trial
Act.In.Sarc study
aCTCL
actieve surveillance
ACTIM
actinic keratosis
actinisch carcinoom
actinium-225-lintuzumab
actinium-225-PSMA
actionability
activated osteoarthritis after immune checkpoint inhibitor treatment
active cancer
active melanoma brain metastases
ACTIVE study
active surveillance
active surveillance for low-risk prostate cancer
active surveillance for prostate cancer
actively treated cancer patients
activering immuunsysteem
ACTs
actual and surrogate Oncotype DX RS distribution
acupuncture
acupuncture for aromatase inhibitor-related joint pain
acupuncture for hot flashes
acute cancer-associated venous thromboembolism
acute care use after initiation of systemic cancer therapy
acute graft-versus-host disease
acute GVHD
acute kidney injury
acute leukemia
acute leukemie
acute lymfoblastische leukemie
acute lymphoblastic leukemia
acute myeloid leukemia
acute myeloïde leukemie
acute promyelocytische leukemie
acute promyeolcytische leukemie
acute toxic effects of the skin
acute toxicity
AD
AD-risico
adagrasib
adagrasib with or without cetuximab
ADAM-studie
ADAM8
ADAMTS-mutaties
ADAPT-IT study
ADAPT-studie
adaptive immune resistance
adaptive randomization
ADAs
ADAURA study
ADAURA trial
adavosertib
ADC as response marker
ADC versus SCC
ADCs
adding 6 months of ADT to PORT
adding durvalumab and olaparib to chemotherapy
adding gemcitabine to adjuvant chemotherapy
adding immunotherapy to first-line chemotherapy
adding MRI and biomarkers
adding OFS to tamoxifen
adding pertuzumab to first-line trastuzumab-docetaxel
adding pertuzumab to trastuzumab and chemotherapy
adding systemic to local therapy for stage I pT1aN0M0 breast cancer
addition of adjuvant capecitabine to standard chemotherapy
addition of ADT or PLNRT to PBRT
addition of androgen deprivation therapy or brachytherapy boost
addition of arsenic trioxide to frontline treatment
addition of bortezomib to first-line dexamethasone-rituximab-cyclophosphamide
addition of bortezomib to melphalan and dexamethasone
addition of BV to chemotherapy
addition of carboplatin to neoadjuvant chemotherapy
addition of celecoxib to adjuvant FOLFOX for stage III colon cancer
addition of chemotherapy to local therapy
addition of chemotherapy to neoadjuvant radiotherapy
addition of concurrent hypo-fractionated RT to failing anti-PD-1 therapy
addition of COX inhibition to immune checkpoint blockade
addition of daratumumab to lenalidomide plus dexamethasone
addition of ibrutinib to first-line bendamustine-rituximab
addition of ICIs to first-line chemotherapy
addition of lenalidomide to R-CHOP
addition of metastasis-directed therapy to systemic therapy
addition of navitoclax to ruxolitinib
addition of ramucirumab to docetaxel
addition of ruxolitinib to neoadjuvant therapy
addition of systemic therapy to definitive radiotherapy
additional cytogenetic abnormalities
additional immune modulators
additional medical expenditures
ADEBAR
adebrelimab
ademanalyse
ademtest
adenocarcinoma of the esophagus and esophagogastric junction
adenocarcinoma of the small intestine
adenocarcinoom
adenoma detection rate
ADH
adherence
adherence among cancer survivors
adherence to healthy lifestyle
adherene to adjuvant endocrine therapy
adherentie
adherentie AET
adherentie orale chemotherapie
ADI-PEG20
adipose tissue distribution
adipositas
adiposity and risk of YOBC subtypes
adiposity and survival
ADIUVO trial
adjunctive ultrasonography
adjuvant 3D-CRT versus image-guided IMRT for cervical cancer
adjuvant abemaciclib plus endocrine therapy
adjuvant abemaciclib plus endocrine treatment
adjuvant AIs
adjuvant alectinib versus chemotherapy
adjuvant anastrazole for 10 or 5 years
adjuvant and concurrent TMZ
adjuvant anthracyclines
adjuvant anti-PD-1 therapy
adjuvant aromatase inhibitor
adjuvant aspirin
adjuvant aspirin for cancer
adjuvant atezolizumab after adjuvant chemotherapy
adjuvant atezolizumab plus bevacizumab
adjuvant bevacizumab
adjuvant capecitabine
adjuvant capecitabine following concurrent chemoradiotherapy
adjuvant carboplatin plus taxanes versus EC followed by taxanes
adjuvant care
adjuvant chemotherapy
adjuvant chemotherapy after cytoreductive surgery
adjuvant chemotherapy after pCR to neoadjuvant CRT
adjuvant chemotherapy after RNU
adjuvant chemotherapy for breast cancer
adjuvant chemotherapy for breast cancer in older women
adjuvant chemotherapy for prevention of colorectal liver metastasis
adjuvant chemotherapy regimens
adjuvant chemotherapy with or without radiotherapy
adjuvant CRT
adjuvant Cs-131 brachytherapy
adjuvant CT after neoadjuvant ET
adjuvant dabrafenib plus trametinib
adjuvant dabrafenib plus trametinib for stage III melanoma
adjuvant dabrafenib plus trametinib versus placebo for BRAF V600-mutated stage III melanoma
adjuvant dabrafenib-trametinib versus anti-PD-1
adjuvant denosumab
adjuvant docetaxel-based chemotherapy for early breast cancer
adjuvant EGFR-TKIs
adjuvant endocrine therapy
adjuvant endocrine therapy in premenopausal breast cancer
adjuvant enzalutamide
adjuvant EP versus EC-P
adjuvant erlotinib for early-stage NSCLC
adjuvant erlotinib versus vinorelbine-cisplatin
adjuvant ET ± CT
adjuvant ET with or without abemaciclib
adjuvant etoposide plus cisplatin
adjuvant everolimus
adjuvant exemestane with OFS in premenopausal breast cancer
adjuvant fluoropyrimidine-oxaliplatin for early-onset CRC
adjuvant FOLFIRINOX versus gemcitabine
adjuvant FOLFOX FLOX
adjuvant GC or CCRT
adjuvant gefitinib versus chemotherapy
adjuvant gemcitabine sensitivity of resectable PDAC
adjuvant goserelin and tamoxifen
adjuvant icotinib
adjuvant icotinib versus chemotherapy
adjuvant imatinib
adjuvant ipilimumab
adjuvant ipilimumab versus IFNα-2b
adjuvant metronomic capecitabine
adjuvant mitotane
adjuvant multimodality therapy
adjuvant nab-paclitaxel plus gemcitabine
adjuvant neratinib
adjuvant nivolumab
adjuvant nivolumab after salvage resection
adjuvant nivolumab plus ipilimumab versus placebo
adjuvant nivolumab versus ipilimumab
adjuvant nivolumab versus placebo
adjuvant nivolumab vs ipilimumab
adjuvant olaparib
adjuvant olaparib for BRCA1 2-mutated breast cancer
adjuvant osimertinib
adjuvant paclitaxel and carboplatin versus CEF-T
adjuvant palbociclib
adjuvant pembrolizumab
adjuvant pemetrexed plus cisplatin versus vinorelbine plus cisplatin
adjuvant PemP versus NP
adjuvant pertuzumab
adjuvant phosphoinositide 3-kinase inhibitors
adjuvant platinum-based chemotherapy
adjuvant radiation
adjuvant radiation therapy
adjuvant radiotherapy
adjuvant RT
adjuvant RT for breast cancer
adjuvant RT for EEC
adjuvant S-1
adjuvant S-1 plus endocrine therapy
adjuvant S-1 with or without docetaxel
adjuvant SCRT versus CCRT or RT alone
adjuvant sintilimab
adjuvant sorafenib
adjuvant TACE after hepatectomy
adjuvant tamoxifen adherence
adjuvant tamoxifen for HR-positive early breast cancer
adjuvant tamoxifen or AI for breast cancer
adjuvant therapies
adjuvant therapy
adjuvant TLPLDC vaccine
adjuvant TMZ with or without IFNα
adjuvant transarterial FOLFOX infusion
adjuvant trastuzumab
adjuvant trastuzumab duration
adjuvant trastuzumab for HER2-positive breast cancer
adjuvant trastuzumab with or without chemotherapy
adjuvant treatment
adjuvant treatment for breast cancer
adjuvant treatment for stage III melanoma
adjuvant treatments
adjuvant versus early salvage radiotherapy
adjuvant versus early salvage radiotherapy after prostatectomy for prostate cancer
adjuvant versus salvage radiotherapy
adjuvant weekly docetaxel plus radiotherapy
adjuvant XT-XEC versus T-FEC
ADJUVANT-studie
adjuvante chemotherapie
adjuvante CRT
adjuvante HER2-remming
adjuvante hormoontherapie
adjuvante systemische therapie
adjvant trastuzumab with or without chemotherapy
adjvuant chemotherapy versus chemoradiotherapy
ADMEC-O trial
ADMIRAL study
ADMIRAL trial
ADNEX
ado-trastuzumab emtansine
adolescent and young adult
adolescent and young adult cancer survivors
adolescent and young adult HL
adolescent overweigh or obesity
adolescents and young adults
adoptive T-cell therapy
ADORE trial
ADR
ADR and postcolonoscopy CRC risk
ADRD
adrebrelimab
adrenal metastases
adrenocortical carcinoma
adrenocortical carcinoma cohort
ADRIATIC trial
ADRRAD study
ADRs
ADT
ADT for nmPCa
ADT for prostate cancer
ADT for prostate cancer in Canada
ADT plus pelvic RT plus radium-223
ADT risk of depression
ADT with or without docetaxel
adult alternative donor HCT
adult AML
adult cancers
adult childhood cancer survivors
adult chilhood cancer survivors
adult craniopharyngioma
adult glioma
adult glioma risk
adult glioma with LM
adult height
adult osteosarcoma patients
adult survivors of childhood ALL
adult survivors of childhood cancer
adult survivors of childhood cancer diagnosed between 1970 and 1999
adult survivors of neuroblastoma
adult T-cell leukemia lymphoma
adult type granulosa cell tumors of the ovary
adult weight gain
adults and children with cancer
advance uterine leiomyosarcoma
advanced acral melanoma
advanced adrenocortical carcinoma
advanced ALK-positive NSCLC
advanced ALK-positive or ROS1-positive NSCLC
advanced anal cancer
advanced anal squamous cell carcinoma
advanced anthracycline-naive sarcoma
advanced B-cell malignancies
advanced B-RAF- or K-RAS N-RAS-mutated solid tumors
advanced BCC
advanced biliary tract cancer
advanced biliary tract cancers
advanced BRAF V600-mutant melanoma
advanced BRAF-mutant melanoma
advanced BRAF-mutated melanoma
advanced BRAF-V600 mutated melanoma
advanced breast cancer
advanced BTC
advanced cancer
advanced cancer patients
advanced cancer-related chronic nausea and vomiting
advanced cancers
advanced carcinoid or pancreatic neuroendocrine tumor
advanced ccRCC
advanced cervical cancer
advanced cHL
advanced chondrosarcoma
advanced chordoma
advanced CLDN18.2 positive gastric cancer
advanced clear cell RCC
advanced colorectal liver metastases
advanced colorectal neoplasms at least ten years after negative coloscopy
advanced CRPC
advanced cutaneous squamous cell carcinoma
advanced dMMR solid tumors
advanced EGA
advanced EGFR T790M mutated non-small cell lung cancer
advanced EGFR-mutant NSCLC
advanced EGFR-mutated or ALK-rearranged NSCLC
advanced EGFR-positive non-squamous NSCLC
advanced endometrial cancer
advanced endometrial carcinoma
advanced ENKTL
advanced epithelial ovarian cancer
advanced epithelioid sarcoma with loss of INI1 SMARCB1
advanced ESCC
advanced esophageal cancer
advanced esophageal squamous cell carcinoma
advanced esophagogastric cancer
advanced extraskeletal myxoid chondrosarcoma
advanced FL
advanced G GEJ adenocarcinoma
advanced G GEJ cancer
advanced gastric cancer
advanced gastric or colorectal cancer
advanced gastric or gastroesophageal junction adenocarcinoma
advanced gastric or gastroesophageal junction and other solid tumors
advanced gastric or gastroesophageal junction cancer
advanced gastroenteropancreatic neuroendocrine carcinoma
advanced gastroesophageal cancer
advanced gastrointestinal cancer
advanced gastrointestinal stromal tumors
advanced germ cell tumors
advanced GIST
advanced GIST with heterogenous KIT PDGFRA mutations
advanced GIST with KIT or PDGFRA mutation
advanced HCC
advanced hepatocellu;ar carcinoma
advanced hepatocellular carcinoma
advanced hepatocellular carcinoma after progression on anti-PD-(L)1
advanced hepatocellular carcinoma in Asian patients
advanced hepatocellular carcinoma with MET overexpression
advanced HER2-negative breast cancer
advanced HER2-negative breast cancer in germline BRCA-mutated patients
advanced HER2-positive breast cancer
advanced HL with large nodal mass
advanced HN CSCC
advanced HNSCC
advanced Hodgkin lymphoma
advanced HR-positive breast cancer
advanced HR+ HER2- BC or TNBC
advanced IDH1-mutant cholangiocarcinoma
advanced indolent lymphoma
advanced leiomyosarcoma
advanced leiomyosarcoma liposarcoma
advanced liposarcoma or leiomyosarcoma
advanced liver cancer
advanced lung adenocarcinoma
advanced lung cancer
advanced malignancy
advanced malignant mesothelioma
advanced MDS in elderly patients
advanced melanoma
advanced melanoma in patients not represented in phase 3 trials
advanced Merkel cell carcinoma
advanced metastatic esophageal squamous cell carcinoma
advanced metastatic medullary thyroid carcinoma
advanced microsatellite instability-high cancers
advanced microsatellite stable colorectal cancer
advanced MPM
advanced mucosal melanoma
advanced nccRCC
advanced non-clear cell RCC
advanced non-clear cell renal cell carcinoma
advanced non-clear-cell RCC
advanced non-small cell lung cancer
advanced non-small cell lung cancer in older adults
advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
advanced non-small cell lung cancer with PD-L1<50% in elderly patients
advanced non-squamous non-small cell lung cancer
advanced non-squamous NSCLC
advanced noncolorectal gastrointestinal cancer
advanced nonsquamous non-small cell lung cancer
advanced nonsquamous NSCLC
advanced nonsquamous NSCLC in elderly patients
advanced NSCLC
advanced NSCLC harboring EGFR exon 20 insertion mutations or common EGFR mutations
advanced NSCLC harboring KRAS G12C mutation
advanced NSCLC in special populations
advanced NSCLC or CRC
advanced NSCLC with EGFR ex19del or L858R alterations
advanced NSCLC with high blood-based TMB
advanced NSCLC with T790M mutated EGFR
advanced or metaastatic colorectal cancer
advanced or metastatic colorectal cancer
advanced or metastatic CRC
advanced or metastatic esophageal squamous cell carcinoma
advanced or metastatic RCC
advanced or metastatic thymic carcinoma
advanced or metastatic urothelial carcinoma
advanced or recurrent endometrial cancer
advanced or recurrent endometrioid endometrial cancer
advanced or refractory desmoid tumors
advanced ovarian cancer
advanced ovarian cancer in patients with BRCA-mutation
advanced ovarian carcinoma
advanced ovarian tubal-peritoneal cancer
advanced ovarium neoplasms
advanced pancreas cancer
advanced pancreatic cancer
advanced pancreatic neuroendocrine tumor
advanced papillary renal cell carcinoma
advanced PDAC
advanced penile cancer
advanced phyllodes tumor of the breast
advanced prostate cancer
advanced pulmonary sarcomatoid carcinoma
advanced rare cancers
advanced rare genitourinary malignancies
advanced RCC
advanced recurrent ovarian cancer
advanced recurrent type B3 thymoma or thymic carcinoma
advanced refractory biliary tract cancer
advanced refractory CRC
advanced refractory esophageal squamous cell carcinoma
advanced renal cell carcinoma
advanced renal-cell carcinoma
advanced RET-mutant medullary thryoid cancer
advanced ROS1 fusion-positive non-small cell lung cancer
advanced salivary gland cancer
advanced salivary gland carcinoma
advanced sarcoma
advanced soft tissue and bone sarcomas
advanced soft-tissue sarcoma
advanced solid cancer
advanced solid cancer in trial-ineligible patients
advanced solid cancers
advanced solid HER2-positive tumors
advanced solid KRAS G12C-mutated tumors
advanced solid malignancies
advanced solid tumors
advanced solid tumors or tenosynovial giant cell tumor
advanced solid tumors with KRAS-G12C mutation
advanced squamous cell carcinoma of the anus
advanced squamous non-small cell lung cancer
advanced squamous non-small-cell lung cancer
advanced squamous NSCLC
advanced stage as end point
advanced stage iNHL
advanced stage mantle cell lymphoma
advanced stage serous borderline ovarian tumor
advanced STS
advanced systemic mastocytosis
advanced thymic carcinoma
advanced thymoma
advanced thyroid cancer
advanced TNBC
advanced triple-negative breast cancer
advanced UC
advanced urological cancers with pre-existing autoimmune disorders
advanced urothelial cancer
advanced urothelial carcinoma
advanced urothelial carcinoma with FGFR1 3 expression
advanced USC with HER2 overexpression
advanced wild-type BRAF melanoma
advanced-stage cancer
advanced-stage Hodgkin lymphoma
advanced-stage Hodgkin’s lymphoma
advanced-stage melanoma
advanced-stage orophryngeal squamous cell carcinoma
Adventist cohort compared with a US Census popiulation
adverse events
adverse events of oral azicitidine
adverse mental health outcomes
adverse pediatric outcomes
ADVL1412 study
AEG
AEGEAN trial
AENEAS trial
AERAS trial
aerobe inspanning
aerobic and muscle-strengthening activity combinations
aerobic and resistance exercise
aerobic exercise during chemotherapy
aerobic physical activity and depression among cancer patients
AET adherence
Af
afami-cel
afatinib
afatinib versus methotrexaat
AFFIRM
AFFIRM-studie
aflibercept
AFP
AFT-01
AFUGEM GERCOR
aG GEJ adenocarcinoma
AG221-AML-005 trial
AGC
AGC with or without liver metastases
age
age at diagnosis
age at diagnosis of colorectal cancer
age at first breast cancer diagnosis
age at initiation of breast cancer screening
age at menarche
age at onset of lung adenocarcinoma
age at ovarian cancer onset
age dependence of modern clinical risk groups
age disparities
age-related disease risks in youger versus older B-NHL survivors
age-specific BMI
agent orange
Agent Orange exposure
AGES-Reykjavik study
aggressive lymphoma
aggressive prostate cancer
aggressive versus non-aggressive prostate cancer
AGILE study
AGITG MAX study
AGO-OVAR 16-studie
AGOC
agressieve fibromatose
agressive squamous cell carcinoma
AGRICAN-studie
aGVHD
AH use
aHCC
aHCC in Japan
aHCC refractory to hepatic arterial infusion chemotherapy
AHELP study
AHEP0731 study
AHL2011 study
aHNSCC
AHOD1221 study
AHOD1331 trial
AI
AI with or without palbociclib
AI-induced arthralgia
AI-therapie
AIC
AIM trial
AIN3
AIO INTEGA trial
AIO-FLOT3 studie
air pollution and breast cancer incidence
airport-related ultrafine particles
AIs
AIs for HR-positive breast cancer
AIT for EBC in postmenopausal patients
AJCC 8th edition stage III melanoma
AJCC CSM-8
AJCC eighth edition staging
AK treatments
AK105-302
AL amyloidosis
AL-amyloïdose
ALBI
albumin-bilirubin grade
ALCANZA-studie
ALCL
aLCNEC
alcohol
alcohol and tobacco consumption
alcohol consumption
alcohol consumption and cancer risk in Australia
alcohol intake
alcoholconsumptie
alcoholgebruik
ALCYONE trial OS analysis
ALCYONE-studie
aldoxorubicine
alectinib
alectinib for crizotinib-resistant ALK-positive NSCLC
alectinib versus crizotinib
ALEX study
ALEX study PRO analysis
ALEX-studie
ALFA-0701 trial
ALFA0701 trial
ALGONQUIN trial
ALiCCS studie
ALiCCS study
ALiCCS-studie
ALICE study
ALINA trial
alisertib
alisertib plus induction chemotherapy
alisertib with or without fulvestrant
ALK inhibitors
ALK inhibitors for NSCLC with ALK-rearrangement
ALK positive advanced NSCLC
ALK rearranged or ROS1 rearranged NSCLC
ALK-positive advanced NSCLC
ALK-positive ALCL
ALK-positive ALCL in pediatric patients
ALK-positive non-small cell lung cancer
ALK-positive NSCLC
ALK-rearranged nonlung solid tumors
ALK-rearranged NSCLC
ALK-remmer
ALK(+) and ROS1(+) NSCLC
ALK1
alkaline phosphatase
ALKi
alkylating chemotherapy
alkylating CRT versus RT
alkylerende chemotherapie
ALL
ALL in children
ALL in children and AYAs
all-cause and cancer-specific death
all-cause and cancer-specific mortality
all-cause and cardiovascular disease mortality
all-cause mortality
ALLCAR study
Alliance A011502
Alliance A071401 trial
Alliance A091401-studie
Alliance N0572-studie
ALLIVE-studie
allo-BMT
allo-HSCT
allo-HST
allogene hematopoïetische stamceltransplantatie
allogene stamceltransplantatie
allogeneic BCMA-targeting CAR T cells
allogeneic blood or marrow transplantation
allogeneic BMT in childhood
allogeneic hematopietic cell transplantation
allogeneic hematopoietic cell transplant
allogeneic hematopoietic cell transplantation
allogeneic hematopoietic cell transplantation outcomes
allogeneic HSCT
allogeneic stem cell transplantation
allogeneic stem cell transplantation for AML or ALL
allogeneic stem cell transplantion
allogeneic transplantation
allogeneic transplantation for myelodysplastic syndrome
allogenic transplant for NHL
alloHCT
alloHCT after PD-1 blockade
alloHCT for AML not in remission
alloHCT for myelofibrosis
alloHCT recipients
alloHCT versus standard consolidation chemotherapy
alloHCT with CB versus MMUD with PTCy
alloHCT without first achieving complete remission
alloHSCT
alloHSCT for myelofibrosis
alloHSCT for pediatric ALL
alloHSCT in women
alloHSCT recipients
alloSCT
allostatic load
almonertinib
aLMS
ALND
alopecie
ALP and LDH prognostic potential
ALPACA trial
alpelisib
alpelisib plus fulvestrant
alpelisib plus nab-paclitaxel
alpelisib plus olaparib
alpelisib-associated hyperglycemia
alpha-fetoprotein
alpha-lipoic acid
ALPINE trial
ALTA-1L
ALTA-1L second interim analysis
ALTA-studie
ALTER 01031 study
ALTER 0303 study
ALTER-H-003 trial
ALTER-S006 trial
alternative cisplatin schedule
ALTERNATIVE study updated results
ALTERNATIVE-studie
ALTTO study sub-analysis
ALUR-studie
alveolar soft-part sarcoma
alvleesklierkanker
ALYCANTE trial
AM
Amara West
AMAROS trial
AMATERASU trial subgroup analysis
AMBASSADOR trial
ambient air pollution
ambulatory function and mortality among cancer survivors
aMCC
amcenestrant
AMD
AMEERA-3 randomized phase 2 trial
American Association for Cancer Research
American Cancer Society nutriton and physical activity guidelines
American Cancer Society richtljnen
AMG 337
AMH
amivantamab
amivantamab plus lazertinib
AML
AML and ALL in AYAs
AML in adult patients
AML in elderly nonfit patients
AML in elderly patients
AML in first relapse
AML in older adults
AML in patients aged 70 years and older
AML in remission
AML MDS
AML MDS in older patients
AML or high-risk MDS
AML or MDS
AML survival
AML with FLT3-ITD mutation
AML with genomic evidence of residual disease
AML with internal tandem duplication of Fms-like tyrosine kinase 3
AML-relapse after allo-HCT
AML-risico
AML17-studie
AML19 trial
AMLSG 09-09 study
aMM
AMPECT study
AMPK variant
AMPK-route
AMPLCaRE study
AMPLE-2 study
amrubicine
anal cancer
analgesic use
analgesics
analgetica
analyse AZURE-studie
analyse binnen PICCOLO-studie
analyse CheckMate 205-studie
analyse COG AAML 1031
analyse CROSS-studie
analyse fase 3-studie CALGB 40503
analyse fase 3-studie GeparQuinto
analyse MA.27-studie
analyse NORDIC-VII studie
analyse STAMPEDE-studie
Analyse van CheckMate 066 en CheckMate 067
analyse van fase 3-studie CAO ARO AIO-04
analyse van STAMPEDE-studie
anamorelin
anaplastic astrocytoma or glioblastoma
anaplastic large-cell lymphoma
anaplastic thyroid carcinoma
anaplastisch grootcellig lymfoom
anaplastisch schildkliercarcinoom
anastrazole with or without fulvestrant
anastrozol
anastrozole
anatomic locations of KCs
anatomic stage
and HIV infection
and rituximab
and time already survived
and triennial mammography screening
androgeendeprivatie
androgeenreceptor
androgeensuppressie
androgen concentrations in prepubertal girls
androgen deprivation for FIR versus UIR prostate cancer
androgen deprivation therapy
androgen deprivation therapy for prostate cancer
androgen receptor expression
androgen receptor signaling inhibitor
androgen-ablative therapy for advanced prostate cancer
aNENs
anesthesia
anesthesiologist volume
anetumab ravtansine
aneuploïdie
ANG1005
angiogenese
Angiome
angiosarcoma
angiosarcomen
angiosarcoom
angiotensin converting enzyme inhibitors
angiotensin II receptor blockers
ANGPT2
ANGPT2 and NOS3 polymorphisms
ANHL12P1 trial
animal and plant protein intake
anlotinib
anlotinib combined with PD-1 PD-L1 inhibitors
anlotinib maintenance therapy
anlotinib plus PD-1 inhibitor
anlotinib plus temozolomide
anlotinib plus TQB2450
anlotinib versus placebo as third- or further-line treatment
anlotinib versus sunitinib
ANNIE study
ANNOUNCE trial
anoikis-resistentie
anorexia nervosa
anorexie
anosmin-1
ANS
aNSCLC
aNSCLC harboring c-Metex14 alterations
aNSCLC in three countries
aNSCLC with CNS metastases
aNSCLC with EGFR exon 20 insertions
aNSCLC with EGFR exon 20ins
aNSCLC with KRAS G12C mutation
aNSCLC with PD-L1 ≥ 1%
aNSCLC with PD-L1 at least 50%
aNSCLC with PD-L1 TPS ≥ 1%
aNSLCL
ansqNSCLC
antacida
anterior temporal lobotomy
anthracycline chemotherapie
anthracyclines
anthracyclines for breast cancer
anthracyclines for breast cancer or lymphoma
anthracyclines for childhood cancer
anthracylcines
anthracyline-containing and taxane-containing chemotherapy
anti GPRC5D CAR T cell therapy
anti-angiogene middelen
anti-angiogenese
anti-angiogenic therapy
anti-B-cell maturation antigen BiTE molecule AMG 420
anti-BCMA GPRC5D bispecific CAR T cell therapy
anti-CD19 and anti-BCMA CAR T-cells
anti-CD19 CAR T-cell therapy
anti-CD19 CAR T-cells
anti-CD22 CAR T-cells
anti-CD30 CAR-T cell therapy
anti-CD7 CAR T cells with anti-CD7 PEBL
anti-CLL based CAR-T therapy
anti-CTLA-4 plus anti-PD-1 blockade
anti-diarrheal strategies
anti-EGFR
anti-EGFR rechallenge therapy
anti-EGFR therapy for metastatic colorectal cancer
anti-HER2 therapy
anti-HER2 therapy for MBC
anti-Hu
anti-humaan T-lymfocyt immunoglobuline
anti-inflammatory mouthwashes
anti-PD-(L)1 for advanced NSCLC
anti-PD-(L)1 monotherapy resistant metastatic melanoma
anti-PD-(L)1 therapy
anti-PD-(L)1 treatment for NSCLC
anti-PD-(L)1 with or without chemotherapy
anti-PD-1
anti-PD-1 antibodies plus RT
anti-PD-1 consolidation
anti-PD-1 immunotherapy for MSS solid tumors
anti-PD-1 L1
anti-PD-1 monotherapy
anti-PD-1 PD-L1 based regimes in advanced solid tumors
anti-PD-1 plus CRT
anti-PD-1 related pneumonitis
anti-PD-1 resistant advanced melanoma
anti-PD-1 therapy
anti-PD-1 therapy for advanced melanoma
anti-PD-1 therapy for solid tumors
anti-PD-1 therapy with or without chemotherapy
anti-PD-1 vs anti-PD-L1 for cancer
anti-PD1 with or without anti-CTLA4
anti-programmed cell death 1 therapy
Anti-T-lymfocten globuline
anti-thymocyte globulin
anti-TNF for steroid refractory toxicity
anti-VEGF therapie
anti-VGEF therapie
antiangiogenese
antibiotic use and risk of colorectal cancer
antibiotics
antibiotics before immune checkpoint inhibitors
antibiotics use and subsequent risk of colorectal cancer
antibodies
antibody drug conjugate MRG003
antibody drug conjugates
antibody-drug-conjugates
anticancer immune checkpoint inhibitors
anticoagulants and breast cancer survival
anticoagulatie
antidepressant use and mortality
antihypertensive drugs
antiogeneseresistentie
antioxidant supplements
antioxidanten
antioxidants
antithymocyte globulin
antithymocytenglobuline
antitumor-werkzaamheid van bisfosfonaten
antiviral treatment
anus squameus celcarcinoom
anuscarcinoom
anuskanker
anxiety and depression symptoms
AO AOA
aOC
aOC or aTNBC
AOM
AON
AOTs
APACT trial
apalutamide
apalutamide for nmCRPC
apalutamide versus placebo for nmCRPC
aPASC
apatinib
apatinib after failure of chemotherapy
apatinib plus oral etoposide
apatinib plus pemetrexed-platinum chemotherapy
APBI versus WBI
aPBSCT for HL
aPC
aPDAC
aPDAC progressing on rucaparib
APHINITY study post-hoc analysis
APHINITY trial 6-year follow-up
APHINITY-studie
API-AI
APICAL-RST trial
apixaban
apixaban versus aspirin
APL
APL in older patients
aPM
apocrine breast cancer
APOLLO study
APOLLO trial
apoptose
appendiceal adenocarcinoma
appendiceal cancer
appendiceal neuroendocrine tumors
appendixcarcinoom
appropriate use criteria for radiation therapy
APPROVE trial
aPRCC
aprepitant
APT trial
APT trial 10-year analysis
AR expression in breast cancer
AR-expression
AR-positive advanced breast cancer
AR-positive triple-negative breast cancer
AR-remming
AR-V7
ARAMIS study
ARANOTE trial
ARASENS trial
ARCAD
ARCAD database individual patients analysis
ARCAD-NADEGE cohort study
ARCADIA trial
ARCAGE-studie
aRCC
aRCC progressing after IO therapy
aRCC with brain metastases
ARCHER 1050
ARCHER 1050-studie
ARCHES study
ARCTIC study
ARD in breast or head and neck cancer patients
ARET0321 trial
ARI0002h
ARIC-studie
ARIEL3-studie
ARIEL4 study
ARIES trial
ARIs
ARIs for prostate cancer
Aristotle study
ARMD
armodafinil for CRF
aRMS
aromatase inhibitor-resistant HR+ HER2- ABC
aromatase inhibitors
aromatase inhibitors versus tamoxifen
aromatase inibitor-induced adverse effects
aromataseremmer
aromataseremmers
ARON-1 study
ARPIs
array comparative genomic hybridization
ARROW study
ARROW trial
ARRY-380
arseentrioxide
arsenic trioxide plus ATRA
arsenicum
ARST1321 study
ART
ART versus ALND after positive SN biopsy
ART-gerichte behandeling
arterial chemotherapy versus sorafenib
arterial thromboembolism preceding cancer diagnosis
artificial intelligence
artificial intelligence algorithms
ARTIS study
ARTIST 2 study
ARTIST 2 trial
ARTO trial
artralgie
ARTSCAN III study
ARv567es
AS for PCa
AS04-adjuvanted HPV-16 18 vaccine
ASAP trial
ASCC
ASCEMBL study
ASCEND study
ASCEND-2
ASCEND-3 final results
ASCEND-5
ASCEND-5 studie
ASCENT final results
ASCENT study
ASCENT trial
ASCERTAIN trial
asciminib
asciminib versus bosutinib
ascites
ASCO
ASCO 2016
ASCT
ASCT versus maintenance chemotherapy consolidation
ASH 2015
Ashkenazi Jewish ancestry
Asian versus non-Asian patients
ASILs
asparaginase-associated pancreatitis
ASPECCT
AspECT study
ASPEN study
ASPIRE-studie
aspirin
aspirin NSAID use
aspirin use
aspirin use and CRC incidence according to lifestyle risk
aspirin use and CRC risk in older adults
aspirin use and ovarian cancer risk
aspirine
aspirine NSAIDs
aspirineprofylaxe
ASPREE study
ASPREE trial
ASPS
asqNSCLC
assessment of lung cancer risk
assessment of screening mammograms
Assisted reproduction
assisted reproductive technologies after breast cancer
assisted reproductive technology
associatie diabetes en kanker
association between age and survival trends after adoption of immunotherapy
association between alcohol consumption and BTC risk
association between Alzheimer disease and cancer
association between meningioma and breast cancer
association between PFS and QOL
association between prediabetes and breast cancer
association between previous infection and cancer risk
association between weight change and breast cancer prognosis
association of adjuvant chemotherapy with overall survival
association of age with efficacy of immunotherapy
association of age with TRAEs and survival
association of BMI with efficacy of ICIs
association of BMI with outcomes
association of BMI with safety profile of nivolumab with or without ipilimumab
association of breast cancer risk with type 2 diabetes and metformin use
association of coffee intake and survival
association of ctDNA and CTCs after NAC with disease recurrence
association of cutaneous toxic effects with outcomes
association of depression and anxiety with mortality
association of diabetes with risk of SAEs during chemotherapy
association of DM with first-line pembrolizumab efficacy
association of endothelial dysfunction and thromboembolism
association of ethnicity and prostate cancer after raised PSA test result
association of extent of tumor resection and survival
association of familial burden of cancer with outcomes of immunotherapy
association of fatigue and outcomes in advanced cancer
association of fiber intake and breast cancer incidence
association of gut microbiome and response to anti-PD-1 therapy
association of hearing impairment with neurocognition
association of height and survival of resectable lung cancer
association of HPV status with survival
association of intensity and duration of alcohol use and risk of head and neck cancer
association of intrinsic subtype with PFS
association of marital status with cancer-specific survival
association of measurable residual disease with DFS and OS
association of MHT with breast cancer subtypes
association of molecular characteristics with OS benefit
association of multifocality with prognosis
association of nativity with survival
association of neoadjuvant chemotherapy with survival
association of neuronal autoantibodies and cognitive impairment
association of obesity with outcomes of breast cancer subtypes
association of obesity with survival outcomes in patients with cancer
association of obesity with toxicity
association of pCR with outcomes in breast cancer
association of PD-L1 expression status with efficacy of PD-1 PD-L1 inhibitors
association of performance status with survival
association of periodontal disease and edentulism with cancer mortality
association of physical activity with cognitive function
association of physical activity with survival
Association of postmenopausal overweight obesitas and subtype-specific breast cancer risk
association of PR status with RS and survival
association of prediagnosis smoking cessation and overall survival
association of preoperative chemosensitivity with survival
association of procedure volume and in-house mortality
association of race and socioeconomic factors with OS
association of recent oncologic treatment with mortality
association of residual DCIS after NAC with breast cancer recurrence
association of response and event-free survival with overall survival
association of RRSO with breast cancer risk
association of sarcopenia with short-term outcomes
association of sedentary behaviors with survival
association of time-to-treatment initiation and survival
association of tumor site with prognosis
association of use of PET-CT with mortality
association with breakthrough infections and complications in cancer patients
association with cancer outcomes
association with cancer risk
association with hepatic malignancy
association with long-term survival
association with lung cancer risk
association with management
association with multiple diseases
association with other cancers
association with other types of tumors
association with rate of treatment for recurrence
association with relapse
association with site-specific cancers
association with survival
association with type of treatment
associations between circulating eosinophils and cancer risk
associations of irAEs with clinical outcomes
associations with mortality
associations with outcomes
associations with prostate cancer risk
associations with season of birth
AST
astma
ASTRO 2015
ASTRO 2016
ASTRRA trial
ASTRUM-005 trial
aSTS
asunercept
ASXL1 mutations
asymptomatic brain metastases
asymptomatic early-stage CLL
asymptomatic mCRPC
asymptomatic WM
ASyMS
AT RT
ATBC Study
ATC
ATC of TILs
ATE
ATEMPT trial
ATEMPT trial 5-year results
atezo-bev
atezo-bev for HCC
Atezo-Brain trial
atezolimuab plus bevacizumab
atezolizumab
atezolizumab for aHCC
atezolizumab for NSCLC
atezolizumab for urothelial carcinoma
atezolizumab plus bevacizumab
atezolizumab plus chemotherapy
atezolizumab plus chemotherapy with or without bevacizumab
atezolizumab plus nab-paclitaxel
atezolizumab plus targeted therapy
atezolizumab versus chemotherapy
atezolizumab versus durvalumab
atezolizumab versus nivolumab versus docetaxel
atezolizumab with or without bevacizumab
atezolizumab with or without CMB305
atezolizumab-bevacizumab for HCC
atezolizumab-vemurafenib-cobimetinib
AtezoTRIBE trial
ATG
ATHENA study
ATHENA-MONO trial
ATL
ATLANTIC-studie
ATLANTIS trial
ATLAS trial
ATM
ATM gene PVs
ATM mutations in cancer
aTNBC
ATOM study
ATOM trial
ATOMIC-Meso trial
atopic dermatitis
atopic eczema and cancer risk
atopie
ATR-blockers
atrial fibrillation
atriumfibrilleren
ATRTs
AtTEnd trial
ATTRACTION-2 studie
ATTRACTION-3 study
ATTRACTION-4 trial
attrition between lines of therapy
atypical breast lesions
atypical bronchopulmonary carcinoids
atypical chronic myeloid leukemia
atypical squamous cell of undetermined signifance
atypical squamous cells of undetermined significance
atypisch meningioom
atypische ductale hyperplasie
atypische hyperplasie
Atypische teratoïde rhabdoïde tumor
atypische teratoïde rhabdoïde tumoren
aUC
AUGMENT study
AUGMENT-101
aumolertinib
AURA
AURA studies
AURA-studie
AURA-substudie
AURA2
AURA3
AURA3 overall survival analysis
AURA3 study
AURA3-studie
AURELIA
AURELIA-studie
AURELIA-substudie
AURIGA study
Aurora A
aurora kinase A inhibition
Australian Melanoma Family Study
auto-immuunziekten
autofagie
autoHCT
autoHSCT
autoimmune disease
autologe stamceltransplantatie
autologous dendritic cell therapy
autologous stem cell transplantation
automated opt-out versus opt-in outreach strategy
autoSCT after complete response to first-line treatment
AVAglio
avapritinib
AVAST-M study
AVAST-M trial
AVAST-M trial analysis
avastin
avelumab
avelumab maintenance
avelumab plus axitinib
avelumab plus cabozantinib
avelumab versus chemotherapy
avelumab versus chemotherapy maintenance
avelumab-palbociclib-axitinib
average risk B-ALL in children
AVERT study
AVERT trial
avoidable cancer deaths by diagnosis prior to metastasis
avoiding peg-filgrastim
avoiding unnessecary surgery
AvR-CHOP study
axatilimab
axi-cel
axi-cel in the non-trial setting
axicabtagene ciloleucel
axillaire lymfeklierdissectie
axillaire radiotherapie
axillaire status
axillaire ultrasound
axillary dissection
axillary lymph node dissection
axillary response
axillary soft tissue pathology
axillary surgery and nodal irradiation
axitinib
axitinib plus avelumab
axitinib plus pembrolizumab
axitinib versus observation
AYA cancer
AYA cancer survivors
AYA-maligniteiten
AYAs
AYAs at end of life
AYAs versus older adults
AYAs with cancer
AZ9291
AZA-MDS-003 study
azacitidine
AZD4547
B-43 trial
B-ALL in CAYAs
B-ALL in patients aged 1-24 years
B-ALL in pediatric and young adult patients
B-cel activering
B-cel lymfoom
B-cel maligniteiten
B-cel precursor-ALL
B-cell ALL
B-cell ALL in children and young adults
B-cell ALL resistant to CD19 immunotherapy
B-cell hematological malignancies
B-cell infiltration
B-cell lymphoma
B-cell lymphomas after CD19-directed CAR T-cell therapy
B-cell malignancies
B-cell non-Hodgkin lymphoma
B-cell precursor acute lymphoblastic leukemia
B-cellymfoom
B-F1RST trial
B-precursos ALL
B-progenitor acute lymphoblastic leukemia
baarmoederhalskanker
BACCI study
BALLET-studie
BAP1 pathogenic variant carriers
bariatric surgery
bariatric surgery after age 60
bariatric surgery and cancer risk in obese adults
bariatric surgery in French obese patients
bariatrische chirurgie
Barrett esophagus
Barrett slokdarm
Barrett-slokdarm
Barrett's esophagus
Barrett's slokdarm
Barrett’s oesophagus
BArT study
basaalcelcarcinoom
basal-like mammacarcinoom
base-edited CAR7 T cells
Baselga
baseline anxiety or depression
baseline CTC count
baseline factors associated with response
baseline metabolic tumor volume as predictive and prognostic biomarker
baseline QOL
baseline tumor burden and overall survival
baseline US and FDG-PET CT
basline plasma tumor mutational burden
bassi
BAT
BAY1436032
BAYOU trial
bazedoxifene plus palbociclib
bb2121
BBB
BBD
BBD-BC
BC
BC characteristics and outcomes related to race ethnicity in Canada
BC risk
BC survivors
BC with three or more SLNs
BC-LMD
BCa
BCBM
BCC
BCCs
BCCSS
BCG
BCG vaccination in childhood
BCG-unresponsive non-muscle-invasive bladder cancer
BCIN+
BCIS
Bcl-2
BCL2 expression
BCLC B2 HCC
BCMA-directed CAR-T
BCMA-targeted CAR-T cell therapy for MM
BCNU
BCP-ALL
BCR
BCR after RT or RP
BCRA-mutated advanced breast cancer
BCRC trial 022
BCRL after ALND
BCS
BCS among women with intellectual disability
BCS for N2 N3 disease
BCS versus mastectomy after neoadjuvant chemotherapy
BCS versus mastectomy for DCIS
BCS with or without RT
BCS with or without RT for large DCIS lesions
BCT
BCT versus mastectomie
BCT versus mastectomy
BCT vs MAST
Be-Well Study
BEACON CRC study
BEACON-studie subgroep-analyse
BEAT Cancer interventie
BEATcc trial
BEB trial
BEBYP-studie
Beckwith-Wiedemann syndrome
BECOME randomized trial
beeld-geleide brachytherapie
beeldvorming
beenmergevaluatie
BEFLICO study
beha
belamaf
belangenconflicten
belantamab mafodotin
belantamab mafodotin for advanced multiple myeloma
belantamab mafodotin plus pomalidomide and dexamethasone
BELIEVE trial
belinostat
BELIS study
BELLE-2 studie
BELLINI trial
BELOB
belotecan versus topotecan
belumosudil
belzutifan
belzutifan plus cabozantinib
bemarituzumab
bempegaldesleukin plus nivolumab
bendamustine
bendamustine lymphodepletion before lisocabtagene maraleucel
bendamustine plus dexamethasone
benefit of healthy lifestyle
benefits and harms of annual
benign biopsy rate
benign ovarian tumor
benign ovarian tumors
benign solid tumors
benigne borstziekte
benmelstobart
benzeen
benzodiazepine
BEP
berberine versus placebo for the prevention of recurrence of colorectal adenoma
BERIL-1
BERT trial
bestraling
BET inhibitor RO6870810
beta-arrestin-1
beta-blocker use
beta-blocker use at time of prostatectomy
beta-blockers
BETA-Text
bètablokkers
between-hospital variation
BEV
bevaciumzab
bevacizumab
bevacizumab and platinum-based combinations
bevacizumab biosimilar
bevacizumab plus chemotherapy
bevacizumab plus CRT
bevacizumab preconditionering voor chemotherapie
bevacizumab versus cetuximab
bevacizumab with or without reirradiation
bevacizumab-etoposide-cisplatin before whole-brain radiotherapy
bevacizumab-resistant high-grade glioma
BEVERLY trial
BEVZ92
BFAST cohort C
BFAST trial
BFM 2009 ALL trial
BFORE trial 5 year follow-up
BFORE-studie
BFR14 trial
BGJ398
bhatia
BI-ALCL
BIA ALCL
biallelic pathogenic CHEK2 variants
BIDOC-studie
biennial
BIG 1-01
BIG 1-98
BIG 1-98 trial analysis
BIG 3-07 TROG 07.01 study
BIG-RENAPE study
bijnierschorscarcinoom
bijniertumoren
bijwerkingen
bilateral and contralateral risk-reducing mastectomy
bilateral breast cancer
bilateral oophorectomy
bilateral oophorectomy and all-cause mortality
bilaterale risicoreducerende mastectomie
BILCAP study
BILCAP study long term outcomes
BILCAP-studie
biliary tract cancer
BIND-014
Bing-Neel syndrome
binimetinib
binimetinib for NRAS-mutated cancers
bintrafusp alfa
biochemical recurrence of prostate cancer
biochemically detected nonadherence to adjuvant tamoxifen
biochemically recurrent prostate cancer
biochemisch recidief
BioItaLEE trial
biologic subtype
biological aging
biological disease-modifying antirheumatic drugs
biologische beschikbaarheid
biomarker
biomarker for response to MET inhibitors
biomarker testing disparities
biomarker voor respons op bevacizumab
biomarker vs MRI-enhanced strategies for prostate cancer screening
biomarker-driven therapies
biomarkeranalyse ASPECCT-studie
biomarkers
biomarkers for detection
biomarkers for nivolumab efficacy
biomarkers for surveillance
biomarkers of activity
biomarkers of breast cancer risk
biomarkers of response to adjuvant chemotherapy
biomarkers of response to ICIs
biomarkers of treatment benefit
biomarkers predicting survival
BioPER trial
biopsie schildwachtklier
biopsy preceding resection
bipolar androgen therapy
BIRC3 mutations
BIRCH-studie
birinapant
birth defects
birth order
birth weight
BIS versus circumference assesements
bisfosfonaat
bisfosfonaten
bispecific CAR-T cell targeting both CD19 and CD22
bispecific CS1-BCMA CAR-T cells
bisphosphonate use and breast cancer risk among women with DCIS
bisphosphonates and risk of cancers
bivalent HPV vaccination
biweekly docetaxel plus ADT
biweekly versus triweekly cabazitaxel
BL-B01D1
blaascarcinoom
blaaskanker
black race
Black versus non-Black patients
black versus nonblack men
Black versus White breast cancer patients
black versus white patients
black versus white women
Black Women's Health Study
Black Women’s Health Study
bladder cancer
bladder cancer in postmenopausal women
bladder cancer progression
bladder cancer risk
bladder cancer VI-RADS score
bladder-preserving trimodality treatment
bladder-sparing TMT
blast-phase CML
blastic plasmacytoïd dendritic cell neoplasm
BLC2001 study
bleeding after ACS
bleeding risk
BLEND study
bleomycin-related pulmonary toxicity
bleomycine
blinatumomab
blinatumomab and POMP maintenance
blinatumomab nonresponse
blinded double reading
bloedgluocse
bloeding
bloedkanker
bloedlipiden
bloedtest colorectaalcarcinoom
blood arsenic levels
blood cholesterol
Blood ICT
blood markers of oxidative stress
blood or marrow transplant
Blood or Marrow Transplant Survivor Study-2
blood pressure
blood tests
blood triglycerides
blood tumor mutational burden
blood-based genomic mutation signature
blood-based test for the detection of multiple cancer types
blood-based tests for multicancer early detection
bloodstream infections
bloodstream infections after curative-intent radiotherapy
BLOOM study
BLOSSOM trial
BLU-667
BLV DNA
BM
BM from BC and NSCLC
BM versus PB
BMAs
BMAs for bone loss in prostate cancer patients receiving androgen deprivation therapy
BMBC
bmCRPC without significant PSA response under enzalutamide
BMD
BMI
BMI and molecular subtypes of premenopausal breast cancer
BMI and outcomes of systemic therapy for metastatic melanoma
BMI and prognosis
BMI and T2D as determinants of response
BMI during maintenance therapy
BMI in early and middle adulthood
BMI surgical treatment
BMM
BMs
BMs from EGFR-mutant NSCLC
BMS-986156
BMT
BMT CTN 1501 study
BMT survivor study
BNT162b2 vaccination in patients undergoing treatment for cancer
BO
body composition
body composition and cardiovascular events
body composition features
body composition phenotypes
body fat
body fat distribution
body fat mass
body fat percentage
body mass index
body mass index and risk of second cancer
body shape trajectory
Boekel
BOLERO-1
BOLERO-2
bone loss in younger breast cancer patients
bone marrow biopsy
bone marrow donor registration
bone marrow plasma cell level
bone marrow versus blood stem cell graft
bone metabolism
bone metastases
bone metastatic melanoma
bone modifying agents
bone sarcoma survivors
bone-metastatic castration-resistant prostate cancer
bone-only metastasis
bone-targeted agents
BONSAI trial
BOOSTER trial
borderline ovarian tumor
borderline ovariumtumor
borderline resectable or locally advanced unresectable pancreatic cancer
borderline resectable pancreatic cancer
borderline resectable PDAC
Borealis-1 studie
Borealis-2 studie
borstbiopsie
borstchirurgie
borstdichtheid
borstimplantaat
borstkanker
borstkanker bij mannen
borstkankerpreventie
borstkankerscreening
borstkankerscreening oudere vrouwen
borstkankersterfte
borstparende chirurgie
borstreconstructie
borstreconstructie na mastectomie
borstsparende chirurgie
borsttomosynthese
borstvoeding
bortezomib
bortezomib induction for NDMM
bortezomib plus chemotherapy
bortezomib plus rituximab maintenance
BOS chordomas
BOSS cohort
BOSTON study
bosutinib
bosutinib for previously treated chronic myeloid leukemia
bosutinib versus imatinib
BOT
bot-SPNs
boteffect
botensilimab plus balstilimab
botmetastasen
botmetastasen van mammacarcinoom
botmetastasering
botmicrometastasen
botox
botpijn
botsarcoom
bovenste-luchtwegkanker
BP-RMS
BPd versus PVd
BPDCN
bPFS
BPH
BPM
BPs
BR
BR-ESCC
BR.36 trial
BRAC1 2-mutation
brachytherapie
brachytherapy for glioblastoma
BRAF
BRAF 594 en 596 mutaties
BRAF 600 wild type melanoom
BRAF HER2 MET RET-alterations
BRAF mutated advanced solid tumors
BRAF mutation
BRAF non-V600-mutant mCRC
BRAF plus MEK inhibition
BRAF plus MEK inhibitors
BRAF V600 mutated metastatic melanoma
BRAF V600-mutated mNSCLC
BRAF V600-mutated NSCLC
BRAF V600-mutated pediatric LGG
BRAF V600-mutated stage III melanoma
BRAF V600E
BRAF V600E mCRC
BRAF V600E mutated CRC
BRAF V600E-mutant mNSCLC
BRAF V600E-mutated biliary tract cancer
BRAF V600E-mutated CRC
BRAF variants
BRAF wild-type advanced melanoma
BRAF-genfusies
BRAF-mutant CRC
BRAF-mutant mCRC
BRAF-mutant melanoma
BRAF-mutant mNSCLC
BRAF-mutated aCRC
BRAF-mutated malignancies
BRAF-mutated melanoma
BRAF-mutated metastatic melanoma
BRAF-remmer
BRAF-remmers
BRAF-remming
BRAF-V600 mutation-positive melanoma
BRAF-V600 or BRAF-nonV600 mutated NSCLC
BRAF-V600E
BRAF-V600E mutant mCRC
BRAF-V600E mutated tumors
BRAF-V600E mutation
BRAF-wt advanced melanoma
BRAFV600-mutant melanoma
BRAFV600-mutant stage III melanoma
brain cancer
brain imaging
brain metastases
brain metastases from melanoma
brain metastases in older patients
brain metastases nivolumab plus ipilimumab
brain metastases of gastroesophageal adenocarcinoma
brain metastases or leptomeningeal disease
brain metastasis
brain metastasis and survival outcomes
brain metastasis outcomes
brain radiotherapy plus pyrotinib and capecitabine
brain tumors
brain volume
brain white matter microstructure
brain-metastatic lung cancer
brain-only mBC
brainstem metastases
BRCA
BRCA mutation carriers
BRCA mutation carriers with breast cancer
BRCA mutational status
BRCA PVs
BRCA-defective tumors
BRCA-mutatie
BRCA-related cancer
BRCA1
BRCA1 2 germline mutations
BRCA1 2 mtuation. risk of contralateral disease
BRCA1 2 mutation
BRCA1 2 mutation carriers
BRCA1 2 mutations
BRCA1 2 mutations and endometrial cancer
BRCA1 2 pathogenic variants
BRCA1 2 pathogenic variants carriers
BRCA1 2 pathogenic variants in women aged 50-75 years
BRCA1 2 PV
BRCA1 2 PV carriers
BRCA1 2 PVs
BRCA1 2 variants
BRCA1 2-associated pT1 breast cancer
BRCA1 2-mutatie
BRCA1 2-mutaties
BRCA1 2-mutations
BRCA1 2-negative Chinese breast cancer patients
BRCA1 and BRCA2 germline pathogenic variants
BRCA1 and BRCA2 mutations
BRCA1 mutation
BRCA1- or BRCA2-mutated breast cancer
BRCA1-mutatie
BRCA1-versus BRCA2-altered mCRPC
BRCA2
BRCA2-associated breast cancer
BRCA2-mutaties
BRCAAway trial
BRCP
BREACH study
breakthrough COVID-19 infections in cancer patients
breakthrough infections after COVID-19 vaccination in patients with cancer
breakthrough SARS-CoV-2 infections in vaccinated patients with cancer
breast and lung cancer mortality in women
breast and prostate cancer
breast angiosarcoma
breast cancer
breast cancer –related lymphedema
breast cancer after radiotherapy for HL
breast cancer and other cancers
breast cancer bone metastasis
breast cancer brain metastases
breast cancer brain metastasis
breast cancer central nervous system metastases
breast cancer chemotherapy
breast cancer chemotherapy dose reduction
breast cancer CMs
breast cancer conservation surgery
breast cancer diagnosis
breast cancer family history
Breast Cancer Family Registry
breast cancer in BRCA PV carriers
breast cancer in childhood cancer survivors
breast cancer in high-risk women
breast cancer in HL survivors
breast cancer in men
breast cancer in older women
breast cancer in sub-Saharan Africa
breast cancer in women
breast cancer in young women
breast cancer incidence after a false-positive mammography result
breast cancer incidence before age 40
Breast Cancer Index
breast cancer leptomeningeal disease
breast cancer lymph node metastases
breast cancer metastases
breast cancer metastatic recurrence
breast cancer molecular subtypes
breast cancer mortality
breast cancer mortality by comorbidty and age
breast cancer mortality rates in U.S. women
breast cancer outcomes
breast cancer ovarium cancer predisposition genes
breast cancer patients
breast cancer patients aged 35 years or younger
breast cancer patients over age 50
breast cancer preventive effects of anastrozole
breast cancer PRS
breast cancer radiation therapy
breast cancer radiotherapy planning CT scans
breast cancer rate after oophorectomy in the general population
breast cancer recurrence
breast cancer risk
breast cancer risk after age 60
breast cancer risk after bariatric surgery
breast cancer risk before age 40 years
breast cancer risk estimation model
breast cancer risk in women ≥50 years
breast cancer screening
breast cancer screening among women with dense breasts
breast cancer screening in average-risk women
breast cancer screening interval
breast cancer screening participation
breast cancer second recurrences afte mastectomy
breast cancer subtype
breast cancer subtype incidence
breast cancer subtypes
breast cancer surgery
breast cancer survival
breast cancer survivors
breast cancer survivorship
breast cancer treated in neoadjuvant setting
breast cancer treatment
breast cancer treatment quality
breast cancer treatments
breast cancer with sentinel-node metastases
breast cancer-related fatigue
breast cancer-related lymphedema
breast cancer-specific mortality
breast cancer-specific survival
breast compression
breast conservation
breast conservation vs mastectomy and reconstruction
breast consevation versus mastectomy
breast desmoid tumor management in France
breast ductal carcinoma in situ
breast feeding experiences
breast intraepithelial neoplasia recurrence
breast milk paclitaxel excretion
breast MRI versus digital tomosynthesis
breast non-invasive disease
breast or ovarian cancer
breast radiotherapy
breast surgery after NAC
breast symptoms
breast tumors
breast-conserving surgery
breast-conserving surgery versus mastectomy for EBC
breast-conserving therapy
breast-conserving therapy in women over 70
breastfeeding
BreastScreen Norway
BRENDA-score
brentuximab vedotin
brentuximab vedotin and risk-adapted node radiation
brentuximab verdotin
brexu-cel as standard therapy
brigatinib
brigatinib after failure of BV
BrighTNess study
BRIM-3 studie
BRIM7 study
BRIM8-studie
BRIs
British Childhood Cancer Survivor Study
BrMs
Broad-based genomic sequencing
BROCADE3 trial
BROCADE3 trial exploratory analysis
bronchopulmonary carcinoids
BRPC
BRRM
BRUIN study
BRUIN trial
bruton's tyrosine kinase
BTC
BTC in patients aged ≥ 70 years
BTC with ERBB2 3 alterations
BTCRC-GU14-003 study
BTCRC-LUN15-029 trial
BTCs
BTK
BTK inhibition
BTK inhibitor therapy
bTMB as biomarker for atezolizumab activity
bulky stage I-II cHL
burden of pancreatic cancer in Europe between 1990 and 2019
Burkitt lymphoma
Burkitt's lymfoom
burnout in cancer care physicians
busulfan plus fludarabine
busulfan plus melphalan conditioning
busulfan-fludarabine versus busulfan-cyclophosphamide
BV
BV plus AVD
BV plus nivolumab
BVd versus DVd
BVD-523
BYLieve study cohort A
BZD
C reactive protein flare
C SCANS studie
C-144-01 study
C-486
C-ALCL
C-CAR066
C-ETACs as hallmarks of cancer
C-ion RT
c-Met protein-expressing NSCLC
c-Met protein-overexpressing EGFR-wildtype NSCLC
C-reactive protein
C-reactive protein trajectories
C-TASK FORCE studie
CA 209-678 trial
CA-125
CA-125 KELIM
CA125
CA180-226 studie
CA19-9
CA209-003 studie
CA209-003 trial
CA209-9JC trial
CA301 study
CABARET-studie
CABASTY trial
cabazitaxel
cabazitaxel plus carboplatin
cabazitaxel versus abiraterone or enzalutamide
CABINET trial
CABIR study
CABONE study
CABOSUN
cabozantanib
cabozantinb
cabozantinib
cabozantinib plus ADT
cabozantinib plus atezolizumab
cabozantinib plus atezolizumab versus sorafenib
cabozantinib plus nivolumab
cabozantinib plus nivolumab and ipilimumab
cabozantinib plus nivolumab with or without ipilimumab
cabozantinib versus everolimus
cabozantinib with or without atezolizumab
cabozantinib-nivolumab sequence
cachexia
CAD
CADC
CADM1 MAL-methylering
cadmium and lead in erythrocytes
cadonilimab
cafeïne
caffeïne
CAG-repeat
CAIRO3
CAIRO4 trial
calcifications and cystic morphology on preoperative imaging
calcitonin receptor-like
calcium
calcium and magnesium intake
calcium supplementation
calciuminname
calculated tumor area
CALGB 30160 RTOG 0538
CALGB 40601 follow-up
CALGB 40903 study
CALGB 50604
CALGB 50801
CALGB 80405 exploratory analysis
CALGB 80803
CALGB 89803-studie
CALGB Alliance 140503
CALGB SWOG 80405
CALGB SWOG 80405 study
CALGB SWOG 80702
CALGB SWOG 80702 analysis
CALGB SWOG 80702 post hoc analysis
CALGB SWOG 80702 study
CALLA trial
CALM trial
CALOR-studie
caloric restriction
CALYPSO trial
CAM
CameL study
CameL trial
Camel-sq trial
camizestrant
camrelizumab
camrelizumab plus apatinib
camrelizumab plus apatinib and fuzuloparib
camrelizumab plus apatinib for advanced cervical cancer
camrelizumab plus chemotherapy
camrelizumab plus famitinib
camrelizumab plus famitinib after PD-1 blockade
camrelizumab plus gemcitabine plus oxaliplatin
camrelizumab plus GEMOX
camrelizumab plus GVD chemotherapy
camrelizumab plus pemetrexed and carboplatin
camrelizumab plus rivoceranib
camrelizumab plus rivoceranib versus sorafenib
camrelizumab with or without decitabine
camrelizumab-apatinib-temozolomide
CanAssist Breast test
cancer
Cancer and Aging Research Group score
cancer and cardiovascular disease intensity an mortality
cancer and cardiovascular risk with tofacitinib in rheumatoid arthritis
cancer and risk of COVID-19 diagnosis and severity
cancer burden in patients with sleep apnea
cancer burden in the oldest-old in The Netherlands 1990 to 2019
cancer cachexia
cancer case trends
cancer cases attributable to modifiable lifestyle risk factors in Switzerland
cancer chemotherapy during pregnancy
cancer clinical trial participants
cancer clinical trials
cancer deaths due to delays in diagnosis in England
cancer detection rate
cancer diagnoses after recent weight loss
cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible
cancer diagnosis
cancer diagnosis during adolescence
cancer diagnosis in primary care
cancer driver genes
cancer drugs approved based on response rate
cancer drugs receiving FDA accelerated approval
cancer emergency presentation
cancer history
cancer immunotherapy
cancer immunotherapy trials
cancer in older adults
cancer in solid organ transplantation recipients
cancer in the prison population in England
cancer incidence
cancer incidence among children and young adults by single year of age
cancer incidence and mortality
cancer incidence and spectrum in children
cancer incidence and survival in older adults
cancer incidence in World Trade Center rescue and recovery workers
Cancer Moonshot goal
cancer mortality
cancer mortality in Europe
cancer of unknown primary
Cancer of unknown rimary
cancer outcomes
cancer patients
cancer patients aged 70 years or older
cancer patients and matched norm population perceived care and well-being
cancer patients treated with anticoagulation
cancer patients undergoing systemic treatment
cancer predisposition screening tool
cancer prevalence
cancer prevalence in medieval Cambridge (UK)
cancer prevention
cancer prevention recommendations
Cancer READMIT Score
cancer recurrence
cancer risk
cancer risk after hematuria diagnosis
cancer risk in children
cancer risk in children and adolescents
cancer risk in individuals with major birth defects
cancer risk in patients with bipolar disorder and unaffected siblings
cancer risk in South Korean GERD patients
cancer risk in women
cancer risks
cancer risks among men
cancer screening
cancer screening in people with mental illness
cancer screening tests
cancer spectrum
cancer surgery in older adults
cancer surgical procedures
cancer survival in Germany
cancer survivors
cancer susceptibility genes
cancer therapy approval timings in the US and Europe
cancer trials
cancer types and risk of delirium
cancer-associated isolated DVT
cancer-associated venous thromboembolism
cancer-related cognitive impairment
cancer-related fatigue
cancer-specific mortality
cancer-testis antigens
cancers attributable to infections
cancers of unknown primary origin
cancers with MUC16-variants
CANDOR study
CANDOR study updated outcomes
canine lung cancer detection
cannabidiol for relief of symptoms in advanced cancer
cannabigerol
cannabinoids for symptom management
cannabis
cannabis use
cannabis use and lung cancer susceptibilty
CanSaRCC study
CanSNET-studie
CANTO prospective cohort study
CANTO skin
CANTO trial
CANVAS trial
CAO ARO AIO-04 study
CAO ARO AIO-04 trial post hoc analysis
CAO ARO AIO-12 trial long-term results
CAP 01 study
CAP 02 trial
CAP 03 trial
CAP trial
CAP-BRAIN study
CAP-studie
CAPability-01 trial
CAPAP-Lung trial
capecitabine
capecitabine maintenance after first-line induction chemotherapy
capecitabine maintenance therapy
capecitabine versus observation
capecitabine-associated hand-foot syndrome
CAPITAL study
CAPItello-291
CAPItello-291 trial
capivaserib for AKT1 E17K-mutated tumors
capivasertib
capivasertib for tumors with AKT mutations
capmatinib
capmatinib plus nivolumab
CAPP-Seq
CAPP2 study
CAPRI trial
CAPRI-GOIM
CAPRICE
CAPSTONE-1 trial
CaPSURE trial
CAPTAIN-1st study
CAPTIVATE study MRD-cohort
CAR T cell therapy
CAR T cells and T-cell therapies for cancer
CAR T-cell therapy
CAR T-cell therapy for relapsed refractory large B-cell lymphoma
CAR T-cellen voor solide tumoren
CAR T-cells for B-cell lymphoma
CAR T-celtherapie
CAR-HEMATOTOX model
CAR-T
CAR-T celtherapie
CAR-T for lymphomas
CAR-T for pediatric ALL
CAR-T therapy
CAR-T-cell therapy in patients with advanced B-cell cancers and HBV-infection
CAR-transduced natural killer cells
CAR19 22 T-cell therapy
Caravaggio study
carbazitaxel
carbon ion RT
carbon nanoparticle suspension lymphografy guided distal gastrectomy
carboplatin
carboplatin dose capping
carboplatin plus nab-paclitaxel
carboplatin plus pemetrexed
carboplatin with or without atezolizumab
carboplatin with radiotherapy
carboplatin-etoposide with or without atezolizumab
carboplatin-paclitaxel with or without trastuzumab
carboplatine
carcinoïd tumoren
CARD study
cardiac dysfunction
cardiac events
cardiac impact of cytokine release syndrome
cardiac outcomes
cardiac safety
cardiac substructure radiation dose and risk of late cardiac disease
cardiale disfunctie
cardiale toxiciteit
cardiale veiligheid
cardiometabolic risk factors
cardiometabolic risk factors and survival after cancer
cardiomyopathy in CCSs
cardioprotective strategies
cardiopulmonary complications
cardiorespiratorische fitheid
cardiorespiratory fitness
cardiotoxiciteit
cardiotoxiciteit anthracylines
cardiotoxiciteit chemotherapie
cardiotoxicity
cardiotoxicity of doxorubicin
cardiotoxicity with encorafenib and binimetinib
cardiovasculair risico
cardiovasculaire toxiciteit
cardiovascular adverse events
cardiovascular disease
cardiovascular disease risk
cardiovascular diseasse
cardiovascular events
cardiovascular events and chronic kidney disease
cardiovascular fitness and muscular strength
cardiovascular mortality
cardiovascular outocmes
cardiovascular risk
cardiovascular risk factors
cardiovascular surveillance
cardiovascular toxicity
CARE study
CareMin650
CARES-310
carfilzomib
carfilzomib for myeloma
carfilzomib-bendamustine-dexamethasone
carfilzomib-lenalidomide-dexamethasone followed by lenalidomide maintenance
carfilzomib-lenalidomide-dexamethasone-daratumumab
CARG tool
CARMENA study
CARMENA-studie
carmustine
Carolina Breast Cancer Study
carotenoïden
carpaal-tunnelsyndroom
CARRIERS consortium
CART-19
CART-SIE study
CARTBCMA-HCB-01 trial
CARTIFAN-1 study
CARTITUDE-1 study
CARTITUDE-1 trial
CARTITUDE-4 trial
CARTS study
CARTTAS study
cascade genetic testing
case-control analysis within IBIS-II
case-mix adjusted comparison of Dutch hospital perfomances
CASPIAN study
CASPIAN study follow-up
CASPS study
CASR
CASSINI study
CASSIOPEIA part 2
CASSIOPEIA study
CASTOR and POLLUX age subgroup analysis
CASTOR subgroup analysis
castratieresistent prostaatcarcinoom
castration-resistant AR-expressing salivary gland cancer
castration-resistant prostate cancer
CATCH
CATCH program
catch-up HPV-vaccination
CATNON study
CATNON trial post-hoc analysis
CATNON-studie
catumaxomab
caudate lobe solitary HCC
cause of death
cause-specific mortality
cause-specific mortality after initial chemotherapy
causes of death
causes of death after breast cancer diagnosis
causes of death among Finnish women with breast cancer
CAVE trial
CBC
CBC prediction
CBC risk
CBC-risico
CBCSG010 study
CBT-I
CBTRUS
CBTS
cc mRCC
CC-220-MM-001 trial
CC-223
CC-486
CC-92480-MM-001 Study
ccA and ccB molecular subtypes
CCEC
CCNE1 expression
CCR7
ccRCC
ccRCC brain metastases
CCRT
CCRT with or without nimotuzumab
CCSS
CCSS cohort
CCTG HE1 study
CD103+ immune cells
CD123 surface expression
CD19 CAR-T cell therapy
CD19 CAR-T cell therapy in children and young adults
CD19 CAR-T for large B-cell lymphoma
CD19-directed CAR T cell therapy
CD19-directed CAR T-cell therapy
CD19-positive lymphoid tumors
CD20-positive diffuse large B-cell lymphoma
CD22-directed CAR T-cell therapy
CD4
CD4 CD8 ratio
CD4+ percentage
CD45-targeted antibody-radionuclide conjugate
CD47 blockade plus rituximab
CD8+ T cell infiltration
CDG
CDH1 mutation carriers
CDK12-mutated prostate cancer
CDK4 6 inhibition
CDK4 6 inhibitor plus AI
CDK4 6 inhibitor plus fulvestrant
CDK4 6 inhibitors
CDK4 6-inhibitors for breast cancer
CDK4 6-remming
CDKN2A alterations in solid tumors
CDKN2A homozygous deletion
CDKN2C
CDS
CDX-110
CDX2
CEA
CEA-specifieke T-cel respons
cediranib
cediranib plus olaparib
cediranib with or without lenalidomide
CEGT
celecoxib
CELESTIAL trial
celiac plexus radiosurgery
cell nest size
cell-free circulating tumor DNA variant allele frequency
cell-free DNA multicancer early detection test
cell-free Epstein-Barr virus DNA
cell-free urine
cellulaire immuuntherapie
cellular immune activation
CelTIL score
CelTIL-score
celvrij circulerend tumor DNA
cemiplab versus investigator’s choice chemotherapy
cemiplimab
cemiplimab after HHIs
cemiplimab plus chemotherapy
cemiplimab Q4W
central adiposity
central adiposity and risk of subsequent breast cancer by menopause status
centrale adipositas
centrally located HCC
ceralasertib (AZD6738)
ceralasertib plus durvalumab
cerebellopontine angle tumors
cerebrospinal fluid microRNA signatures
cerebrospinal fluid tumor DNA genotyping
cerebrospinale vloeistof
ceritinib
cervical cancer
cervical cancer and precancer risk
cervical cancer incidence
cervical cancer patients with or without mental disorder
cervical cancer screening
cervical cancer survivors
cervical chordomas
cervical conization
cervical dysplasia after HPV vaccination
cervical HPV-testing
cervical neoplasia
cervical screening
cervicale glandulaire neoplasie
cervicale intra-epitheliale neoplasie graad 3
cervicale intraepitheliale neoplasie
cervicale-slokdarmkanker
cervixcarcinoom
cervixcarcinoomscreening
cervixconisatie
cervixkanker
cervixkankerscreening
cervixlaesies
cesarean delivery
cesium-131 brachytherapy
CESM
CeTeG NOA-09 study
CETSA
cetuximab
cetuximab maintenance
cetuximab plus nivolumab
cetuximab-IRDye800
cetuximab-related infusion reactions
cetuximab-resistant recurrent metastatic HNSCC
cetuximab-resistentie
CEVOREM trial
CF-WBI
cfDNA
cfDNA blood-based test for CRC screening
cfDNA genotyping
cfDNA in CSF
cfDNA methylation signatures
CFS
CGC
CGT
cGVHD
cGVHD in pediatric patients
ch
CH and subsequent lung cancer risk
CH and t-MN
CH in long-term pediatric cancer survivors
CHAARTED trial eight-year survival
CHAARTED-analyse
CHAARTED-studie
CHANCE2201 study
change in mammographic density
change in PD-L1 expression
change in serum uric acid level
change in trust in US government health agencies
change of breast cancer subtype during neoadjuvant chemotherapy
changes from 1993-2015
changes in alcohol consumption
changes in cancer diagnoses and stage distribution
changes in length and complexity of oncology guidelines since 1996
changes in survival since 1995
changes in taste and smell of food
changes in urological cancer surgical volume and length of stay
changes in weight and waist circumference during menopause
changes of body mass index or waist circumference
changes of diet after cancer diagnosis
characteristics and outcomes
characteristics and prognosis
characteristics and prognosis of luminal and basal subtypes
characteristics in young versus old patients
characteristics of high-volume lung segmentectomy hospitals
Charlson-score
CHART trial
CHB
ChcekMate 066 five-year results
CHD
CheckMate 012
CheckMate 016-studie
CheckMate 017 and 057 trials
CheckMate 017 en 057
CheckMate 017 en CheckMate 057
CheckMate 017-studie
CheckMate 025
CheckMate 026-studie
CheckMate 032 study
CheckMate 037
CheckMate 040
CheckMate 040 cohort 6
CheckMate 040 five year follow-up
CheckMate 040 study
CheckMate 064
CheckMate 066
CheckMate 066 study
CheckMate 067
CheckMate 067 five-year survival
CheckMate 067 trial
CheckMate 069
CheckMate 069 066 en 067
CheckMate 078
CheckMate 141
CheckMate 141-studie
CheckMate 142
CheckMate 142 first-line therapy cohort
CheckMate 143 study
CheckMate 153
CheckMate 204
CheckMate 204 study
CheckMate 205 study
CheckMate 214
CheckMate 214 long-term follow-up
CheckMate 214 study
CheckMate 214 trial
CheckMate 214 trial 42-months results
CheckMate 227
CheckMate 227 part 1 three-year update
CheckMate 227 study
CheckMate 227-studie
CheckMate 238 and EORTC 18071
CheckMate 238 five-year follow-up
CheckMate 238 four-year results
CheckMate 238-studie
CheckMate 274
CheckMate 275
CheckMate 358
CheckMate 358 trial
CheckMate 370-studie
CheckMate 384 study
CheckMate 401
CheckMate 436 study
CheckMate 459 trial
CheckMate 511 trial
CheckMate 568
CheckMate 577 study
CheckMate 648
CheckMate 648 study
CheckMate 649
CheckMate 649 3-year follow-up
CheckMate 649 HRQOL analysis
CheckMate 743 trial
CheckMate 76K trial
CheckMate 77T
CheckMate 816 study
CheckMate 816 trial
CheckMate 817
CheckMate 901
CheckMate 908
CheckMate 914 trial part A
CheckMate 920 study
CheckMate 9ER long-term follow-up analysis
CheckMate 9ER study
CheckMate 9ER trial
CheckMate 9KD
CheckMate 9LA study
CheckMate studies
CheckMate-032 study
CheckMate-067
CheckMate-142
CheckPAC trial
checkpoint blockade
checkpoint blockade immunotherapy
checkpoint inhibitor therapy
checkpoint inhibitor-resistant metastatic melanoma
checkpoint inhibitors for various types of melanoma
checkpoint kinases
CHEERS
CHEK2 1100delC
CHEK2 germline pathogenic variants
CHEK2-mutaties
CHEK2*1100delC
chemerin plasma concentration
chemobrain
chemoimmunotherapy
chemoimmunotherapy in patients with a poor performance status
chemopreventie mammacarcinoom
chemopreventie van mammacarcinoom
chemoprevention of CRC
chemoprevention of recurrence
chemoprevention with low-dose aspirin
chemoradiation plus durvalumab
chemoradiotherapie
chemoradiotherapy
chemoradiotherapy versus radiotherapy
chemoradiotherapy with proton versus photon therapy
chemorefractory BTC
chemorefractory metastatic colorectal cancer
chemorefractory or relapsed gestational trophoblastic neoplasia
chemoresection
Chemoresistentie
chemosensitizatie
chemotherapie
chemotherapie tijdens zwangerschap
chemotherapie-geïnduceerd ovariumfalen
chemotherapie-geïnduceerd POF
chemotherapie-geïnduceerde febriele neutropenie
chemotherapie-geïnduceerde misselijkheid en braken
chemotherapy
chemotherapy adherence
chemotherapy after colorectal cancer liver metastasectomy
chemotherapy after progression on EGFR-TKIs
chemotherapy alone versus combined modality therapy
chemotherapy and ICU admission in last phase of life
chemotherapy and radiotherapy long-term adverse impact on dental health
chemotherapy benefit
chemotherapy demands
chemotherapy for breast and prostate cancer
chemotherapy for breast cancer
chemotherapy for childhood cancer
chemotherapy for CRC
chemotherapy for early-stage breast cancer in older women
chemotherapy for EBC
chemotherapy for nonmetastatic breast cancer
chemotherapy for pediatric AML
chemotherapy free treatment
chemotherapy plus atezolizumab for NSCLC
chemotherapy plus immunotherapy
chemotherapy plus pembrolizumab versus chemotherapy
chemotherapy plus ponatinib
chemotherapy regimens
chemotherapy response
chemotherapy response score
chemotherapy timing in pregnancy
chemotherapy use
chemotherapy versus observation
chemotherapy with bevacizumab or temsirolimus
chemotherapy with or without cetuximab
chemotherapy with or without pembrolizumab
chemotherapy with versus without bevacizumab
chemotherapy with versus without total hysterectomy
chemotherapy-associated cognitive fatigue and evening physical fatigue
chemotherapy-free treatment
chemotherapy-induced alopecia
chemotherapy-induced amenorrhea
chemotherapy-induced anemia
chemotherapy-induced cardiotoxicity
chemotherapy-induced nausea and vomiting
chemotherapy-induced neutropenia in adult NSCLC-patients
chemotherapy-induced ovarian dysfunction in breast cancer patients
chemotherapy-induced peripheral neuropathy
chemotherapy-induced thrombocytopenia
chemotherapy-induced toxicities
chemotherapy-ineligible HL patients
chemotherapy-naïve non-squamous NSCLC
chemotherapy-related amenorrhea
chemotherapy-related cognitive impairment
chemotherapy-related hematological toxicity
chemotherapy-related toxicities
chemotherapy-related vomiting in children and adolescents
chest CT plus x-ray versus x-ray follow-up
chest radiation for childhood cancer
chest-irradiated cancer survivors
CHF
CHHiP-studie
chiauranib
child and adolescent survivors of malignancies
child self-report versus caregiver report
Child-Pugh class B
childbearing potential
childbirth
childhood ALL
childhood ALL survivors
childhood AML
childhood and adolescent ALL in The Netherlands 1990-2015
childhood and AYA cancer survivors
childhood and young adult ALL
childhood B-ALL
childhood B-cell ALL
childhood brain tumors
childhood cancer
childhood cancer survival in immigrants
Childhood Cancer Survivor Study
childhood cancer survivors
childhood central nervous system tumors
childhood leukemia
childhood leukemia among offspring
childhood leukemia and lymphoma survivors
childhood leukemia risk
childhood leukemia; maternal hormonal contraception use
childhood medulloblastoma survivors
childhood nasopharyngeal carcinoma
childhood ovarian non-seminomatous germ cell tumors
children
children and adolescents with cancer
children and AYAs with cancer
children with cancer
children with cancer at home
children with FA or AT
Children’s Oncology Group
Children’s Oncology Group AALL0434 study
Children’s Oncology Group study
Children’s Oncology Group Study AALL03N1
chimeric antigen receptor
China Kadoorie Biobank cohort
Chinese Alliance for Research in Thymomas database
CHIP
chirurgie
cHL
cHL after PD-1 blockade monotherapy
cHL in young patients
cHL survivors
CHM
choice between first-line endocrine versus chemotherapy
CHOICE-01 trial
cholangiocarcinoma
cholangiocarcinoom
cholecystitis
cholesterol lowering drug use and breast cancer survival
chondrosarcoma
chondrosarcoom
CHOP
CHOP with or without alemtuzumab
chordoma
chordoom
chromische lymfocytische leukemie
chromocolonoscopy versus white-light colonoscopy
chromosoom 21
chromosoominstabiliteit
chromothripisis
chronic comorbidities
chronic fatigue in long-term survivors
chronic health conditions
chronic hepatitis B
chronic irAEs
chronic liver disease mortality
chronic lymphocytic leukemia
chronic musculosketal pain in cancer survivors
chronic myeloid leukemia
chronic myeloid leukemia in chronic phase
chronic myelomonocytic leukemia
chronic neutrophilic leukemia
chronic pain
chronic phase CML
chronic radiation-induced xerostomia
chronical medical conditions and late effects in survivors
chronisch graft-versus-host disease
chronische fase CML
Chronische fase-CML
chronische lymfatische leukemie
chronische lymfocytische leukemie
chronische lymfoide leukemie
chronische myelomonocytische leukemie
CHRONOS trial
Chronos-1
CHRONOS-1 study two-year follow-up
CHRONOS-3 study
CHRYSALIS cohort E
CHRYSALIS study
chubb
chyleuze ascites
chylothorax and chylous ascites
CI versus CE
CIA
cigarette type
CIK therapy
cilengitide
cilta-cel
cilta-cel for RRMM in Chinese patients
ciltacabtagene autoleucel
CIMBA
cimetropium bromide
CIMP
CIN
CIN 3
CIN2 3
CIN2 3 spontaneous regression
CIN2+ detection
CINP
cinrebafusp alfa
CINV
CIO
CIOD
CIP
CIPN
CIPN in breast cancer survivors
cirAEs
circadiaan ritme
CIRCULATE-Japan GALAXY
circulating AR-status and resistance to Lu-177-PSMA-617
circulating biomarkers
circulating breast cancer risk factors in normal weight postmenopausal women
circulating cytokines
circulating DNA
circulating estradiol level
circulating HPV DNA
circulating immune cells
circulating immune markers
circulating levels of specific lipid groups
circulating lipids and breast cancer prognosis
circulating protein biomarkers for CRC risk
circulating proteins
circulating sex hormone levels
circulating tumor cell-count driven therapy
circulating tumor cells
circulating tumor DNA
circulating tumor DNA analysis
circulating tumor DNA kinetics predict outcomes
circulerend DNA
circulerend tumor-DNA
circulerende tumorcellen
circulerende tumorcellen; detectie nieuwe mutaties
circulerende vetzuren
CIRT
CIRT for unresectable pelvic bone sarcoma
CIRT versus en bloc resection
CISIG
cisplatin
cisplatin and fluorouracil versus carboplatin and paclitaxel
cisplatin for cancer in children
cisplatin-induced hearing loss in children and AYAs
cisplatin-ineligible operable high-risk UC
cisplatin-related hearing loss and tinnitus
cisplatin-unfit NSCLC patients
cisplatine
cisplatine plus gemcitabine and IMRT
CITADEL-203
CITN-10 study
citrusfruit
CITYSCAPE trial
cixutumumab
CL versus cBCS
cladribine
cladribine and low-dose cytarabine-based regimens
CLAP study
ClarIDHy study
ClarIDHy trial
CLARITY study
CLASS-01 trial
CLASS02 trial
classic and variant hairy cell leukemia
classic Hodgkin lymphoma
classic or endemic KS
classical Kaposi sarcoma
CLASSICAL-Lung clinical trial
claudine 18.2
CLDN18.2-positive gastric or gastroesophageal adenocarcinoma
CLDN18.2-redirected CAR T cells for gastrointestinal cancers
CLEAR
clear cell renal cell carcinoma
CLEAR study
CLEAR trial
CLEOPATRA study final results
Clevers
clinical actionability of cancers
clinical and genetic risk factors
clinical and genomic risk
clinical and lifestyle characteristics
clinical and molecular features
clinical and molecular predictors of very late recurrence
clinical benefit and regulatory outcomes
clinical benefit of genomicprofiling
clinical calculator for prediction of recurrence
clinical characteristics
clinical characteristics and outcomes
clinical features
clinical features and outcomes
clinical features for prediction of survival
clinical impact of tumor burden
clinical management
clinical meaningful outcomes
clinical models to predict response and survival
clinical outcomes
clinical outcomes and prognostic factors
clinical prognostic stage group system
clinical significance of adult T-cell leukemia lymphoma
clinical stage I gastric cancer
clinical stage I nonseminoma
clinical stage I NSCLC
clinical stage I seminoma
Clinical Treatment Score at 5 years
clinical trial effect
clinical trial enrollment
clinical trial evidence
clinical trial participation
clinical trials
clinical utility of qPCR plasma EGFR mutation detection in advanced lung cancer
clinical value
clinically N2 non-small cell lung cancer
clinically node-positive breast cancer
clinically node-positive breast cancer with downstaging to ypN0 after NACT
clinician-level knowledge
clinicogenomic classifier
clinicopathologic characteristics
clinicopathologic features
clinicopathologic phenotype
clinicopathological characteristics
clinicopathological features and prognosis after RO resection
clinicopathological predictors of outcomes
CLL
CLL 2007 SA-studie
CLL in patients intolerant to BTK inhibitor or PI3K inhibitor
CLL in younger patients
CLL resistant to venetoclax
CLL SLL
CLL therapies after venetoclax discontinuation
CLL therapy guided by MRD
CLL with coexisting conditions
CLL with comorbidities
CLL with TP53 aberrations
CLL-IPI
CLL10
CLL14 study
CLL14 trial
CLL2-BAG study
CLLM1-studie
CLM
CLND
clofarabine
clofarabine plus total body irradiation conditioning
CLOG1302-studie
CLOLE
clomid
clomifeen
clomifeencitraat
clonal hematopoiesis of indeterminate potential
Clozel
CLUE II cohort
CME
CML
CML after ABL kinase inhibitor failure
CML in chronic phase
CML in chronic phase in older patients
CML with T351I mutation
CML without MMR after 2 years of TKI
CML-BP
CML-CP
CML-CP after 2 or more TKIs
CML-studie IV
CMM
CMML
CMML and sAML
CMS risk
CMSs
CMV
CMV viremia after hematopoietic stem cell transplant
CMV-viremie
CN-AML
cN+ M0 BCa
CNAs
CNBSS
CNF
CNS disease
CNS disease control with cranial radiotherapy and ICIs versus chemotherapy
CNS efficacy
CNS efficacy analysis
CNS lymphoma
CNS metastases
CNS metastases of breast ancer
CNS metastasis
CNS NGGCTs
CNS relapsed or refractory B-ALL
CNS response
CNS tumors
CNS tumors in children
CNS tumors in young adult patients
CNS-DLBCL
CNS-lymfoom
CNS-metastasen
CNS-recidief HER2-tumoren
CNS-tumoren
CNS-tumoren; impact van behandelcentrum
CNSL
CNV signature
co-occuring MET amplification
co-occuring NOTCH and HR mutations
CO.26 study
coadministration of CD19- and CD22-directed CAR T-cell therapy
cobas
cobimetinib
cobimetinib plus vemurafenib
COBRA KAI Study
COBRA study
COBRA-score
coBRIM-studie
cochlear radiation dose
CodeBreaK 101 substudy
CodeBreaK 200
CodeBreaK 200 trial
CodeBreaK100 trial
codon 12 13 versus codon 61 mutation
coffee intake
COG AALL0232 study
COG AALL0434
COG AALL0622-studie
COG AALL0932 study
COG AALL1231 trial
COG AALL1331 study
COG AALL1621
COG AAML0631-studie
COG AAML1331 trial
COG AEWS0031 trial
COG ARAR0331 study
COG AREN0533-studie
COG trial ACNS0333
COG-studie AAML0531
COG-studie AREN0532
cognitief functioneren
cognitieve disfunctie
cognitieve klachten
cognitieve veranderingen na chemotherapie
cognition
cognition after endocrine versus chemoendocrine therapy
cognitive and behavioral development of 9-year-old children
cognitive and functional toxicities
cognitive and neurobehavioral impairment
cognitive decline
cognitive functioning
cognitive performance
cohabitation and breast cancer risk
COIN colorectal trial
colectomie
colitis-associated CRC risk prediction
collider stratification bias
COLOFOL-studie
Cologuard
colon and rectal cancer
colon cancer
colon cancer drug metabolism
Colon Cancer Family Registry
colon cancer peritoneal recurrence
colon cancer risk
colon cancer surgery
colon surgery
colon-NET
coloncarcinogenese
coloncarcinoom
colonkanker
colonoscopic diagnosis of early-onset versus average-onset CRC
colonoscopie
colonoscopy after positive FIT
colonoscopy bowel preparation
colonoscopy in individuals older than 75 years
colonoscopy screening
colonoscopy screening intervals
colonoscopy-based CRC screening
COLOPEC trial
colorectaakanker
colorectaaladenomen
colorectaaladenoom
colorectaalcarcinoom
colorectaalkanker
colorectaalkankerscreening
colorectaalneoplasie
colorectaalpoliepen
colorectal
colorectal adenomas
colorectal cancer
colorectal cancer incidence in Americans approaching screening age
colorectal cancer lever metastasis
colorectal cancer molecular subtypes
colorectal cancer mortality
colorectal cancer precursors
colorectal cancer risk
colorectal cancer screening
colorectal cancer survival models
colorectal carcinogenesis
colorectal liver metastases
colorectal neoplastic polyps
colorectal peritoneal metastasis
colorectale chirurgie
colorectale levermetastasen
colorectale neoplasie
coloscopie
COLUMBA study
COLUMBUS trial
COLUMBUS trial 5-year update
COMBI-AD
COMBI-AD studie
COMBI-AD study
COMBI-d studie
COMBI-MB studie
COMBI-v
CombiDT
combination antiemetics
combination of genetic and environmental risk scores
combination of HAI and systemic chemotherapy
combination of HDAC and mTOR inhibition
combination of ICI and TKI
combination of ICIs
combination of osimertinib and bevacizumab
combination strategy
combined analysis of N9831 and NSABP B-31
combined BRAF- and MEK-inhibition plus PD-1 blockade
combined CTLA-4 and PD-1 inhibition
combined effect of breast density and BMI
combined inhibition of PD-1 and BRAF and MEK
combined lifestyle factors
combined modality treatment
combined nivolumab and bevacizumab
combined PD-1 blockade and VEGF inhibition
combined risk factors score
combined surgical approach
combined-modality therapy
COMFORT-studies
COMMAND study TP53-mutated AML
COMMANDS trial
commercial gene expression tests
commercial tisagenlecleucel
common cancers
common medications
CoMMpass study
community jury
comorbid depression
comorbiditeiten
comorbidities
comorbidity prevalence in cancer
comparative safety of ICIs
comparison between men and women
comparison Hong Kong and USA
comparison of 5-aza and HSCT
comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing HSCT
comparison of black and white patients
comparison of CBT and MRDT
comparison of clinical studies and real-world outcomes
comparison of early-onset and average-onset colorectal cancers
comparison of first-line treatments
comparison of five guidlelines
comparison of outcomes across neoadjuvant and adjuvant treatments
comparison of PD-L1 protein expression between primary and metastic lesions
comparison of survival by treatment type
comparison of systemic treatments
comparison of three MIBG regimens
comparison of two induction therapies
comparison of two RT fractionation schedules
COMPASS study
COMPASS trial
COMPASSION-03 trial
COMPASSION-04 trial
COMPASSION-16 trial
CompLEEment-1 trial subgroup analysis
complementaire en alternatieve behandelingen
complementary and alternative medications
complementary medicine
complete mesocolic excision
complete remission with vismodegib
complete response to neoadjuvant CRT
COMPLETE study
completion of chemotherapy for breast cancer
complex cancer surgery
complex gastrointestinal cancer surgery
complex karyotype
complication rate and outcomes
complication risk
complications after surgery for colorectal cancer
complications of axillary surgery
COMPOSE-studies
composite GRFS and CRFS outcomes
compromised immune microenvironment
computationele pathologie
computed tomography screening
computer-assisted colorectal adenoma detection
Computer-geassisteerde chirurgie
CONCERTO trial
CONCERVE Study
conclusions of publcations
concomitant discontinuation of adjuvant hormone therapy and cardiovascular therapy
concomitant mutations
concomitant PPIs
concomitant PPIs and CDK4 6 inhibitors
concomitant use
CONCORD-2
CONCORD-3
CONCORD-3 study
concurrent capecitabine and stereotactic radiation
concurrent cetuximab and nivolumab
concurrent chemoradiotherapy
concurrent chemoradiotherapy with IMRT versus IMPT
concurrent CRT followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil
concurrent intrathecal and intravenous nivolumab
concurrent olaparib and radiotherapy
concurrent tissue and ctDNA profiling in a multicancer cohort
concurrent use of anticoagulants and ibrutinib
conditional cancer-specific survival
conditional immune toxicity rate
conditional local recurrence risk
conditional recurrence-free survival
conditional relative survival
conditional risks of BF and PCSD
conditional survival
conditional survival after five recurrence-free years
conditional survival after resection
conditionele ziektevrije overleving
conditioning after autoHCT
conditioning with G-CSF and decitabine
CONDOR trial
CONFIRM trial
congenital heart disease
congenital tooth agenesis
congestive heart failure
conjunctival melanoma
CONKO-004
connexine 30
consecutive mammography screening examinations
consensus definitions
consensus molecular subtypes
consequences of negative confirmatory trials
conservative management
CONSIGN
consistent physical activity
CONSOLE study
consolidation radiotherapy
consolidation with WBRT or stem-cell transplantation
consoliderende radiotherapie
Consomic Xenograft Model
constitutional mismatch repair deficiency syndrome
CONTACT-01 trial
CONTACT-03 trial
contemporary hormonal contraception
contemporary immuno-oncology combination therapy
contemporary lenalidomide-based regimens
contemporary radiation therapy for ESFHL
CONTESSA 2 study
continuation of lorlatinib beyond progressive disease
continuation of screening after age 70 years
continuous growth model
continuous lenalidomide maintenance for MM
continuous tumor-size-based end points
continuous versus 1-year nivolumab
continuous versus intermittent dosing of dabrafenb-trametinib
CONTINUUM trial
CONTINUUM-studie
contralateraal mammacarcinoom
contralateral breast cancer
contralaterale borstkanker
contralaterale mastectomie
contralaterale profylactische mastectomie
convalescent plasma therapy
conventional versus hypofractionation
conventional versus moderate hypofractionated RT
conversion surgery
CONVERT-studie
CONVINCE-studie
coopERA Breast Cancer trial
copanlisib
copanlisib for tumors with PIK3CA mutations
copanlisib plus gemcitabine
COPD
COPD and lung cancer
copy number alteration screening
copy number loss
CORE-001 trial
coronary artery calcifications
corpus uteri cancer
correlation between RFS and OS after resection of CLM
correlation between surrogate end points and overall survival
correlation of CTCs or DTCs with Oncotype DX recurrence score
correlation with overall survival
corticosteroid refractory ICI-induced enterocolitis
corticosteroïden
corticosteroids
corticosteroids for immune-related adverse events
cosibelimab
COSMIC-021 cohort 6
COSMIC-021 study
COSMIC-311 study
COSMIC-312 trial
COSMIC-313
COSMIC-313 trial
COSMOS trial
cost-effective global care for cancer in children
cost-effectiveness
cost-effectiveness of CAR T-cell therapy
cost-effectiveness of intraoperative MRI
cost-effectiveness of lung cancer screening
cost-effectiveness of nivolumab-ipilimumab combination therapy
cost-effectiveness of prostate RT
cost-effectiveness of surveillance
Costa RIca
Costa Rica HPV Vaccine Trial
cotinine
COVID-19
COVID-19 after CAR T-cell therapy for B-cell malignancies
COVID-19 among US cancer survivors
COVID-19 and rates of cancer diagnosis in the US
COVID-19 first wave
COVID-19 hospitalized patients
Covid-19 hospitalized patients with lymphoma
COVID-19 in patients with hematological malignancies
COVID-19 in patients with thoracic malignancies
COVID-19 incidence and mortality
COVID-19 lockdown
COVID-19 mortality in patients with various cancers
COVID-19 mortality risk
COVID-19 mRNA vaccine
COVID-19 outcomes
COVID-19 pandemic
COVID-19 sequelae
COVID-19 severity and outcomes in patients with cancer
COVID-19 vaccination
COVID-19 vaccine
COVID-19-infected cancer patients
COVIDSurg Collaborative
COX-2 inhibition
coxibs
CP-B uHCC
CP-CML
CP-genen
CPA use
CpG-B
CPI-613
CPIs
CPM
CPPT
CPRC5D-targeted CAR T cells
CPX-351
CR after LRT plus IO
CR24
CRA
craniopharyngioma
craniopharyngioma in adults
craniotomie
CRB-401 phase 1 trial
CRBSI
crc
CRC and precursor lesions in adults younger than 50 years
CRC detection
CRC diagnosis
CRC in Taiwan
CRC incidence
CRC incidence and mortality
CRC incidence and mortality after polypectomy
CRC incidence and mortality after snigle negative screening colonoscopy
CRC incidence and mortality in Asia
CRC incidence in Canada
CRC intrinsic subtypes
CRC liver metastases
CRC lung metastasis patients
CRC prevention
CRC prognosis
CRC risk
CRC risk among survivors
CRC risk associated wiht lifetime excess weight
CRC risk following polypectomy
CRC risk in Lynch syndrome
CRC screening in European countries
CRC screening program
CRC stage at diagnosis before versus during the COVID-19 pandemic
CRC stage distribution
CRC surgery in older patients
CRC survival
CRC survivors
CRC with asymptomatic synchronous metastases
CRC with BRAF V600E mutation
CRC with ERBB2 amplification overexpression
CRC with G12C-mutation
CRC with high tumor mutaional burden
CRC-biomarkers
CRC-diagnose
CRC-PM
CRC-PREVENT trial
CRC-risico
CRC-screening
CRCD
CRCPM
CREATE-studie
crenigacestat
cretostimogene grenadenorepvec plus nivolumab
CRF
cribriform groeipatroon
CRICKET trial
crizotinb
crizotinib
crizotinib plus chemotherapy
crizotinib-resistant ALK-positive NSCLC
CRLM
CRLX101
CRN
crofelemer for CID
Crohn’s disease
CRONOS study
CROSS
CROSS trial ten-year outcomes
CROSS versus FLOT
CROSSFIRE trial
crossover or pembrolizumab rechallenge after recurrence
CROWN study
CROWN Trial
CRP
CRP flare-response
CRP-niveau
CRPC
CRPC with bone metastases
CRS
CRS + HIPEC
CRS for advanced-stage OC
CRS HIPEC
CRS plus chemotherapy versus chemotherapy alone
CRS plus HIPEC
CRS with or without HIPEC
CRS-207
CRS-HIPEC
CRS-HIPEC cost effectiveness
CRS-HIPEC for CRC PMs
CRS-HIPEC for CRPM
CRT
CRT and local excision versus TME for T2-T3ab N0 M0 rectal cancer
CRT as alternative for NSCLC surgery with predicted high risk of irradical resection
CRT for esophageal cancer
CRT for HNC
CRT for LA HNC
CRT versus CT
CRT with cisplatin versus cetuximab
CRT with liposomal paclitaxel plus cisplatin
CRT with or without metformin
CRTCOESC trial
cryoablation
cryoablation for lung metastases
cryoablation with excision
cryotherapy
CS tumors
CS1002 with or without CS1003
CSCC
cSCC of head and neck
cSCC risk after diagnosis actinic keratosis
CSCC-HN
CSCCs
CSF penetration of anti-PD-1 antibodies
CSM
CT
CT examinations
CT lung cancer screening
CT radiation exposure before age 22 years
CT-based biomarkers
CT-guided high-dose-rate interstitial brachytherapy
CT-longkankerscreening
CT-P10
CT-P6 versus trastuzumab
CT-screening longkanker
CT041
cT1-2N0 breast cancer
cT1T2No OTSCC
cTACE
CTCAE
CTCL
CTCs
CTCs and early relapse
ctDNA
ctDNA after NACT
ctDNA after neoadjuvant chemotherapy
ctDNA alterations
ctDNA analysis
ctDNA analysis to direct therapy
ctDNA analysis to guide adjuvant therapy
ctDNA and risk of progression after long-term response
ctDNA as a risk stratifying biomarker
ctDNA as biomarker of response to palbociclib-fulvestrant
ctDNA as marker of MRD
ctDNA as response indicator
ctDNA dynamics
ctDNA for early detection of MRD and risk stratification
ctDNA for monitoring disease status
ctDNA in CSF and plasma
ctDNA markers for early progression
ctDNA methylation
ctDNA methylation haplotypes
ctDNA mutations
ctDNA predicts response and prognosis
ctDNA profiling
ctDNA reflects response and survival
ctDNA response
ctDNA sequencing
ctDNA TMB and response to first-line pembrolizumab
ctDNA-guided de-escalation of targeted therapy
ctDNA-guided therapy
ctHPV DNA
ctHPV DNA in saliva
ctHPVDNA after surgery for HPV-associated OPSCC
ctHPVDNA monitoring in recurrence surveillance
CTL019 for pediatric B-ALL
CTLA-4
CTLA-4 blokkade
CTLC
CTONG1104 study
CTP
CTRCD
CTS5 risk score
CUDC-907
CUETO
cumulative burden of major surgical interventions
cumulative burden of psychiatric disorders and self-harm across 26 adult cancers
cumulative GRAS score
cumulative incidence of CIHL
cumulative incidence of CVD
cumulative risk of false-positive result
CUP
CUPISCO study
curatie
curative intent treatment for bladder cancer
curative-intent resection
CURB oligoprogression trial
current or former smoking
cutaan squameus celcarcinoom
cutaan squameus celcarcinoom van hoofd en hals
cutaan T-cel lymfoom
CUTALLO trial
cutane bijwerkingen
cutaneous adverse events
cutaneous BCC
cutaneous HNSCC with regional lymph node metastasis
cutaneous malignant melanoma
cutaneous melanoma
cutaneous melanoma survivors
cutaneous SCC
cutaneous squamous cell carcinoma
cutaneous toxicities
cutaneous toxicity
CUX1-ALK rearrangement
CV risk
CVD
CVD and stroke following cancer in older adults
CVD risk
CVD risk after GnRH agonists versus GnRH antagonists
CVD risk factors
CVD risk factors and colorectal cancer
CVEs
CVSS-studie
CX.5 SHAPE trial
CXB
CXCL8-CXCR1 2 axis
CXCR4 expression in lung cancer
CXM
cycline D1
cyclofosfamide
cyclophosphamide
cyclophosphamide for prevention of aGVHD
cyclophosphamide-bortezomib-dexamethasone
cyclophosphamide-free chemotherapy for ovarian protection
CYP2D6 genotype
CYP3A
CYPIDES trial
cyproteronacetaat
cyramza
cystatin-C
cystectomie
cystectomy versus trimodality therapy
cytarabine
CYTO-CHIP study
CyTOF of peripheral blood
cytogenetically defined high-risk multiple myeloma
cytogenetisch normaal AML
cytokine levels
cytokine-induced killer cell therapy
cytokines
cytology testing
cytoreductive surgery
Cytosponge-trefoil factor 3
D-2-hydroxyglutaraat
D-index-guided early antifugal therapy
D-Rd
D-Rd versus Rd
D-TORCH trial
D-VCd
D-Vd versus Vd
D-VMP
D-VTd versus VTd
D-VTd versus VTd for newly diagnosed multiple myeloma
DA-EPOCH plus InO
DA-EPOCH-R versus R-CHOP
DAAs
DaBlaCa-13 study
dabrafenib
dabrafenib plus trametinib
dabrefenib plus trametinib
dacarbazine for metastatic melanoma
dacomitinib
DADI
DAFI
daily aspirin
daily insulin dose
daily sitting time
daily step counts
dairy intake during adolescence and risk of colorectal adenoma
DAISY trial
DALLT cohort
dalpiciclib
Danish Breast Cancer Group Internal Mammary Node study
Danish Breast Cancer Group Partial Breast Irradiation Trial
Danish cancer patients
DAOH
DAPHNe trial
daratumumab
daratumumab for AL amyloidosis
daratumumab plus lenalidomide maintenance after transplantation
daratumumab-based regimens
daratumumab-based treatment
daratumumab-bortezomib-dexamethasone
darm-microbioom
darm-stamcellen
darmflora
darmkanker
darolutamide
darolutamide maintenance
darolutamide plus ADT
DARPin drug candidate MP0250
DART S1609 neuroendocrine cohort
DART SWOG 1609
DART SWOG 1609 Cohort 47
DART SWOG S1609
DART-studie
dasatinib
dasatinib plus blinatumomab
dasatinib plus dendritic cell vaccines targeting TBVAs
dasatinib versus imatinib
DASCERN randomized study
DASFREE 5-year analysis
DAstop2 trial
DATA-studie
Dato-DXd
Dato-DXd versus docetaxel
David A. Karnofsky Memorial Award and Lecture
DAVLEC trial
davoli
DAWN-studie
DAWNA-2 trial
DAWT
DB
DBCG 07-READ studie
DBCG HYPO trial
DBMS
DBT versus DM
DC-CIK
DCCSS-LATER 2 psycho-oncology study
DCCSS-LATER 3
DCd with or without P
DCE-MRI
DCF chemotherapy
DCIS
DCIS adjacent to IBC
DCIS and early stage HR-positive breast cancer
DCIS and node-negative breast cancer
DCIS before age 50 years
DCIS grading
DCIS in the male breast
DCIS of the breast
DCIS risk
DCIS size and margin status
DCOG-LATER cohort
DCOG-LATER cohort study
DCOG-LATER studie
dd BV plus ICE chemotherapy
dd-chemotherapie
DDCT
DDGP versus SMILE
DDLT
DDR gene aberrations
DDR gene mutations
DDR-HRR altered mCRPC
de novo HER2-positive metastatic breast cancer
de novo metastatic breast cancer
de novo metastatic nasopharyngeal carcinoma
de novo metastatic prostate cancer
de novo mHSPC
de novo stage IV breast cancer
de novo stage IV HER2-positive MBC
de novo stage IV versus distant metastatic recurrent NSCLC
De-ESCALaTE HPV study
de-escalation of axillary surgery
de-escalation of TKIs
DEAR study
death and dementia risk
death from unintentional injury among cancer patients
Debio 1143 plus high-dose cisplatin CRT
Debio0932
Decipher
decision support system
decision-making
decitabine
decitabine plus camrelizumab
dedifferentiated chordoma
deep learning
deep learning model
deep molecular response
deepening of response after completing therapy
defactinib
DeFi trial
deficient mismatch repair stage III colon cancer
definition of positive CRM
definitive local therapy
definitive radiotherapy
definitive RT
definitive stereotactic body radiotherapy
degarelix
DEL
delay of cancer surgery
delayed CINV in pediatric patients
delayed hearing loss
delayed immune-related adverse events
delayed surgical treatment
delirium
DeLLphi 300
DeLLphi-301 trial
dementia
demographic characteristics
dendritic cell-based immunotherapy
Denemarken
denosumab
denosumab or zoledronic acid in cancer patients
dense breast tissue
dentaal trauma
dental extractions and ORN risk
dental health and lung cancer risk
DEP KP80 study
depatux-M
depressie
depression
depression and suicidal ideation
depth of response
dermatofibrosarcoma protuberans
DESKTOP III trial
desmoïd
desmoid tumors
DESMOPAZ study
DESTINY study
DESTINY-Breast01
DESTINY-Breast01 study
DESTINY-Breast02
DESTINY-Breast02 trial
DESTINY-Breast03
DESTINY-Breast03 subgroup analyses
DESTINY-Breast03 trial
DESTINY-Breast04
Destiny-Breast06 trial
DESTINY-CRC01 trial
DESTINY-CRC02
DESTINY-Gastric01 study
DESTINY-Lung01
DESTINY-Lung01 trial
DESTINY-Lung02 trial
DESTINY-PanTumor01
DESTINY-studie
detectie
Detectie borstkanker
detectie colorectaalkanker
detecting genomic biomarkers in plasma versus tissue
detection advanced neoplasia
detection bias
detection early-stage OPSCC
detection of circulating tumor DNA after surgery for nmCRC
detection of colon cancer recurrences
detection of CTCs during follow-up
detection of germline variants
detection of invasion of detrusor muscle
detection of microsatellite instability
detection of mutations in ctDNA
detection of non-index lesions
detection of prostate cancer
detection of relapse
determinants of breast cancer risk
determinants of optimal adjuvant therapy
determinants of outcomes
determinants of survival
determinants of tumor cell PD-L1 expression
determinants of uptake of active surveillance
determinants of xerostomia
development of new drugs
devimistat in combination with gemcitabine and cisplatin
dexamethason
dexamethasone
dexanethasone
dexrazoxane
DFCI 11-001 study
DFP-10917
DFS
DHA
DHAP
DHL
DHL and THL
diabetes
diabetes and cancer risk
diabetes in long-term cancer survivors
diabetes mellitus
diagnose longcarcinoom
diagnosis and treatment
diagnostic low-dose ionizing radiation in youth
diagnostic scrutiny
diagnostic value of FDG PET CT
diagnsotic performance of feacal immunochemical test
DICER1 pathogenic variants
diet and survival
diet qualiity
diet quality
diet quality and risk of prostate cancer grade reclassification during active surveillance
dietary carbohydrate quality and human health
dietary carbohydrates
dietary fat
dietary fiber
dietary fiber and yogurt
dietary intake
dietary intake of antioxidants
dietary modification and breast cancer mortality
dietary polyunsaturated fat
dietary sodium restriction
dietary supplement use
dietary supplement use and documentation
dietary supplement use during chemotherapy
differences in treatment outcomes
different cancer types
different types of plant-based dietary patterns and CRC risk
differential activity of PARP inhibitors
differential response to neoadjuvant endocrine therapy
differential ribosome measurements of codon reading
differentiated thyroid cancer
difficult patients
diffuse large B cell lymphoma
diffuse large B-cell lymphoma
diffuse large B-cell lymphoma-specific mortality
Diffuse midline H3K27-altered gliomas in the spinal cord
Diffuse optical spectroscopic imaging
diffuse type TGCT
diffuse-type giant cell tumor
diffusion-weighted MRI
diffuus grootcellig B-cel lymfoom
diffuus intrinsiek ponsglioom
difluoromethylornithine maintenance
digestive tract cancer
digital breast tomosynthesis
digital breast tomosythesis
digital remote monitoring
digital screening mammografie
DigniCap
digoxine
DII
DIP
DIPG
DIPG patients ≥ 10 years of age
DIPG-BATS studie
direct-acting antivirals
direct-to-patient outreach
discontinuation imatinib for CML in children
discontinuation of anti-PD-1 antibody therapy
discontinuation of first-line dasatinib for CML
discontinuation of immune suppression
discontinuation of TKIs for de novo CP-CML
discontinuous SBRT
discordance between CA-125 progression and RECIST progression
discordance between primary and matched metastatic breast cancer
disease burden
disease control after radiotherapy
disease progression in cancer patients
disease trajectories and mortality after breast cancer
disease-free survival
diseases and deaths in middle-aged adults
disontinuation of trastuzumab
disparaties in cancer incidence by sexual orientation
disparities
disparities by race ethnicity and age
disparities in access to high-volume pancreatectomy centers
disparity between children and AYAs
dispositional optimism
disruption of FIT-screening programmes
distal cholangiocarcinoma
distal rectal cancer
distale pancreatectomie
distant disease-specific survival
distant metastasis of salivary gland cancer
distant metastatic breast cancer
distant recurrence of breast cancer
distant versus supraclavicular lymph node metastases
DisTinGuish trial
distress
Distress Thermometer
divarasib
divarasib plus cetuximab
DLBCL
DLBCL in elderly frail patients
DLBCL in patients aged 18-65 years
DLBCL survivors
DLBCL-RT
DLGG
DM
DMFS
dMMR CC
dMMR colon cancer
dMMR MSI mCRC
dMMR MSI metastatic gastrointestinal cancer
dMMR MSI-H PaC
dMMR MSI-H solid tumors
dMMR PDAC
dMMR subgroup analysis
DMPM
DN
DNA damage immune response
DNA Damage Immune Response signatrue
DNA damage repair mutations
DNA damage response targeting treatments
DNA next-generation sequencing
DNA promoter-hypermethylering
DNA repair gene aberrations. platinum-base chemotherapy
DNA-methylering
DNA-test
DNA-thioguanine concentration
DNMT3A-mutatie
DOACs versus LMWH for prevention of recurrent VTE in cancer patients
DOACs versus LMWHs
docetaxel
docetaxel and trametinib
docetaxel-based neoadjuvant chemotherapy and en bloc resection
docetaxel-cyclophosphamide for breast cancer
docetaxel-PM plus trastuzumab-pkrb
documentaire
doelgerichte behandeling
DOLPHIN phase 2 nonrandomized trial
dominant TCR clone
donor clonal hematopoiesis
donor-derived anti-CD19 CAR T cells
donor-derived CD7 CAR T-cells
donor-derived expanded NK-cells to prevent relapse
DoR
dordaviprone (ONC201)
DOREMY study
dormancy-genen
dose dense doxorubicin-cyclophosphamide and-paclitaxel
dose optimization
dose reduction of preoperative RT
dose-adjusted EPOCH-R
dose-dense adjuvant chemotherapy plus trastuzumab
dose-dense versus standard chemotherapy
dose-individualized FP therapy
dosisescalatie
DOSISPHERE-01 study
dostarlimab
dostarlimab for endometrial cancer
dostarlimab in doublet triplet combinations
DOT1L
double expressor DLBCL
doublet therapy for de novo mCSPC
DOVIGIST-studie
Down syndrome and ALL in children and AYAs
downstaging before liver transplant
doxorubicin delivery from ultrasound-triggered liposomes
doxorubicin for adolescent and adult HL
doxorubicin for sarcoma
doxorubicin plus pembrolizumab
doxorubicin with or without ICI
doxorubicine
dPFSors after PD-1 blockade for melanoma or NSCLC
DPP-4 inhibition for aGVHD proylaxis
DPYD genotyping
DPYD*2A variant carrying cancer patients
DRAGON IV CAP 05 trial
DRD-positive mUC
DREAM study
DREAMM-2 study
DREAMM-2 trial final analysis
DREAMM-7
DREAMM-8 trial
DREAMseq trial
driver-negative advanced non-small cell lung cancer
drivers of patients rating of cancer care in Switzerland
droge mond
droplet digital PCR
DRRD
DRUG Access Protocol
Drug Rediscovery Protocol
drug response predictor
drug-drug interactions
drug-funding reimbursement
DRUP trial
drye eye syndrome
DSMM XI-studie
DSRCT
DSTP30865
dt-GCT
DTC
DTCs
DTX3 copy number in breast cancer
dual PD-1 and HER2 blockade for aGC
DUBLIN-3 trial
ductaal carcinoom in situ
ductal carcinoma in situ
DUD
dunne-darmadenocarcinoom
dunne-darmneoplasie
DUO Crossover Extension Study
DUO study
durability of response to SARS-CoV-2 BNT162b2 vaccine
duration of adjuvant trastuzumab
duration of ADT with postoperative radiotherapy
duration of androgen deprivation therapy added to RT for PCa
duration of immunotherapy
duration of response
DURIGAST trial
durvalumab
durvalumab after CRT
durvalumab and tremelimumab with definitive CCRT
durvalumab for NSCLC
durvalumab for solid tumors in HIV-1 infected patients
durvalumab or placebo after CRT for stage III NSCLC
durvalumab plus chemotherapy
durvalumab plus CRT
durvalumab plus gemcitabine and cisplatin
durvalumab plus olaparib
durvalumab plus olaparib plus cediranib
durvalumab plus radiotherapy
durvalumab plus targeted therapy
durvalumab plus tremelimumab
durvalumab with or without stereotactic body radiotherapy
durvalumab with or without tremelimumab
durvalumab-cisplatin-pemetrexed
DURVAST study
dutasteride
Dutch Bone Metastasis Study
Dutch MINDACT cohort analyis
Dutch trends in incidence and prognosis
duvelisib
duvelisib plus romidepsin
DV
DYNAMIC study
DYNAMIC trial
dynamics of ctDNA
DYNAMO study
DYPD genotyping
dysfagie
dyslipidemia
dyspnea in cancer patients
dyspnoe
E GEJ cancer
e-sigaretten
E1609 study
E1912 study
E1912 updated results
E2F8
E3805-studie
E3A06 study
E3N
E3N cohort
E4
E5103 study
E7389-EF plus nivolumab
E75
EA
EA2108 study
EAA
EAC
EAC and GEJ adenocarcinoma
EADC
EAGLE study
EAGLES study
early and locally advanced breast cancer
early AYAs
early breast cancer
early breast cancer or ductal carcinoma in situ
early breast cancer treatment
early cancer surveillance
early cervical cancer
early changes in ctDNA
early CRC
early CRP kinetics as predictive biomarker
early death
early detection and monitoring progression of gastric cancer
early detection and prognosis prediction
early diagnosis
early discontinuation of endocrine therapy
early donor identification
early experience
early HER2-positive breast cancer
early HR-positive breast cancer
early interdisicplinary supportive care
early intervention
early invasive breast cancer mortality
early local therapy
early markers for cardiovascular disease
early melanoma recurrence despite adjuvant anti-PD-1 therapy
early metabolic response
early mortality
early multinodular HCC
early noninvasive detection of response
early onset CRC
early onset female cancer survivors
early palliative care use
early phase ICI-trials
early prediction of chemoradiotherapy-induced cardiotoxicity
early prediction of response
early prediction of response or progression
early predictors of pathologic complete response to neoadjuvant therapy
early rectal cancer
early recurrence
early recurrence after resection
early relapse detection
early stage breast cancer
early stage breast cancer in older women
early stage breast cancer outcome
early stage EGFR-mutated NSCLC
early stage ER-positive breast cancer
early stage ER-positive breast cancer in older women
early stage prostate cancer
early stage TNBC
early stage triple-negative breast cancer
early thymic precursor acuut lymfoblastische leukemie
early thymic precursor-like phenotype ALL
early TNBC
early trastuzumab interruption
early triple-negative breast cancer
early-life alcohol intake
early-onset cancers
early-onset colorectal cancer
early-onset colorectal cancer among women
early-onset CRC
early-onset familial breast cancer
early-onset pancreas cancer
early-onset pancreatic cancer
early-onset severe infections
early-onset versus late-onset CRC
early-stage breast cancer
early-stage breast cancer in elderly patients
early-stage breast cancer in the elderly
early-stage breast cancer in young women
early-stage breast cancer recurrence
early-stage cancers
early-stage cervical cancer
early-stage cutaneous T-cell lymphoma
early-stage endometrial cancer
early-stage gastric cancer
early-stage hepatocellular carcinoma
early-stage HER2-positive breast cancer
early-stage Hodgkin lymphoma
early-stage HR-positive breast cancer
early-stage lung cancer
early-stage MCC
early-stage melanoma micrometastases
early-stage non-small cell lung cancer
early-stage non-small lung cancer
early-stage NSCLC
early-stage or isolated lung parenchymal recurrent node-negative NSCLC
early-stage oropharyngeal squamous cell carcinoma
early-stage PaC
early-stage pediatric HL
early-stage primary cutaneous melanoma
early-stage TNBC
early-stage unfavorable cHL
early-stage unfavorable classic Hodgkin lymphoma
early-stage unfavorable HL
EAST ENERGY trial
EBC
EBCC-12 postponed
EBMT ALWP study
EBRT for localized prostate cancer
EBRT for prostate cancer
EBV
EC
EC with ERBB2 3 alterations
EC with lymph node metastasis
EC-CRT-001
ECD
Echelon-1 studie
ECHELON-1 study
ECHELON-1 trial
ECHELON-2 study
ECHO-202 KEYNOTE-037
ECLIPSE trial
ECOG PS
ECOG PS 2
ECOG-ACRIN 2511 study
ECOG-ACRIN 5508 study
ECOG-ACRIN E1412 study
ECOG-ACRIN E1609 study analysis
ECOG-ACRIN E1912 study
ECOG-ACRIN E2211
ECOG-ACRIN E2810
ECOG-ACRIN E3311 trial
ECOG-PS
economic evaluation
ECX)
ED
ED-SCLC
ED-SCLC in elderly patients
Edinburgh Pain Assessment and management Tool
education level related inequalities in cancer mortality in Europe
educational level
educational outcomes
EE2012 trial
één-maands mortaliteit
eenarmige versus gerandomiseerde fase 2-studies
eerdere kanker
EF-14
efbemalenograstim alfa
effect modification
effect modifiers of low-dose tamoxifen
effect of immunotherapy time-of-day infusion
effect of racial concordance on patient trust
effect on early cancer detection
effectivity and safety of BNT162b2 vaccine in patients undergoing treatment for cancer
effects of GVHD on long-term outcomes
effects of HER2 alterations
efficacy of adjuvant chemotherapy
efficacy of BNT162b2 mRNA vaccine in patients with CLL
efficacy of ICIs
efficacy of immunotherapy
efficacy of medications for reduction of risk of primary breast cancer in women
EFVPTC
EGA
EGCG for prevention of postoperative RT-induced dermatitis in breast cancer patients
EGD for detection of gastric neoplasms
EGFR
EGFR amplification
EGFR amplified glioblastoma
EGFR copy number gain
EGFR ex20ins-mutant NSCLC
EGFR exon 20 insertion-mutated NSCLC
EGFR inhibition
EGFR inhibition resistance
EGFR mutant NSCLC
EGFR mutated advanced non-small cell lung cancer
EGFR mutated metastatic non-small cell lung cancer
EGFR mutated NSCLC
EGFR mutation status
EGFR mutation-positive advanced NSCLC
EGFR mutation-positive MET-amplified NSCLC after EGFR TKIs
EGFR mutation-positive NSCLC with leptomeningeal metastases
EGFR T790 mutated aNSCLC detected in plasma
EGFR T790M
EGFR T790M mutant NSCLC
EGFR T790M-positive advanced NSCLC with leptomeningeal metastases
EGFR T790M-positive NSCLC
EGFR T790M-positive NSCLC in elderly patients
EGFR therapy resistant NSCLC
EGFR wild-type aNSCLC
EGFR-amplified GEA
EGFR-amplified recurrent glioblastoma
EGFR-blokkade
EGFR-mutant and MET-amplified NSCLC
EGFR-mutant aNSCLC
EGFR-mutant lung adenocarcinoma
EGFR-mutant lung cancer
EGFR-mutant mNSCLC
EGFR-mutant non-small cell lung cancer
EGFR-mutant NSCLC
EGFR-mutant NSCLC with liver metastases
EGFR-mutant RET fusion-positive non-small cell lung cancer
EGFR-mutated advanced non-small cell lung cancer
EGFR-mutated advanced non-small-cell lung cancer
EGFR-mutated advanced NSCLC
EGFR-mutated aNSCLC
EGFR-mutated LA M NSCLC
EGFR-mutated lung adenocarcinoma
EGFR-mutated non-small cell lung cancer
EGFR-mutated nonsquamous NSCLC after EGFR-TKI therapy
EGFR-mutated NSCLC
EGFR-mutated NSCLC in elderly or frail patients
EGFR-mutated NSCLC with brain metastases
EGFR-mutated NSCLC with LMs
EGFR-mutatie
EGFR-mutaties
EGFR-TKI
EGFR-TKI with or without thoracic radiotherapy
EGFR-TKIs
EGFR-TKIs for stage IIIB IV EGFR-mutant NSCLC
EGFR-variant NSCLC
EGFR+ and ALK+ NSCLC
EGFRex20ins mutation-positive NSCLC
EGFRex20ins-positive mNSCLC
EHCC
eHealth support
eierstokkanker
eiwitbiomarkers
elacestrant
elacestrant (RAD1901)
ELCC 2017
elderly cancer patients
elderly HR-positive breast cancer patients
elderly patients
elderly patients with advanced non-small cell lung cancer
electric power morcellation
electroacupuncture
electroacupuncture for postoperative ileus
electronic nose
electroporated plasmid IL-12
ELEVATE TN study
ELEVATE-TN 4-year follow-up
elevated CRP
elevated platelet count
elevated vitamin B12 levels
ELIANA study QOL analysis
ELIANA trial
Eliasof
eliminating surgery
ELM-2 trial
ELOQUENT-3 study
ELOQUENT-3 trial
elotuzumab
elranatamab
ELRP
ELSA
eltrombopag
ELTS-score
emactuzumab
EMBARK trial
EMBRACA study
EMBRACA-studie
EMBRACE-I study
EMBRACE-studie
embryonale hersentumoren
EMD
EMERALD trial
emergency department use and unplanned hospitalization
EMERGING-CTONG 1103 study
emesis
emetogenic chemotherapy in pediatric patients
EMILIA
EMN09 study
emotionele uitputting
EMP of the head and neck
EMPIRE-1 study
EMPOWER-Cervical 1 trial
EMPOWER-Lung 1
EMPOWER-Lung 1 trial
EMPOWER-Lung 3
EMPOWER-Lung 3 part 2
EMPOWER-Lung 3 trial
EMT
EMVI
EMZL
ENACT trial
enasidenib plus azacitidine
encorafenib
encorafenib plus binimetinib
encorafenib-binimetinib-cetuximab
ENCORE-601 study
end of life use of systemic therapy
END versus observation
end-of-life care
end-of-life quality indicators
end-of-life zorg
ENDEAVOR-studie
ENDOANGEL system
endocriene behandeling
endocriene effecten
endocriene therapie
endocrine deficiency
endocrine diseases
endocrine pathways dysregulation
endocrine resistance
endocrine therapies
endocrine therapy
endocrine therapy adherence
endocrine therapy for breast cancer
endocrine therapy resistance
endocrine therapy response
endocrine treatment
endocrine treatment versus chemotherapy
endocrine-resistant ABC
endocrine-resistant mBC
endocrine-responsive lobular carcinoma of the breast
endometrial ancer
endometrial cancer
endometrial cancer risk
endometrial cancer surgery
endometrial cancer survival
endometrioïd endometriumcarcinoom
endometrioïd epitheliaal ovariumcarcinoom
endometriosis
endometriosis typology and ovarian cancer risk
endometrium-adenocarcinoom
endometriumcarcinoom
endometriumkanker
EndoPredict
endoprosthetic reconstruction for lower extremity bone tumors
endoscopic or open resection
endoscopic surgery versus intensity-modulated radiotherapy
endoscopist ADR
endotheliaal ovariumcarcinoom
ENDS
ENDURANCE trial
ENEC
energetic capacity
ENESTfreedom
ENESTfreedom trial
enfortumab vedotin
ENGOT-EN5 GOG-3055 SIENDO
ENGOT-EN6 GOG-3031 RUBY
ENGOT-OV16 NOVA study
ENGOT-OV16 NOVA trial
ENHANCE 1 study
enhanced recovery after surgery
enhancer of zeste homolog 2
ENITEC consortium
ENKTL
ENLIVEN study
enobosarm
ENOC
enocrafnib
ensartinib
ensartinib versus crizotinib
entecavir
entecavir with or without interferon-α
enteropancreatic neuroendocrine tumors
enterovirus
enthusiasm hypothesis
entinostat with nivolumab and ipilimumab
entospletinib
ENTRATA trial
entrectinib
Environmental Quality Index
ENZ or ABI for mCRPC
ENZ vs AA
ENZA-p trial
enzalutamide
enzalutamide for castration-resistant prostate cancer
enzalutamide plus trastuzumab
enzalutamide versus bicalutamide
ENZAMET study
ENZAMET trial
enzastaurine
EOC
EOC in Black women
EOC in high income countries
EOC stage IC2 IC3
EOCRC
EOCRC versus LOCRC
EOPC
EOPM
EORTC
EORTC 10995
EORTC 1325 Keynote-054 studie
EORTC 1325 KEYNOTE-054 study
EORTC 1325 KEYNOTE-054 trial
EORTC 1325-MG KEYNOTE-054
EORTC 1325-MG KEYNOTE-054 3-year follow-up
EORTC 18071
EORTC 22922 10925 study
EORTC 22922 10925-studie
EORTC 22952-26001 trial exploratory analysis
EORTC 26101 analysis
EORTC 26951
EORTC LYSA FIL H10 and NCRI RAPID joint analysis
EORTC study 22033-26033
EORTC-62092
EPA
epacadostat
EpCAM-positieve tumoren
EPCORE NHL-1
EPCORE NHL-1 trial
epcoritamab
EPd versus Pd
ependymoom
epertinib
EPHOS-B
EPHOS-B trial long-term results
ephrinB2 inhibition plus pembrolizumab
EPI-CT cohort study
epi-drugs
EPIC
EPIC and UK Biobank prospective cohort studies
EPIC cohort
EPIC-analyse
EPIC-NL
EPICAL trial
EPICAP-studie
epichaperome-targeted positron emission tomography for tumor imaging
epidemiologic trends
epidemiological characteristics
epidemiology and outcomes
epidemiology of primary and metastatic brain tumors in children
epidemiology of VTE
epidural use
epidurale metastasen
epigenetic age acceleration
epigenetic editing
epigenetische stabiliteit
epigenetische veranderingen
epilepsy risk factors
epirubicin
epitheliaal ovariumcarcinoom
epithelial ovarian cancer
epithelial ovarian cancer risk
epithelial ovarian cancer survivors
epithelial ovarian carcinoma
epitinib
Epitopes-HPV02 ancillary study
Epitopes-HPV02 study
EPOC
EPOC1706 study. advanced gastric cancer
EPOCH study
eprenetapopt (APR-246) plus azacitidine
eprenetapopt plus azacitidine
eprenetapopt-azacitidine maintenance
eprenetapopt-venetoclax-azacitidine
EPSILoN
Epstein Barr virus-specific autologous cytotoxic T lymphocytes
Epstein-Barr virus serology-based screening
Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte
EQoL-MDS
EQOL-MDS trial
eque-cel
ER low-positive breast cancer
ER positive breast cancer
ER status
ER status and breast cancer survival
ER- en PR-testen
ER-low positive breast cancer
ER-low-positive breast cancer
ER-negatief mammacarcinoom
ER-negatieve borstkanker
ER-negatieve tumoren
ER-positief HER2-negatief gevorderd mammacarcinoom
ER-positief mammacarcinoom
ER-positieve borstkanker
ER-positive advanced breast cancer
ER-positive advanced breast cancer after aromatase inhibitor failure
ER-positive BC
ER-positive breast cancer
ER-positive breast cancer in postmenopausal women
ER-positive early-stage breast cancer
ER-positive HER2 negative ABC
ER-positive HER2 negative breast cancer
ER-positive HER2-negative advanced breast cancer
ER-positive HER2-negative breast cancer
ER-positive HER2-negative breast cancer in elderly patients
ER-positive HER2-negative MBC
ER-positive HER2-negative primary breast cancer
ER-positive node-positive breast cancer in elderly patients with comorbidities
ER-targeted PET
ER+ HER2-
ER+ HER2- BC
ER+ HER2- breast cancer
ER+ HER2- MBC after failure of AI
ERA 223 study
era-by-era analysis of survival
eRAPID intervention
ERAS
ERBB2 HER2-positive metastatic breast cancer
ERBB2 mRNA expression
ERBB2 mutations in solid tumors
ERBB2 plasma copy number
erdafitinib
erdafitinib versus chemotherapy
Erdheim-Chester disease
erfelijke borst- en eierstokkanker
erfelijke syndromen
erfelijkheid
ERG- and PTEN-defined prostate cancer
eribulin
eribulin plus cyclophosphamide
eribulin plus everolimus
eribulin plus gemcitabine
eribulin plus pembrolizumab
eribulin versus S-1
eribulin with or without pembrolizumab
eribuline
ErkentNIS
erlotinib
erlotinib for advanced EGFR-mutated NSCLC
erlotinib plus vemurafenib
ersatzdroge
Erβ1
Erβ2
ES
ES SCLC
ES-NSCLC
ES-SCLC
ES-SCLC after platinum-based chemotherapy
ES-SCLC in chemo-naïve patients
ESAS-scores
ESCC
ESCC detection by microRNA profiling
ESCC in older patients
ESCORT study
ESCORT-1st study
ESD
ESGC
ESHAP
eSMART study
ESME trial
ESMO
ESMO-MCBS H
ESO-Shanghai 13
esomeprazole
esophageal adenocarcinoma
esophageal and esophagogastric junction adenocarcinoma
esophageal and gastric cancer
esophageal and GEJ adenocarcinoma
esophageal cancer
esophageal cancer in older patients
esophageal cancer surgery
esophageal gastroesophageal junction cancer
esophageal squamous cell carcinom
esophageal squamous cell carcinoma
esophagectomy
esophagectomy for cancer
esophagogastric adenocarcinoma
esophagogastric cancer surgery
ESPAC-4 secondary analysis
ESPAC5 trial
ESR1 mutations
ESR1 mutations in CTCs and ctDNA
ESR1-amplificatie
essential thrombocythenia and polycythemia vera
estetrol
ESTHER cohort study
esthesioneuroblastoom
esthetische uitkomst
ESTIMABL2 trial
estimated gained lifetime
estimated projection of US cancer incidence and deaths to 2040
estimates of overtreatment with adjuvant systemic therapy
estimating risk of pancreatic cancer in the general population
estimating survival
estimation of risk by HCPs
estradiol levels
estrogen monotherapy
estrogen receptor-positive recurrent endometrial cancer
estrogen therapy after breast cancer diagnosis
ET
ET outcomes
ET with or without ribociclib
ET with versus without CDK4 6 inhibitors
ETD EOD
ETER701 trial
ethnic disparities in ERBB2 amplification in gastric cancer
etirinotecan pegol
etnische diversiteit
ETP-ALL LBL
ETS
EU cancer mortality prediction for 2023
EU cancer mortality predictions for 2024
EU-regelgeving
EURECCA
Euro-E.W.I.N.G.99
Euro-Ski
EURO-SKI studie
EUROCARE-5
EUROCARE-6
EuroNet-PHL-C1
European cancer mortality
European Code against Cancer
European Mantle Cell Lymphoma Elderly Trial
European trends in NST use for node-positive breast cancer
Europese kankermortaliteit
EURTAC
EUTOS
EV-101 study
EV-201 study
EV-201 trial
EV-202 trial
EV-301 study
EV-302 trial
EV-assay
EV-pembrolizumab
evaluation of adjuvant chemotherapy after neoadjuvant FOLFIRINOX
evaluation of hematuria
evaluation of systemic treatments
EVAN study
event order
EVEREST trial
everolimus
everolimus plus ET
everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer
everolimus plus letrozole and metformin
everolimus plus octreotide
everolimus plus pazopanib
everyday clinical practice
EVICT
EVIDENCE study
evofosfamide
EWALL-INO trial
Ewing and Ewing-like sarcoma in adults
Ewing sarcoma
Ewing sarcoom
Ewing-2008
ex vivo IFNγ production
eXalt3 study
exceptional responder
exceptional response to RAI
excess body weight
excess long-term morbidity with modern treatment
excision margin size
EXCITE-studie
exclusive breastfeeding duration
exemestaan
exemestaan plus everolimus
exemestane dose regimens
exemestane with or without enzalutaimde
exemstaan
exercise
exercise and nutrition intervention
exercise intervention in cancer patients
exercise versus usual care
exhaled breath tests
exogenous estrogen
exogenous hormone use
exome sequencing-based screening
exosomal lncRNA-GC1
exosomen
expansie van fase 1-studie PCD4989g
expansion of cancer risk profile
explaining risk factors
Exploratieve analyse MARQUEE-studie
exposoom
exposure to occupational carcinogens in 195 countries
expressie stromagenen in CRC
EXPRESSION III-studie
expression of biomarkers
expression of insulin-like growth factor-1 receptor on CTCs
EXTEND phase 2 randomized trial
EXTEND trial
extended adjuvant letrozole therapy
extended endocrine benefit
extended follow-up of PALOMA-2 study
extended postgastrectomy follow-up
EXteNET
ExteNET-studie
extension of aromatase inhibitor therapy
extensive stage
extensive stage small cell lung cancer
extensive-stage small cell lung cancer
extensive-stage small-cell lung cancer
extent of resection
external beam radiation therapy
external validation of risk calculators
extracapsular extension in sentinel node
extracorporeal photopheresis
extracranial chondrosarcoma
extracranial disease control
extracranial oligometastasis
extracranial oligometastatic breast cancer
extrahepatic CCA
extrahepatic malignancies
extrahepatisch cholangiocarcinoom
extrameningeal primary SFT
extranodal natural killer T-cell lymphoma
extranodale extensie
extraocular retinoblastoma
extrapleural pneumonectomy
extrauterine disease
extremity cooling
EZH2
EZH2 inhibitor SHR2554
FACE
facial nerve function
facial-aging app
facility patient volume and survival
facility volume
facilty volume and mortality
FACT-HN-RAD
factors affecting recurrence and survival
factors affecting sentinel node metastasis
factors associated with duration of diagnostic interval
factors associated with risk of body image-related distress
factors associated with risk of progression
factors associated with vomiting control
factors explaining sex differences
factors influencing multidisciplinary tumor board recommendations
factors leading to alpelisib discontinuation
factors predicting invasive breast cancer recurrence
failure to rescue rates
FAK inhibition for meningiomas with somatic NF2 mutations
FAKTION study
FALCON
fall and fracture risk
false positive FIT
familair mammacarcinoom
familiaal colorectaalcarcinoom
familiaal risico
familiaire adenomateuze polyposis
familiaire adenomateuze popyposis
familial adenomatous polyposis
familial and hereditary cancer syndromes
familial platelet disorder
familiale adenomateuze polyposis
familiegeschiedenis
familiegeschiedenis prostaatkanker
family history
family history of breast cancer
family history of cancer
family history of OC and BC
family history of plasma cell disorders
family history-based screening
famitinib plus camrelizumab and nab-paclitaxel
FaMRIsc study
FAP-IL2v plus atezolizumab
fase 2-studie BOLERO-4
fase 2-studie BOLERO-6
fase 2-studie KEYNOTE-224
Fase 2-studie SWOG S0801
fase 3- studie DREAM
fase 3-studie AURA3
fase 3-studie BrighTNess
fase 3-studie COLUMBUS
Fase 3-studie CRITICS
fase 3-studie ETNA
fase 3-studie FATA-GIM3
fase 3-studie GEC-ESTRO
Fase 3-studie KEYNOTE-045
fase 3-studie METEOR
Fase 3-studie MONALEESA-3
fase 3-studie MONALEESA-7
fase 3-studie NETTER-1
Fase 3-studie PERSEPHONE
fase 3-studie PRODRIGE 9
Fase 3-studie SAKK 75 08
Fase 3-studie SWOG S9921
fase 3-studie TROG 05.01
fase 3-studies
FAST study
FAST-Foward noninferiority phase 3 study
fasting-mimicking diet
FASTRACK II trial
fatal ICI-associated toxic effects
fatalisme
fatigue
fatigue in cancer patients
favorable histology Wilms tumor
favorable-risk AML in patients younger than 60 years
FCR
FCT
FDA approval of novel cancer therapies between 2000 and 2016
FDA oncology drug approvals in 2018
FDA-approved novel oncology drugs
FDG PET CT after 1 week predicts response
FDG-PET
FDG-PET CT
FDG-PET scanning
feasibility
febriele neutropenie
fecal and plasma short-chain fatty acdis
fecale immunochemische test
fedratinib
female and male breast cancer. global trends 1990-2017
female breast cancer risk
female invasive breast cancer patients
female reproductive and hormonal factors
female survivors of childhood and adolescent cancer
FENIX
fentanyl
fentanyl sublinguale spray
fenylketonurie hyperfenylalaninemie
fermented dairy foods
fertiliteitspreservatie
fertility drugs
fertility preservation
fertility treatment
fertility-sparing surgery
FFCD-ANABASE
FGFR pathway alterations
FGFR2-rearranged ICC
FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma
FGFR3 mutation
FGFR4 alterations predict efficacy
FGFRs
FH02 study
FHBC
FHWT
FIA
ficlatuzumab with or without cetuximab
ficonalkib
fifteen-year results
FIGHT trial
FIGHT-207 trial
FIGHTDIGO-studie
FIGO score 5 or 6 gestational trophoblastic neoplasia
fijne motoriek
fijnstof
FIL MIRO trial
FIL_ReRi trial
FIL-HD0801 study
final OS analysis
Final OS results from SOLO2 study
final overall survival analysis of IMpassion130
final results of CheckMate 204
final survival outcomes
Finale analyse FIRST-studie
finale analyse van GOG 240-studie
finale overlevingsresultaten van KEYNOTE-006
financial links
financiële toxiciteit
finasteride
fine-needle biopsy
Finland Capecitabine Trial 15-year follow-up
finotonlimab
FinRSPC study
FinXX-studie
FIR prostate cancer
FIR-studie
FIRE-3
FIRE-4.5 trial
FIRE-SCLC Cohort Study
firefighters
FIREFLY-1 trial
FIRES
first line anlotinib
first line therapy
first relapse B-ALL in children and AYAs
first responders exposed to WTC disaster
first- versus second-line CDK4 6 inhibitor
first-degree relatives of pancreas cancer patients
First-iGAP study
first-in-human study of ivuxolimab-utomilumab combination
first-line abiraterone or enzalutamide
first-line abiraterone-prednisone for mCRPC with bone metastases
first-line afatinib combined with anti-EGF vaccination
first-line anlotinib plus platinum-etoposide
first-line anlotinib plus toripalimab
first-line anlotinib-oxaliplatin-capecitabine
first-line anti-PD-1 or targeted therapy
first-line apatinib plus gefitinib
first-line atezolizumab
first-line atezolizumab plus bevacizumab
first-line atezolizumab plus chemotherapy
first-line atezolizumab-bevacizumab versus sunitinib
first-line aUC treatment
first-line avelumab
first-line avelumab for mMCC
first-line axi-cel
first-line azacitidine plus venetoclax
first-line bavacizumab plus trebananib without chemotherapy
first-line befotertinib versus icotinib
first-line BEMPEG plus NIVO
first-line bevacizumab-erlotinib
first-line blinatumomab
first-line BV plus AVD
first-line BV plus nivolumab
first-line cabozantib and nivolumab with or without CBM588
first-line cabozantinib
first-line cadonilimab plus anlotinib
first-line camrelizumab plus famitinib
first-line camrelizumab plus RT
first-line carboplatin versus cisplatin
first-line carboplatin-paclitaxel with or without bevacizumab
first-line CCRT
first-line cemiplimab
first-line chemo-immunotherapy for stage IV NSCLC
first-line chemotherapy plus PD-(L)1 blockade
first-line chemotherapy with or without bevacizumab
first-line chemotherapy with or without immunotherapy
first-line chemotherapy with or without pembrolizumab
first-line chemotherapy with sugemalimab versus placebo for mNSCLC
first-line CHOP or R-CHOP
first-line cisplatin-pemetrexed-nivolumab
first-line cladribine with concurrent or delayed rituximab
first-line CLL treatment
first-line combinations of immune checkpoint inhibitors and chemotherapy
first-line dacomitinib versus afatinib
first-line DADI trial
first-line donafenib versus sorafenib
first-line dose-dense early postoperative intraperitoneal chemotherapy
first-line everolimus plus bevacizumab
first-line FOLFIRINOX
first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel
first-line gemcitabine-trastuzumab-erlotinib combination
first-line ibrutinib
first-line ibrutinib plus rituximab
first-line ibrutinib plus venetoclax
first-line ibrutinib-venetoclax versus chlorambucil-obinutuzumab
first-line ICI
first-line ICI plus chemotherapy versus bevacizumab plus chemotherapy
first-line ICIs
first-line ICIs for mM
first-line ICIs with or without chemotherapy
first-line imatinib plus binimetinib
first-line immunotherapy for SCLC
first-line ipatasertib plus paclitaxel for advanced TNBC
first-line lenvatinib
first-line lenvatinib plus transarterial chemoembolization
first-line lenvatinib versus atezolizumab plus bevacizumab
first-line lorlatinib versus crizotinib
first-line mCRC
first-line mFOLFOX6 plus bevacizumab versus cetuximab
first-line nab-paclitaxel plus carboplatin for aNSCLC in clinical practice
first-line niraparib plus pembrolizumab
first-line nivolumab
first-line nivolumab plus cabozantinib for advanced RCC
first-line nivolumab plus ipilimumab
first-line nivolumab plus ipilimumab and chemotherapy
first-line NSCLC treatment
first-line obinutuzumab plus lenalidomide
first-line options
first-line osimertinib
first-line osimertinib versus afatinib or erlotinib
first-line pazopanib
first-line pembrolizumab
first-line pembrolizumab for advanced NSCLC with low PD-L1 expression
first-line pembrolizumab for NSCLC
first-line pembrolizumab monotherapy
first-line pembrolizumab plus lenvatinib
first-line pembrolizumab plus R-CHOP
first-line PLD-IFO
first-line PVAB
first-line quavonlimab (anti-CTLA-4) plus pembrolizumab
first-line R-CODOX-M R-IVAC chemotherapy
first-line R2 versus rituximab-chemotherapy
first-line radioembolization plus chemotherapy
first-line regorafenib with nivolumab and chemotherapy
first-line S-1 versus anthracyclines
first-line selinexor plus R-CHOP
first-line selpercatinib
first-line serplulimab plus chemotherapy
first-line sintilimab with pegaspargase-gemcitabine-oxaliplatin
first-line SRS versus WBRT
first-line sunitinib
first-line systemic treatment options
first-line systemic treatment strategies
first-line tebentafusp versus investigator’s choice
first-line tebentafusp versus nivolumab plus ipilimumab
first-line therapies
first-line therapy
first-line tislelizumab plus chemotherapy
first-line tislelizumab versus sorafenib
first-line TKIs
first-line toripalimab plus bevacizumab
first-line toripalimab plus chemotherapy
first-line TPEx versus EXTREME
first-line trastuzumab
first-line treatment
first-line treatment options
first-line Tumor Treating Fields plus chemotherapy
first-line vemurafenib plus obinutuzumab
first-line venetoclax combinations
first-line venetoclax plus 3 + 7 daunorubicin-cytarabine
first-line venetoclax plus azacitidine for AML
first-line venetoclax-obinutuzumab versus chlorambucil-obinutuzumab
first-line versus second line daratumumab
first-line zuberitamab plus CHOP
first-recurrence GBM
first-relapse rhabdomyosarcoma
FIRSTANA-studie
FIRSTMAPPP study
FIRSTMAPPP trial
fistula
FIT
FIT cohort
FIT implementation in guaiac-based screening program
FIT screening
FIT screening and risk of CRC death
FIT-detection of advanced colorectal neoplasia
FIT-screening
fitheid
fitness
five miRNA-model
five versus two years adjuvant zoledronate
five-miRNA based classifier
five-year analysis
five-year follow-up of CPX-351 versus 7+3 cytabine and daunorubicin
five-year outcome
five-year outcomes
five-year outcomes with cobimetinib plus vemurafenib
five-year PROs
five-year survival outcomes
five-year survivors of adolescent and young adult cancer
five-year survivors of chldhood cancer
fixed duration of venetoclax-rituximab
fixed-duration ibrutinib-venetoclax
fixed-duration MRD-guided approach
FKBPL
FL
FLAIR trial
FLAME trial
FLAMES trial
FLASH trial
FLAURA study
FLAURA-studie
FLAURA2 trial
flavonoïden
flexibele sigmoïdoscopie
flexibele-sigmoïdoscopie
FLIPPER trial
Florence Trial long-term results
FLOT4 study
FLOT4-studie
flow cytometry status
FLT3-internal tandem duplication mutated AML
FLT3-ITD AML
FLT3-ITD positive AML
FLT3-ITD-positive acute myeloid leukemia
FLT3-mutated R R AML
fluciclovine versus PSMA PET-CT
fludarabine
FLUOGLIO-studie
fluoropyrimidine
fluoropyrimidine therapy
fluoropyrimidines
fluoroscopie
fluorouracil-leucovorin
fluzoparib
FLYER study
FMD
FMT plus tislelizumab and fruquintinib
FN
FN after chemotherapy for breast cancer
FNMTC
focal adhesion kinase
focal boost
focal versus extended IRE
FOCUS-cohort
FOCUS4-C trial
FOCUS4-N trial
FOENIX-CCA2 Study
FOHAIC-1 trial
Fol-BRITe study
FOLFIRI
FOLFIRI plus bevacizumab or aflibercept
FOLFIRI plus cetuximab or bevacizumab
FOLFIRI plus durvalumab with or without tremelimumab
FOLFIRINOX
FOLFIRINOX and chemoradiotherapy
FOLFIRINOX induction for LAPC
FOLFIRINOX salvage treatment
FOLFOX
FOLFOX hepatic arterial infusion
FOLFOX4
FOLFOXIRI
FOLFOXIRI plus bevacizumab
FOLFOXIRI plus panitumumab
FOLFOXIRI-bevacizumab
FOLFOXIRI-bevacizumab versus doublets-bevacizumab
FOLH1 expression
foliumzuur
FOLL05-studie
folliculair lymfoom
follicular and other CD20+ non-Hodgkin lymphoma
follicular lymphoma
follow-up after discontinuation
follow-up after resection
follow-up after treatment cessation
Follow-up analyse van CheckMate 067-studie
follow-up analyse van JFMC34-0601
follow-up of overdue abnormal cancer screening test results
follow-up van overlevers
food insecurity in cancer survivors
forego medical care
foritinib
formaldehyde
FOrMAT-studie
FoRT trial
FORT-1 trial
FORT-2 multinational phase 1b trial
FORUM study
fosaprepitant
fosaprepitant meglumine
FosNTP versus FosAPR
fotofarmacologie
four-factor prognostic model
FOXA1-expressie
FOXA2
FOXC1
FOxTROT trial
FP in BC patients
FP with or without oxaliplatin
FPD AML
FR
FRACTION-RCC trial
fractionated gamma knife radiosurgery
fractionated pre-operative SRS
fractionated stereotactic radiosurgery
fractionated stereotactic radiotherapy
fractionation schedule of CCTRT
fracture risk
fracture risk prediction in cancer patients
fracturen
fractures
fractuurrisico
fragiele ouderen
fragiliteit
fragmentation of surgery and chemotherapy
frailty and neurocognitive decline
frailty and survival
FRAX
FREEDOM2 trial
frequency and outcomes
frequency and outcomes of brain metastases
frequency and quantity of alcohol consumption
frequent aspirin use
frequent cystoscopy
FRESCO study
FRESCO-2
fresolimumab
front-line fludarabine-cyclophosphamide-rituximab
front-line ibrutinib for CLL patient populations not included in RESONATE-2
frontline acalabrutinib plus venetoclax and obinutuzumab
frontline dasatinib
frontline FCR
frontline hyper-CVAD plus ofatumumab
frontline hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab
frontline ibrutinib-rituximab followed by R-HCVAD
frontline low-dose versus standard dose dasatinib
frontline ponatinib versus imatinib
frontline targeted therapy plus low-intensity chemotherapy
frontline therapies
frontline therapy for AML in elderly patients
frontline treatment for pediatric AML
frontline treatments
fruit
fruit and vegetable consumption
fruquintinib
fruquintinib in Chinese patients in clinical practice
FRUTIGA trial
FS118
FSRT
FSS versus RS
FTD versus HD-MA
FTD-TPI
FTD-TPI with or without bevacizumab
FTL3-mutatie
Fudan CUP-001
FUJI cohort
fulvestrant
fulvestrant plus capivasertib
fulvestrant plus palbociclib
fulvestrant versus AIs
FUMANBA-1 trial
functional outcomes
FURLONG study
FURLONG trial
furmonertinib
furmonertinib versus gefitinib
FUS-ERG and RUNX1-CBFA2T3
fusion gene
Fusobacterium nucleatum
futibatinib
future cancer risk
FUTURE-C-PLUS study
FUTURE-SUPER trial
fuzuloparib maintenance
fuzuloparib plus apatinib
fysieke activiteit
FZOCUS-2 trial
G GEJ adenocarcinoma
G GEJ cancer
G-CSF support
G-CSFs
g-NETs
G84E
GAIA CLL13 4-year follow-up
gain-of-function mutatie
gait speed
galactography
galblaascarcinoom
GALEN study
galeterone
gallbladder cancer
GALLIUM study
gallium-68 labelled PSMA-11 PET
gallium-68 PET-MRI
GALLIUM-studie
galunisertib
galunisertinib plus neoadjuvant chemoradiotherapy
galwegcarcinoom
gamma knife radiosurgery
GammaTile brachytherapy
ganglioside vaccine for high-risk neuroblastoma
ganglioside-monosialic acid
ganitumab
GAP BRAIN phase 3 study
GARD
garlic
GARNET study
GARNET trial
garsorasib
GASTO 1028 study
GASTO1003 trial
gastric adenocarcinoma
gastric and duodenal cancer
gastric cancer
gastric cancer detection one year after negative endoscopy
gastric cancer family history
gastric cancer in Helicobacter pylori-infected patients
gastric cancer prevention
gastric cancer risk
gastric cancer surgery
gastric cancer with synchronous peritoneal metastases
gastric gastroesophageal junction AC
gastric gastroesophageal junction adenocarcinoma
gastric or esophagastric junction adenocarcinoma
gastric or gastric-esophageal junction adenocarcinoma
gastric or gastro-esophageal junction cancer
gastric or gastroesophageal junction adenocarcinoma
gastric or gastroesophageal junction cancer
gastric or GEJ adenocarcinoma
GASTRIPEC-I trial
gastritis
gastro-intestinale mucositis
gastro-intestinale stromale tumoren
gastro-oesofagaal adenomcarcinoom
gastroenteropancreatic neuroendocrine tumors
gastroesophageal adenocarcinoma
gastroesophageal cancer
gastroesophageal reflux disease
gastrointestinal bleeding
gastrointestinal cancer
gastrointestinal neuroendocrine carcinoma
gastrointestinal stromal tumor
gastrointestinal stromal tumors
gastroïntestinale kanker
gastroïntestinale stromale tumoren
Gattelli
GAUDI
GBC
GBCA
GBD 2019
GBM
GBM in elderly patients
gBRCAm HER2-negative mBC
GBS
GBSM
GBV-C
GC
GC GEJC
GC with synchronous PMs
GC012F
GC1008
GC4419
GCA
GCC
GCC19 CART
GCIG INTERLACE trial
GCPM
GCT
GCTB
GCTs
GD
GD2-CART01
GDP
GEA
GEC
GECCOR-GB study
gedatolisib
gedatolisib plus paclitaxel and carboplatin
gedatolisib plus palbociclb and ET
GeDDiS-studie
gedifferentieerd schildkliercarcinoom
gedissemineerde tumorcellen
gefitinib
gefitinib alone or with chemotherapy
gefitinib and erlotinib
gefitinib continuation after progression
gefitinib plus chemotherapy
GEICAM 2003-11_CIBOMA 2004-01 study
GEICAM 2010-04 study
GELAD chemotherapy with sandwiched radiotherapy
GELATO trial
GELLC-7 trial
gelokaliseerd prostaatcarcinoom
GEM
GEM-1402 study
GEM20110714 study
gemcitabine
gemcitabine plus adavosertib
gemcitabine plus cisplatin induction chemotherapy
gemcitabine plus nab-paclitaxel and ficlatuzumab
gemcitabine with or without berzosertib
gemcitabine with or without ramucirumab
gemcitabine-eribulin combination
gemcitabine-trastuzumab-pertuzumab after pertuzumab-based therapy
gemcitabineresistentie
gemetastaseerd mammacarcinoom
gemetastaseerd melanoom
gemetastaseerde borstkanker
gemetastaseerde borstkanker; trastuzumab
gemetastaseerde colorectaalkanker
GEMPAX study
GemPred
GEMSTONE-201
GEMSTONE-301 trial
GEMSTONE-302
GEMSTONE-302 trial
gemtuzumab ozogamicin
gemtuzumab ozogamicine
GEN501 and SIRIUS final results
gender differences
gene expression markers in peripheral blood
gene expression profiles
gene expression profiling assay
gene expression signature to predict response
gene signature for predicting lymph node status
gene variants and subsequent neoplasms
gene variants associated with increased cancer risk
gene-specific prevention strategies for OC and BC
geneesmiddelinteracties
generalizibilty among different ethnicities
Generations Study
genetic alterations
genetic and clinical predictors
genetic factors
genetic prognostic and predictive factors
genetic risk
genetic risk for overall cancer
genetic susceptibility
genetic testing
genetically defined renal tumors
genetically determined cutaneous nevi
genetically predicted low-density lipoprotein level
genetically proxied inhibition of HMG-CoA reductase
genexpressie
genito-urinaire maligniteiten
genmethylering
genome sequencing
genome-edited donor-derived anti-CD19 CAR T cells for pediatric and adult B- ALL
genome-wide association study
genome-wide diet-gene interaction
genome-wide variants
genomic alterations
genomic analysis in NRG Oncology RTOG 9802
genomic biomarkers predicting anti-PD-(L)1 response
genomic characterization
genomic classification and clinical outcome
genomic correlates
genomic correlates of progression or response
genomic determinants of clinical outcomes
genomic determinants of early recurrence
genomic determinants of outcomes
genomic identification of HRD
genomic profiling
genomic profiling of prostate cancers from met with African and European ancestry
genomics and outcomes
genotoxic pks E. coli
genotyping before first-line therapy
genotyping lung adenocarcinoma
GENUINE trial
genvarianten
GEOMETRY mono-1 study
GEP-NETs
GeparNuevo analysis
GeparNuevo study
GeparOcto secondary analysis
GeparQuattro-studie
GeparSepto
GeparSepto long-term outcomes
GeparSixto trial
GeparX trial
gepegyleerd liposomaal doxorubicine
geptanolimab
geptanolimab (GB226)
gerandomiseerde fase 2-studie PrE0102
GERD treatment
Gerecke
geriatirc patients
geriatric assessment impairments
geriatric comanagement
Geriatric Prognostic Indicator
germ cell tumors
germline BARD1 gene variants
germline BRCA PALB2 mutation
germline BRCA pathogenic variant
germline BRCA PVs and ovarian reserve
germline BRCA-mutated metastatic pancreatic cancer
germline BRCA-mutated mPaC
germline BRCA1 2 mutation
germline BRCA1 2 pathogenic variants
germline BRCA2 mutations
germline CDH1 variants and lifetime cancer risk
germline CDH1 variants in HLBC
germline genetic testing
germline genetic testing after cancer diagnosis
germline mutaties
germline mutations
germline mutations in DNA repair genes
germline PALB2 pathogenic variants
germline pathogenic variants in 28 genes
germline predisposition gene mutations
germline PTEN variants in children and adults
germline PVs in cancer predisposition genes
germline sequencing analysis
germline variant status
germline variants in DNA repair genes
germline variants in natural killer cells
germline variations in drug transporters
geserreerde poliepen
geslachtshormonen
gestation and birthweight of offspring
gestational trophoblastic neoplasia
gestationele trofoblasttumor
GETNE-TRASGU study
GETUG-AFU 16 study 112-months follow-up
gevorderd cervixcarcinoom
gevorderd maag-adenocarcinoom
gevorderd melanoom
gevorderd niercelcarcinoom
gevorderde borstkanker
gevorderde maagkanker
geweichtsverlies
gezondheidsutiliteitsindex
gFOBT
GFPC 08-2015 ENERGY trial
GFR
GFR; niercelcarcinoom; urotheelcarcinoom
GGO lung adenocarcinoma
GHSG HD13-15 trials
GHSG HD17 study
GI adverse events
GI cancer
GI malignancies
GI malignant neoplasms
giant-cell tumor of bone
gilteritinib
gilteritinib as post-transplant maintenance
GIMEMA-MMY-3006 trail
GIST
GISTs
GK
GK-SRS with or without EGFR-TKIs
GKRS
GKRS for BMs of non-pulmonary primary tumors
GLARIUS-studie
glasdegib
GLASS study
Gleason score 9-10 prostate cancer
glembatumumab vedotin
glioblastoma
glioblastoma in elderly patients
glioblastoma in patients aged 80 years and older
glioblastoma in poor perfomance status patients
glioblastoma multiforme
glioblastoma recurrence
glioblastoma with methylated MGMT promoter
glioblastoom
glioma
glioma risk
glioma with BRAF-V600E mutation
gliomas
gliomen
glioom
glitazonen
global burden in 2019
global burden of 30 cancers among men in 2022 and projections for 2050
global burden of breast cancer
Global Burden of Cancer
global burden of cancer attributable ro risk factors
global burden of cancer attributable to infections in 2018
global burden of cancer in 2020 attributable to alcohol consumption
Global Burden of Disease Study
Global Burden of Disease Study 2019
global cancer incidence and mortality from 2010 to 2019
global expanded access program
global incidence and mortality for 29 cancer groups in 2019
global incidence and mortality trends
global longitudinal strain
global pediatric cancer care
global retinoblastoma presentation analysis by national income level
global trends
global variations in incidence by histological subtype
glofitamab
GLORY trial
glottic squamous cell carcinoma
GLOW study
GLOW trial
GLP-1RAs
glucocorticoid treatment
glucocorticoid-refractory cGVHD
glucose lowering drugs
GLUT-
GLUT-14
glutamine
glutathion-S-transferase P1
glycaan-gerelateerde genen
glypicaan-1
GM-CSF
GM1 for OIPN
GMMG-CONCEPT trial
GMMG-HD7 trial
GMMG-MM5 trial
GNAS variants in solid tumors
GNCC
GnHRa
GNOS-PV02 plus pembrolizumab
GnP or mFFX
GnRH-agonist
GnRHa
GO
GO30103 trial
GO30140 study
GO42144 trial
goals of care in last years of life
GOG 0212 study
GOG 281 LOGS
GOG Study 279
GOG-0213 studie
GOG-0213 study
GOG-0218 final OS-analysis
GOG-0218 studie
GOG-0277
Golestan Cohort Study
golidocitinib
gonadotropine
Google Translate
GORILLA-3004 study
GORTEC 2007-01 studie
GORTEC 2014-01 TPExtreme study
GOSAFE Study
gosereline
GÖTEBORG-2 ISRCTN study
GOYA-studie
GP-led versus surgeon-led colon cancer survivorship care
GPRC5D-targeted CAR T cells
grade 1-2 AEs
grade 2 oligodendroglioma
grade migration during the last decade
graded cardiac response criteria
graft failure
graft versus host disease
graft-versus-host disease
graft-versus-host disease prophylaxis
grain consumption and dietary fiber intake
GRASPA
GRAVITAS-301 trial
GRCCC cohort study
GRECCAR 2-studie
GREEN study subgroup analysis
GRIFFIN study
grijpkrachtverlies
grip strength
groeicurves naevi
groeisnelheid
groenten
groentenconsumptie
GROINSS-V-II
grootcellig granulair lymfocytaire leukemie
grootcellig neuro-endocrien longcarcinoom
grootte van lymfekliermetastasen
gross total versus subtotal resection
gross-total resection
grote-korrel lymfocyten leukemie
growth hormone deficiency
growth rate of untreated hemangioblastomas
growth rates
GSK2857916
GT-30
GT90001 plus nivolumab
GTN
GTT
GU-toxiciteit
guadecitabine
guanylaatcyclase
GUIDANCE-03 trial
gumarontinib
gut microbiota and metabolites
GVAX pancreas
GVHD
GVHD prevention after haploidentical HCT
GVHD prophylaxis
GWAS
GX-188E
Gxplore-002 study
Gxplore-005 study
gynecologic cancers
gynecologic oligometastatic and oligoprogressive tumors
gynecological brain metastases
gynecological cancer
gynecologische maligniteiten
H-RT versus C-RT
H. pylori
H. pylori infection status
H. pylori screening
HA-WBRT + SIB for brain metastases
HA-WBRT + SIB versus conventional WBRT
haarverlies
hafnium oxide nanoparticle
HAI
HAI chemotherapy
HAI pump chemotherapy plus systemic therapy
HAIC
HAIC with FOLFOX
HAIP floxuridine chemotherapy versus resection
hair dye use and prostate cancer risk
hair products
hairy cell leukemia
hairy-cell leukemie
hallmarks of cancer
HALO 202-studie
HALT-D trial
Ham-Wasserman lecture
Hamilton Fairley Award
hand-voet huidreacties
hand-voet syndroom
hand-voetsyndroom
HannaH study final analysis
haplo versus UD transplantation
haplo-HSCT
haplo-HSCT versus chemotherapy
haplo-identieke HSCT
haplo-SCT
haploidentical HSCT
haploidentical versus unrelated cord blood transplantation
haploidentical versus unrelated SCT
haploidentical; sibling; matched unrelated donor
HARMONi-A study
harms of exercise training
HART
hartfalen
hartfalen na auto-HCT
HAS
HBOC
HBOT for late local toxic effects
HBOT in breast cancer patients
HBV-related HCC
HBV-related HCC risk
HBV-vaccinatie
HC
hcc
HCC diagnosis
HCC expressing CD147
HCC in children compared to young adults
HCC in HBV- or HCV-infected patients
HCC overall survival
HCC risk
HCC risk algorithm
HCC risk in patients with HBV and or HCV infection
HCC screening in a cohort of at-risk patients
HCC surveillance in cirrhosis patients
HCC with extrahepatic metastasis
HCC with MVI
HCC with portal vein tumor thrombus
HCL
HCMV reactivation during radiochemotherapy
HCRN GU16-257 trial
HCT
HCV
HCV-associated indolent NHL
HD 0607 trial
HD IL-2
HD-MTX for prevention of CNS progression
HD12 study
HD16 trial
HD18-studie
HD201
HD21 trial
HD9 study
HDAC inhibition
HDCT plus autoHSCT
HDCT plus PBSCT
HDL-cholesterol level and risk of hematologic malignancy
HDR-brachytherapie
head and neck cancer
head and neck cancer risk after hematologic cancer
head and neck cancer surgery during COVID-19 pandemic
head and neck procedures
head and neck squamous cell carcinoma
head en neck cancer
Head Start III
health care contact days
health care use
health consequences
health literacy
health maintenance practices
Health Professionals Follow-up Study
health promotion among cancer survivors
health-related quality of life
healthy eating patterns
healthy immigrant effect
healthy lifestyle
healthy lifestyle and liver cancer risk
healthy older adults
healthy postpolypectomy lifestyle
hearing impairment
hearing loss
heart failure
heart failure risk
heavily pretreated HR-positive HER2-negative metastatic breast cancer
heavily pretreated MBC
heavily pretreated PROC
heavy smokers
HECTOR model
hedgehog inhibitors
hedgehog-signaalroute
HEI-2010
heldercellig niercelcarcinoom
heldercellig ovariumcarcinoom
Helicobacter pylori
Helicobacter pylori treatment
HELIOS study
HeLiX randomized clinical trial
hematologic cancer patients
hematologic cancers and COVID-19
hematologic malignancies
hematologic malignancies in older patients
hematologic malignant neoplasms
hematological cancer
hematological disorders
hematologische maligniteiten
hematopoietic cell transplantation
hematopoietic score predicts outcomes
hematopoietic stem cell transplantation
hematopoietic stem cell transplation
hematopoïetische celtransplantatie
hemicolectomy versus appendectomy
hemispheric-specific clinical presentation
hemochromatosis HFE p.C282Y homozygosity
hemorrhagic cystitis following allotransplantation
hENT1 expression
HEPAR PluS study
hepatectomy in academic versus community cancer center
hepatectomy with or without adjuvant mFOLFOX6
hepatic arterial infusion chemotherapy
hepatic artery infusion pump chemotherapy
hepatitis B virus infection
hepatitis B-virus
hepatitis C
hepatobiliary cancers
hepatocallular carcinoma
hepatocellulair carcinoom
hepatocellular carcinoma
hepatocellular carcinoma and pancreatic ductal adenocarcinoma
hepatocellular carcinoma with portal vein invasion
hepatocellular carcinoma with preoperative portal vein tumor thrombus
hepatospleen T-cel lymfoom
hepatotoxiciteit
hepatotoxicity
HER2
HER2 amplification
HER2 exon 20 insertions
HER2 exon 20 mutant NSCLC
HER2 expressing UCS
HER2 expression discordance between primary and metastatic breast cancer
HER2 expression testing
HER2 gene expression levels
HER2 mutated aNSCLC
HER2 negative advanced gastric gastroesophageal junction cancer
HER2 peptide vaccines for prevention of breast cancer recurrence
HER2 pro-oncogene signalering
HER2-0 and HER2-low mBC
HER2-altered advanced solid tumors
HER2-amplified LA M BTC
HER2-amplified mCRC
HER2-amplified non-breast gastroesophageal tumors
HER2-directed therapies
HER2-expressie
HER2-expressing cancers
HER2-expressing mCRC
HER2-expressing or mutated advanced solid tumors
HER2-expressing prostate cancer
HER2-gedreven NSCLC
HER2-HER3 dimerization
HER2-low
HER2-low advanced breast cancer
HER2-low breast cancer
HER2-low expression
HER2-low versus HER2-negative breast cancer
HER2-low versus HER2-negative mBC
HER2-low versus HER2-null
HER2-low versus HER2-zero MBC
HER2-low-positive breast cancer
HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy
HER2-mutant lung cancer
HER2-mutant metastatic cervical cancer
HER2-mutant mNSCLC
HER2-mutant NSCLC
HER2-negatief mammacarcinoom
HER2-negatieve borstkanker
HER2-negatieve MBC
HER2-negative
HER2-negative advanced G GEJ cancer
HER2-negative BC
HER2-negative BRCA mutated resectable breast cancer
HER2-negative breast cancer
HER2-negative early breast cancer
HER2-negative MBC
HER2-negative metastatic breast cancer
HER2-negative node-positive breast cancer
HER2-negative tumors
HER2-overexpressing breast cancer
HER2-overexpressing mGEA
HER2-overexpressing mNSCLC
HER2-positief mammacarcinoom
HER2-positief metastatisch mammacarcinoom
HER2-positieve borstkanker
HER2-positieve vroege borstkanker
HER2-positive ABC
HER2-positive ABC MBC
HER2-positive aCRC
HER2-positive advanced breast cancer
HER2-positive advanced G GEJ cancer
HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
HER2-positive advanced gastric or gastroesophageal junction cancer
HER2-positive advanced solid malignancies
HER2-positive and AR-positive advanced breast cancer
HER2-positive and biopsy-proven node-positive breast cancer
HER2-positive BC with BMs
HER2-positive BCBM
HER2-positive BCBMs
HER2-positive biliary tract cancer
HER2-positive breast cancer
HER2-positive breast cancer and brain metastases
HER2-positive breast cancer brain metastases
HER2-positive breast cancer neoadjuvant lapatinib plus trastuzumab
HER2-positive breast cancer survivors
HER2-positive breast cancer with brain metastases
HER2-positive BTC
HER2-positive de novo metastatic breast cancer
HER2-positive EAC
HER2-positive early breast cancer
HER2-positive early breast cancer in elderly
HER2-positive early-stage breast cancer
HER2-positive EBC
HER2-positive esophagogastric adenocarcinoma
HER2-positive esophagogastric cancer
HER2-positive gastric cancer
HER2-positive gastro-esophageal adenocarcinoma
HER2-positive LA M UC
HER2-positive localized breast cancer
HER2-positive MBC
HER2-positive mBC in Europe
HER2-positive mBTC
HER2-positive metastatic breast cancer
HER2-positive metastatic breast cancer after ≥ 2 HER2-directed regimens
HER2-positive non-metastatic breast cancer
HER2-positive R MBC
HER2-positive salivary duct carcinoma
HER2-positive stage II or III breast cancer
HER2-scoringsysteem
HER2-screening
HER2-targeted ADCs
HER2-targeted CAR T cell therapy
HER2-targeted therapies
HER2-targeted therapy
HER2+ BC
HER2+ breast cancer
HER2+ breast cancer brain metastases
HER2+ mCRC
HER2CLIMB
HER2CLIMB brain metastases subgroup analysis
HER2CLIMB randomized phase 2 study
HER2CLIMB study
HER2CLIMB study exploratory analyses
HER2DX
HER2DX model
HER2DX pCR-score
HER3 overexpression
HER3-DXd
HER3-mutant mammacarcinoom
HERA
HERA trial
HERALD EPOC 1806
herb and supplement use
HERBY-studie
herceptin
herceptin-biosimilar
herceptine
hereditary diffuse gastric cancer
Heritage
HERIZON-BTC-01
HERO study
heropname
herpes zoster after autologous stem cell tranplantation
hersenmetastasen
hersenmetastasen mammacarcinoom
hersenmetastasering
hersenmicrobloedingen
hersentumoren
HERTHENA-Lung01
Heterocephalus glaber
heterogeneity between SEER counties
heterogeneity of IHC
HF-WBI
HFSRT
HGG
HGGs
HGS OC
HGSC at RRSO
HGSOC
HIDAC versus IDAC consolidation
hidden-genome classifier
hidradenitis suppurativa
HIFU
high burden of clonal hematopoiesis
high hereditary breast cancer risk
high PD-L1 expressing NSCLC
high risk early breast cancer
high risk locally advanced rectal cancer
high risk melanoma
high risk of colorectal peritoneal metastasis
high RS
high sensitivity C reactive protein
high TIL and pCR
high TMB tumors
high versus low dose lenalidomide maintenance after transplantation
high- or very high-risk localized prostate cancer in patients ≤ 65 years
high-dose carboplatin
high-dose chemotherapy
high-dose chemotherapy and 3D conformal radiation
high-dose cyproterone acetate
high-dose folic acid use during pregnancy in epilepsy patients
high-dose intensity-modulated chemoradiotherapy
high-dose once-daily RT
high-dose versus standard-dose twice daily thoracic RT
high-dose vitamin D
high-dose-rate brachytherapy
high-grade and low-grade glioma
high-grade brainstem gliomas
high-grade breast DCIS
high-grade glioma
high-grade gliomas in children
high-grade gliomas in pediatric patients
high-grade mature B-cell NHL in children and adolescents
high-grade osteosarcoma of the extremities
high-grade ovarian cancer
high-grade prostate cancer
high-grade UTUC
high-intensity focused ultrasound
high-intermediate and high risk early stage EC
high-mobility group box 1
High-molecular-mass hyaluronan
high-PD-L1 expressing NSCLC with brain metastases
high-risk ALL in children
high-risk AML
high-risk AML in remission
high-risk asymptomatic bone metastases
high-risk B-ALL
high-risk biochemically recurrent prostate cancer
high-risk breast cancer
high-risk cancer surgery
high-risk CSPC
high-risk DLBLC
high-risk early breast cancer
high-risk EBC
high-risk endometrial cancer
high-risk extremity trunk STS
high-risk factors and real-world outcomes
high-risk features
high-risk first-relapse B-ALL in children
high-risk HCC
high-risk HNC patients
high-risk LBCL
high-risk localized gastrointestinal stromal tumor
high-risk locally advanced rectal cancer
high-risk locally advanced squamous cell carcinoma of head and neck
high-risk low-grade glioma
high-risk luminal breast cancer
high-risk lymphoma
high-risk mature B-cell non-Hodgkin’s lymphoma in children
high-risk medulloblastoma
high-risk medulloblastoma in children
high-risk melanoma
high-risk MIUC
high-risk mNSCLC
high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
high-risk neuroblastoma
high-risk non-muscle-invasive bladder cancer
high-risk nonmetastatic breast cancer
high-risk oral squamous cell carcinoma
high-risk pediatric HL
high-risk prostate cancer
high-risk resected melanoma
high-risk retinoblastoma
high-risk rhabdomyosarcoma
high-risk SM
high-risk smoldering multiple myeloma
high-risk smoldering myeloma
high-risk soft tissue sarcoma
high-risk stage 2 colon cancer
high-risk stage II melanoma
high-risk uveal melanoma
high-volume metastatic hormone-sensitive prostate cancer
higher-risk MDS or CMML
HIIT
HiLo trial
hilotherapy versus frozen gloves
HIMALAYA study
HIMALAYA trial
HIPEC
HIPEC + CS
HIPEC after CRS
histologic regression
histological biomarkers
histologically rare triple-negative breast cancers
histologische regressie
histology-tailored versus standard neoadjuvant chemotherapy
histopathologic features
historical 90-day mortality
history of atopy
history of use of statins and COX-2 inhibitors
HIV
HIV AIDS
HIV infection
HIV infection in elderly patients
HIV RNA
HIV status and survival
HIV-associated Kaposi sarcoma
HIV-infection
HL
HL diagnosis during pregnancy
HL in elderly patients
HL survivors
HL with high risk of failure after autoHSCT
HL-behandeling
HLA antigen mismatch
HLA-A*03 and response to immune checkpoint blockade in cancer
HLA-matched or alternative donors
HLA-matched sibling donor transplantation
HLA-mismatched unrelated donor HCT
HMA plus venetoclax
HMAs for high-risk MDS or AML
HMAs plus venetoclax for HR-MDS
HMIE versus open esophagectomy
hMPV
HMR 2.0
HMT for BC
HNC
HNC risk
HNC survivors
HNC versus onther cancers
HNCs
HNMCC
HNSCC
HNSCC in older patients
HNSCC patients
HNSCC surgery
Hodgkin and non-Hodgkin lymphoma
Hodgkin lymfoom
Hodgkin lymphoma
Hodgkin lymphoma in children and adolescents
Hodgkin lymphoma survivors
Hodgkin's lymfoom
Hodgkin’s lymphoma
hofd-hals Merkel celcarcinoom
hoge dosering chemotherapie
Hokusai VTE-Cancer studie
holmium-166 after lutetium-177-dotatate
home administration of trastuzumab
homeobox B13
homocysteïne
homologous recombination deficiency
hoofd hals squameus celcarcinoom
hoofd halscarcinoom
hoofd halskanker
hoofd-hals melanoom
hoofd-hals squameus celcarcinoom
hoofd-halscarcinoom
hoofd-halskanker
hoofdhuidkoeling
hoog-risico B-ALL
hoog-risico cervixcarcinoom
hoog-risico CML
hoog-risico melanoom
hooggradig sereus ovariumcarcinoom
HOPE trial
horizontale transfer
hormonal therapy
hormonal therapy resistance
hormone receptor low positive breast cancer
hormone-modulating breast cancer therapy
hormone-naïve metastatic prostate cancer
hormoonreceptor positieve borstkanker
hormoontherapie
hospital connectedness
hospital frailty risk score
hospital variation in treatment and survival in The Netherlands
hospital volume
hospitalisatie
hospitalization
hospitalization after adolescent and young adult cancer
hospitalizations and ED visits after CAR T-cell therapy
hospitalized patients with active cancer
hot flashes
HOVON 105 ALLG NHL 24
HOVON 105 study
Hovon 143 study
HOVON-143 trial
HOVON124 ECMW-R2
HOVON141 VISION trial
How Long studie
HP SCC
HPC-SFT
HPD
HPTC
HPV
HPV ctDNA
HPV ctDNA after CRT
HPV DNA in penile cancer and intraepithelial neoplasia
HPV DNA persistence
HPV genotypes
HPV infection
HPV load and genotype analysis
HPV status
HPV status and HPV16 viral load
HPV types
HPV types 16 18 in cervical precancers
HPV vaccination
HPV vaccination and anal HSIL+ and cancer
HPV vaccine
HPV-16 18 vaccin
HPV-associated epithelial cancers
HPV-associated malignancies
HPV-associated OPSCC
HPV-associated oropharyngeal carcinoma
HPV-associated oropharyngeal squamous cell carcinoma
HPV-associated SNSCC
HPV-FOCAL trial
HPV-independent and HPV-associated vulvar SCC
HPV-infectie
HPV-negative head and neck squamous cell carcinoma
HPV-negative HNSCC
HPV-orofarynxcarcinoom
HPV-positive oropharyngeal cancer
HPV-positive oropharyngeal squamous cell cancer
HPV-positive oropharyngeal squamous cell carcinoma
HPV-related malignancies
HPV-related OPSCC
HPV-related oropharyngeal cancer and cancer of unknown primary
HPV-typen
HPV-unrelated locally advanced HNSCC
HPV-vaccinatie
HPV+ OPC
HPV+OPSCC
HPV16 18-positive advanced cervical cancer
HPV16- and or HPV18-positive recurrent of advanced cervical cancer
HPV16-E6 serology test
HPV16-related cancerISA101
HR-deficiëntie
HR-MDS
HR-NB
HR-NBL1 SIOPEN study
HR-NL81 SIOPEN
HR-NMPC
HR-positief mammacarcinoom
HR-positief metastatisch mammacarcinoom
HR-positive advanced breast cancer
HR-positive advanced postmenopausal breast cancer
HR-positive and HER2-negative T1a bN0M0 breast cancer
HR-positive BC
HR-positive breast cancer
HR-positive breast cancer brain metastases
HR-positive breast cancer in young women
HR-positive early breast cancer
HR-positive early-stage breast cancer
HR-positive EBC
HR-positive HER2 negative metastatic breast cancer
HR-positive HER2-negative aBC
HR-positive HER2-negative advanced breast cancer
HR-positive HER2-negative advanced or metastatic breast cancer
HR-positive HER2-negative breast cancer in older patients
HR-positive HER2-negative early breast cancer
HR-positive HER2-negative mBC
HR-positive HER2-negative metastatic breast cancer
HR-positive HER2-negative metastatic breast cancer in older women
HR-positive HER2-positive advanced breast cancer
HR-positive HER2-positive early-stage breast cancer
HR-positive metastatic breast cancer
HR-status
HR+ HER- ABC
HR+ HER- BC
HR+ HER2- ABC
HR+ HER2- aBC progressing beyond CDK4 6 inhibitor
HR+ HER2- breast cancer
HR+ HER2- breast cancer in real-world patients
HR+ HER2- breast cancer survival
HR+ HER2- EBC
HR+ HER2- MBC
HR+ HER2- vroeg-stadium mammacarcinoom
HR+ HER2-ABC
HR+ HER2+ breast cancer
HR+ MBC
HRBOC
hrCT
HRD
HRGI cancers
HRP ovarian cancer
HRQoL
HRQOL impact
HRQOL in long-term survivors
HRQOL in prostate cancer
HRR-deficient metastatic castration-resistant prostate cancer
HRT
HRT and breast cancer risk
HRT versus CRT
hs-cTnT
HSC
HSCT
HSCT-bijwerkingen
HSCT-TMA in adults
Hsp70
HT
hTERT-DCs
hu14.18K322A
hu3F8
huCART19
HUDSON trial
huidkanker
huidkankerscreening
huidmaligniteit
huidneoplasmen
huisartsenzorg
humaan papillomavirus
human equilibrative nucleoside transporter 1
human readers versus machine-learning algorithms
hyaluronic acid
hybrid minimally invasive esophagectomy
hyper-CVAD followed by blinatumomab
hyperbaric oxygen therapy
hypercalcaemia of malignancy
hypercalcemie
hyperemesis gravidarum
hyperfractionated versus standard fractionated IMRT
hyperleukocytosis
hyperprogression
hyperprogressive disease
hyperproliferatie van stamcellen
hypertensie
hypertension
hyperthermic intraperitoneal chemotherapy
hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery
hyperthermische intraperitoneale chemoperfusie
hypervascular intracranial tumors
HYPO-RT-PC study
hypodiploid ALL in children
hypofarynxcarcinoom
hypofractionated adjuvant radiotherapy
hypofractionated breast RT for 1 week versus 3 weeks
hypofractionated IMRT
hypofractionated postmastectomy radiation therapy
hypofractionated postmastectomy radiotherapy
hypofractionated preoperative radiotherapy
hypofractionated RT
hypofractionated SRS
hypofractionated SRT to the resection cavity
hypofractionated stereotactic radiotherapy
hypofractionated stereotactic radiotherapy after surgery for brain metastases
hypofractionated versus conventional RT
hypofractionated versus conventionally fractionated RT
hypofractionated versus conventionally fractionated whole-breast irradiation
hypolipidemic drugs
hypomethylating agents
hyponatremie
HYPOR
HYPORT-STS
HYPRO
hysterectomy
I CARE study secondary outcome
I CARE trial
I T DIN GM-CSF
I-131 labelled metuximab
i-ALCL
I-SPY 2 trial
I-SPY2 three-year follow-up analysis
I-SPY2 trial
I+V versus FCR
iadademstat plus azacitidine
iAMP21
IARC
IBC
IBC versus SBC
IBC with exceptional response to NST
IBCSG 23-01 trial
IBD
iberdomide plus dexamethasone
IBI351
IBIS II
IBIS-I
IBIS-II trial 10 year follow-up
IBM Watson
IBR
ibrutinib
ibrutinib –bortezomib
ibrutinib discontinuation
ibrutinib followed by ofatumumab consolidation
ibrutinib for CLL
ibrutinib maintenanc
ibrutinib monotherapy
ibrutinib plus fludarabine
ibrutinib plus palbociclib
ibrutinib plus rituximab
ibrutinib plus venetoclax
ibrutinib versus ofatumamab
ibrutinib with or without ublituximab
ibrutinib-obinutuzumab-venetoclax combination
ibrutinib-rituximab versus chemoimmunotherapy
ibrutinib-rituximab versus placebo-rituximab
ibuprofen
ICANS prophylaxis with anakinra
ICARIA-MM study
ICARIA-MM subgroep analysis
ICB
ICB for SCLC
ICBP SURVMARK-2 study
ICC
ICC versus STC
iCCA
ICd versus Id
ICE3 trial
ICI
ICI dosing strategy
ICI effectiveness
ICI efficacy
ICI for aNSCLC
ICI for GBM
ICI monotherapy
ICI plus VEGFR inhibitor therapy for aRCC
ICI rechallenge
ICI therapy
ICI therapy in IBD patients
ICI treated mUC
ICI treatment
ICI use during pregnancy
ICI use in real-life practice
ICI versus chemotherapy
ICI with or without chemotherapy followed by resection of primary tumor
ICI with or without SBRT
ICI with or without SRS
ICI-AKIs
ICI-associated irAEs terminology
ICI-associated neurotoxicities
ICI-induced autoimmunity
ICI-naïve A R NSCLC
ICI-pretreated stage IV NSCLC
ICI-refractory advanced melanoma
ICI-related multisystem immune-related adverse events
ICI-related myocarditis
ICIs
ICIs after EGFR TKIs
ICIs and chemotherapy
ICIs for advanced cSCCs
ICIs for advanced gastrointestinal cancers
ICIs for advanced non-small cell lung cancer
ICIs for advanced NSCLC
ICIs for advanced NSCLC in clinical practice
ICIs for advanced PLC
ICIs for advanced solid tumors
ICIs for aGEC
ICIs for aNSCLC
ICIs for cancer
ICIs for cancer in clinical practice
ICIs for cancer in patients with autoimmune disease
ICIs for HNSCC
ICIs for lung cancer or malignant melanoma
ICIs for melanoma
ICIs for melanoma in patients with preexisting autoimmune disease
ICIs for metastatic cancer
ICIs for metastatic cancers in solid organ transplant recipients
ICIs for metastatic melanoma. early prediction of pseudoprogression
ICIs for metastatic renal and urothelial cancer
ICIs for mNSCLC
ICIs for mRCC
ICIs for MSI-H metastatic colorectal cancer
ICIs for mUC
ICIs for non-small cell lung cancer
ICIs for NSCLC
ICIs for NSCLC in patients with pre-existing autoimmune disorders
ICIs for solid malignancies
ICIs for solid tumors
ICIs plus anlotinib
ICIs plus anti-VEGF therapy with or without TACE
ICIs plus bevacizumab
ICIs plus chemotherapy
ICIs with or without denosumab
ICLL-07 FILO trial
ICLL07 FILO study
ICON6-studie
ICON8 study
ICON8-studie
ICPi
ICs
ICU-opname
idarubicine plus cytarabine plus nivolumab
IDC versus ILC
iddEPC-studie
ide-cel
IDEA collaboration
IDEA database
IDEA-collaboration
idecabtagene vicleucel
idelalisib
identification of patients with high recurrence risk
identification of patients with underrecognized symptoms
IDH mutant and wildtype LGG
IDH mutation
IDH mutation status
IDH wildtype glioblastoma
IDH-mutant CNS WHO grades 2 or 3 astrocytoma
IDH-mutant diffuse glioma
IDH-mutant lower-grade glioma and glioblastoma
IDH-mutated acute myeloid leukemia myelodysplastic syndrome
IDH-wildtype GBM
IDH-wildtype supratentorial GBM
IDH1 2-mutant low-grade glioma
IDH1 IDH2-mutant solid tumors
IDH1 mutation
IDH1-expressie
IDH1-mutant glioma
IDH1-mutant LGG
IDH1-mutant solid tumors
IDH1-mutated AML
idiopathische membraneuze nefropathie
idiopatische MCD
IDO PD-L1 targeting peptide vaccine plus nivolumab
Idylla
IELSG-19 studie
IELSG32 trial 7-year results
IELSG32-studie
ieramilimab with or without spartalizumab
IES
IFCT-0302 trial
IFCT-2104 CAPMATU
IFD
IFG
IFM 2009
IFN-onderhoudsbehandeling
IFRT
IFTC-1703 R2D2 trial
Ig paraproteïn
IGBT
IGF-1
IGF-1R expressie
IGF2-AS
IgM MGUS
IGT
IHC
IHCA
IHCC
IHGV mutational status
IHP
IHT
iIC versus iC
IIIA-N2 NSCLC
ijzersuppletie
IKEMA trial
IKFZ1-deletie
IKFZ1-deletion
IKZF1-deletie
IL-12 plasmid transfection
IL-6
IL-8
ILC
ILC in premenopausal patients
illness perception and outcomes in cancer
iLLUMINATE study
image-guided intensity modulated radiation therapy
Imaging
imaging surveillance
imaging-based prostate cancer screening
IMAJEM-studie
imatinib
imatinib after other multi-kinase inbitors
imatinib plus binimetinib
iMATRIX study
IMbrave 150 study
IMbrave050
IMbrave150
IMbrave150 study
IMbrave151
IMbrella A trial
IMCL-2015 trial
IMD
IMDC
imetelstat
IMiDs
imiquimod
immediate vs deferred cytoreductive nephrectomy
IMmotion 151 trial
IMmotion 151-studie
IMmotion151 trial
immune cells in mesothelioma microenvironment
immune checkpoint blockade
immune checkpoint inbition for cancer
immune checkpoint inhibition
immune checkpoint inhibition for unresectable HCC
Immune Checkpoint Inhibitor
immune checkpoint inhibitor associated acute kidney injury
immune checkpoint inhibitor for NSCLC
immune checkpoint inhibitor induced pituitary dysfunction
immune checkpoint inhibitor rechallenge after irAE
immune checkpoint inhibitor therapy
immune checkpoint inhibitor trials
immune checkpoint inhibitor-induced colitis
immune checkpoint inhibitor-mediated diarrhea and colitis
immune checkpoint inhibitors
immune checkpoint inhibitors for AML
immune checkpoint inhibitors for metastatic cutaneous melanoma
immune effector cell-associated neurotoxity syndrome
immune effects of rituximab
immune health
immune infiltration
immune markers of nivolumab response
immune microenvironment
immune phenotype
immune response
immune status
immune-mediated diarrhea and colitis
immune-related adverse events
immune-related adverse events and efficacy of avelumab
immune-related enteritis
immune-related gene expression in osteosarcoma
immune-related meningitis
immune-related pneumonitis
IMMUNED study
immunocheckpoint blockade
immunochemottherapy
immunocompromised cancer patients
immunogenicity and safety in patients with solid cancer
immunogenicity of metastatic breast cancer
immunogenomic biomarker analysis
immunoglobuline lichte-keten amyloïdose
immunologically quiescent melanoma
immunomodulatory TNBC
immunophenotyping of TILs and PBLs
Immunoscore
immunosuppression
immunosuppressive therapy for management of MDS
immunotherapeutic boost
immunotherapy
immunotherapy after chemotherapy and radiation for stage III NSCLC
immunotherapy after surgery of the primary tumor
immunotherapy for advanced cancers
immunotherapy for advanced non-small cell lung cancer
immunotherapy for advanced stage cancer
immunotherapy for EGFR ALK wild-type advanced NSCLC
immunotherapy for melanoma
immunotherapy for metastatic melanoma
immunotherapy for NSCLC
immunotherapy initiation at EOL
immunotherapy or chemoimmunotherapy
immunotherapy plus stereotactic radiotherapy
immunotherapy rechallenge
immunotherapy versus BSC
immunotherapy versus chemotherapy
immunotherapy with or without live bacterial supplementation
immunotherapy-based TNT
immunotherapy-related pruritus
immutherapy
immuuncheckpointremmers
immuunrespons
immuunsuppressie
immuuntherapie
IMPAC
IMPACT
impact of adjuvant regimes
impact of adjuvant therapies on outcomes
impact of advances in treatment
impact of age
impact of age and frailty
impact of age at diagnosis on survival
impact of age on melanoma response to bevacizumab
impact of age on outcomes
impact of age on outcomes of dual anti-HER2 therapy
impact of alcohol and smoking and FRP
impact of ancestry on frequency of actionable alterations
impact of antibiotics
impact of antiviral therapy for chronic hepatitis C
impact of asparaginase discontinuation on outcome
impact of attending surgeon
impact of baseline body mass index
impact of biopsy frequncy on metastasis and mortality
impact of BMI
impact of body composition factors
impact of bone metastases
impact of BRAF V600E K mutation status
impact of breast cancer treatment on employment
impact of breast screening programme on mortality in England
impact of calcium channel blocker use
impact of cancer on COVID-19 outcomes
impact of care fragmentation on outcomes
impact of celebrity’s disclosure of leukemia
impact of center volume on outcomes of adverse events
impact of centralization within hospital systems
impact of cisplatin-based chemotherapy on risk of metachronous contralateral disease
impact of Combined Positive Score
impact of comorbidities on overall survival
impact of concomitant antihypertensive medication
impact of concomitant PPIs on survival
impact of concurrent dexamethasone on clinical benefit
impact of conditioning intensity
impact of COVID-19 on treatment and short-term mortality
impact of COVID-19 pandemic
impact of cumulative exposure to premenopausal obesity
impact of detailed family history
impact of diet
impact of disease stage
impact of ECD
impact of EGFR mutation and ALK rearrangement
impact of epigenetics on association of aspirin use with mortality after breast cancer
impact of ER status on survival
impact of ET adherence
impact of experimental molecular-matched therapies on cancer outcomes
impact of facility caseload
impact of facility surgical caseload volume on survival
impact of FIT-screening on CRC incidence and outcomes in The Netherlands
impact of follow-up time
impact of germline BRCA1 or BRCA2 or PALB2 mutation on platinum response
impact of germline mutations
impact of glycemic status
impact of high TMB on response rates
impact of HIV infection
impact of hormone receptor status
impact of ILD on outcomes of lung cancer surgery
impact of imaging intensity on survival after systemic therapy
impact of intratumoral Escherichia
impact of low-dose aspirin
impact of lower airway dysbiosis on progression
impact of metabolic syndrome
impact of moderate-to-vigorous intensity physical activity
impact of molecular subtype and race
impact of molecular subtypes on incidence and prognosis of CNS metastases
impact of NST on postoperative complications
impact of obesity
impact of oophorectomy on breast cancer survival in patients with CHEK2 mutations
impact of optimizing diagnostic workup and reducing time to treatment
impact of overweight and obesity
impact of overweignt and obesity
impact of patient age
impact of POD24 on survival
impact of polypharmacy on AI adherence
impact of poverty
impact of pre-existing CVD on mortality
impact of pregnancy on genomic landscape
impact of primary tumor surgery
impact of prior CT or RT on efficacy of durvalumab for NSCLC
impact of prior or concurrent antibiotic therapy
impact of prior ruxolitinib
impact of prior therapy
impact of prior treatment
impact of prior treatments
impact of probiotics use
impact of race
impact of race and age on response to NACT and long-term outcomes
impact of race ethnicity
impact of race ethnicity on OS
impact of race on outcomes
impact of race on outcomes of definitive RT
impact of radiation facility volume
impact of screening
impact of screening on OPE diagnosis
impact of solid cancer on in-hospital mortality
impact of stewardship program
impact of subtype on axillary pCR to neoadjuvant therapy
impact of subtype on GKS outcomes
impact of surveillance
impact of T2D
impact of the COVID-19 pandemic on new diagnoses of cancers
impact of TP53 genomic alterations on CD19 CAR T-cell therapy
impact of treatment modality on performance of prognostic factors
impact of tumor size and high-risk features on chemotherapy benefit
impact on antitumor immunity in cancer patients
impact on breast cancer incidence and mortality
impact on breast cancer risk
impact on cancer risk in men
impact on cancer stage at diagnosis
impact on COVID-19 survival
impact on CRC incidence and mortality
impact on CRC screening rate
impact on diagnosis and initial treatment of breast cancer in The Netherlands
impact on Dutch lung cancer care
impact on frequency of biopsy and tumor grade
impact on functional age and mortality
impact on long-term risk of morbidity
impact on memory
impact on metastatic behavior and outcome
impact on OC risk in African American and White women
impact on OS
impact on outcome
impact on outcomes
impact on outcomes of durvalumab for NSCLC
impact on patients’ treatment experience and treatment discontinuation
impact on recurrence and survival
impact on sexual function
impact on short-term mortality
impact on survival
impact on survival and recommended treatment intensity
impact on survival of cancer patients
impact on survival of patients with cancer
impact on treatment and survival of cancer patients
impact on treatments for metastatic solid cancer in the USA
IMPACT program
IMPACT study
Impact van timing van adjuvante chemotherapie voor vroeg-stadium mammacarcinoom
IMPACT-studie
IMPACT2
IMPARTER
IMpassion031 trial
IMpassion130 study
IMpassion130 study updated results
IMpassion130 trial
IMPATTO study
implementation of best practices in pancreatic care
implications of minimal residual disease detection
IMPORT LOW study
IMpower010
IMpower010 study
IMpower010 trial
IMpower110 study
IMpower130 trial
IMpower132 trial
IMpower133 Study
IMpower133 updated analyses
IMpower150 final overall survival analyses
IMpower150 regimen
IMpower150 study
IMpower150 trial safety and PROs
IMpower150-studie
IMPRESS-studie
IMPROVE study
improvements in survival between 2009 and 2022
improvent over time in posttransplant outcomes
improving PCa diagnosis
IMPT
IMROZ trial
IMRT
IMRT alone
IMRT for HNC
IMRT versus 3D-CRT
IMRT versus 3DCRT for prostate cancer
IMRT versus SBRT
IMRT with or without cisplatin
IMspire150
IMspire150 second interim analysis
IMspire150 study
IMspire150 trial
IMT
IMvigor130 study
IMvigor211-studie
in situ mammacarcinoom
in utero chemotherapy exposure
in utero exposure to maternal cancer
in utero pembrolizumab exposure
in-breast tumor recurrence
in-hospital mortality
INAVO120 trial
inavolisib
incidence
incidence and mortality in England
incidence and mortality of colon and lung and prostate cancer
incidence and mortality of second primary cancers
incidence and outcomes
incidence and outcomes of lung cancer
incidence and patterns of cancer
incidence and predictors of diabetes mellitus
incidence and predictors of SPCs
incidence and risk factors
incidence and survival among solid organ transplant recipients
incidence and survival in the USA 1973-2015
incidence and survival outcomes
incidence of adverse events with various therapies
incidence of and mortality from malignancies after CIN treatment
incidence of cancer
incidence of cancer and CVD
incidence of cancer diagnoses
incidence of hypothyroidism
incidence of pneumonitis
incidence of recurrence 10-32 years after primary diagnosis
incidence of recurrence and time to recurrence in Denmark
incidence of relapse
incidence of second primary melanoma
incidence of subtypes
incidence of T790M mutation in cfDNA
incidence of thyroid cancer in WTC-exposed rescue workers
incidence of vulvar precancerous lesions and cancer
incidence of young adult cancers in Canada
incidence trends
incidence trends in Finland
incidence trends of breast cancer molecular subtypes by age and race in the US
incident breast cancer
incident cancer
incident cancer risk
incident cardiovascular events
incident comorbidities
incident type 2 diabetes duration
incidental pulmonary embolism in cancer patients
incidentally detected lung nodules
incidentally found pediatric brain tumors
incidentie
incidentie mammacarcinoom USA
Incidentie van cardiovasculaire gebeurtenissen in ICI-behandelde patiënten
incomplete pregnanacy
increase since 2017
increased α-fetoprotein
increasing dose intensity of chemotherapy
INDAR
indatuximab ravtansine
independence
independent roles
indeterminate pulmonary nodules
index lymph node
individual and neighborhood-level SES
individual oncogenic HPV types
individual patient data meta-analysis
individual patient-level analysis
individual patient-level data meta-analysis
individualised axitinib regimen
individualized prognostic model
indolent lymfoom
indolent mammacarcinoom
indolent MCL
indoor tanning
Indoor tanning industry
indoximod
indoximod plus pembrolizumab
inductie-chemoradiatie
inductiechemotherapie
induction chemotherapy
induction chemotherapy for AML
induction chemotherapy for NPC
induction CRT with or without sintilimab
induction CT followed by CCRT
induction CT followed by RT versus CRT
induction CT followed by standard CRT
induction toripalimab and chemotherapy
infant lymphoblastic leukemia
infants
infectie
infertility and risk of breast cancer in men
infigratinib
inflammatie
inflammation
inflammation and clinical decline
inflammation cascade
Inflammatoir mammacarcinoom
inflammatoire voeding
inflammatory and insulinemic dietary patterns
inflammatory biomarkers and survival
inflammatory blood markers
inflammatory bowel disease
inflammatory bowel disease and risk of adenocarcinoma and NETs in the small bowel
Inflammatory breast cancer
inflammatory markers